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THESIS SUMMARY 
PD is a progressive neurodegenerative disease that results in intolerable 
disability for most patients despite the best current medical and surgical therapies. A 
treatment that slows, or stops clinical progression is the major therapeutic goal of 
current PD research. 
Multiple avenues of research including epidemiology, molecular genetics and 
cell biology have identified links between Parkinson’s disease (PD) and Type 2 
diabetes mellitus (T2DM). Several recent discoveries have highlighted common 
cellular pathways that potentially relate neurodegenerative processes with abnormal 
mitochondrial function and abnormal glucose metabolism. In parallel with these 
advances, a treatment for insulin resistance (Exenatide) has been evaluated as a 
possible disease modifying drug in PD, which forms the core of my PhD. 
 Exenatide is the synthetic version of Exendin-4, confirmed to be an agonist of 
the Glucagon-like-peptide-1 (GLP-1) receptor, and resistant to the normal GLP-1 
enzymatic degradation processes. The aim of this thesis is the evaluation of 
Exenatide’s possible role as a potential neuroprotective/disease modifying agent in 
PD (with only preliminary insights regarding its mechanisms of action in 
neurodegeneration). This study presents the following data: 
1. Methods used to obtained proof of concept data from patients with 
moderate PD treated with Exenatide to provide preliminary support for 
its further study. 
2. An exploration of possible objective measures of differences resulting 
from Exenatide exposure in a PD biomarker- SPECT imaging, using 
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statistical parametric mapping of a subgroup of patients treated with 
Exenatide. 
3. Prolonged follow up of these patients to further try and help distinguish 
placebo effects from possible biological effects of Exenatide in PD. 
4. An attempt to identify a possible mechanism of action of Exenatide in 
our cohort of patients. Glucose tolerance tests were performed as an 
indirect measure  of insulin resistance. 
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1 INTRODUCTION 
1.1 SUMMARY 
Parkinson’s disease (PD) is a common neurodegenerative disease, affecting 
1% of the population over age 65 (de Rijk et al. 2000; Kis et al. 2002). The PD 
research field is a rapidly moving one. As mechanisms underlying pathogenesis are 
being elucidated, novel therapies are making their way from the laboratory to the 
clinic. This chapter aims to highlight the most relevant updates in PD pathogenesis, 
especially recent discoveries related to the relationship between diabetes and the 
brain that have generated considerable recent research interest. A lot of research in 
recent years has focused on neurodegeneration/cell death associated with chronic 
Type 2 Diabetes Mellitus (T2DM). It has been widely proposed that 
neurodegeneration conditions may result from a complex interaction between T2DM 
and brain aging, as disruptions in shared molecular networks lead to both chronic 
diseases. 
In parallel with these advances, Glucagon-like peptide 1 (GLP-1) is a hormone 
that facilitates insulin release under high blood sugar conditions. It is particularly 
noteworthy that GLP-1 also has a similar growth factor-like properties to insulin. 
Exenatide is a GLP-1 agonist used in T2DM. 
Numerous pre-clinical studies utilising cellular and animal neurodegeneration 
models have established Exenatide’s neurotrophic and neuroprotective properties. 
The aim of this chapter is to provide background on the potential benefit of using 
Exenatide as a possible disease modifying drug in PD, (with preliminary insights 
regarding its mechanisms of action in PD). 
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1.2 PD PATHOGENESIS 
Today there is a well-described clinical and pathological phenotype of PD. 
There has been widespread adoption of the UK Brain Bank criteria (Hughes, et al. 
1992a; Hughes et al. 1992b) as a reliable way of making the clinical diagnosis of PD. 
The cornerstone of these clinical criteria is that the patients exhibit “bradykinesia”. 
PD is clinically characterized by the appearance of changes in motor function 
(bradykinesia, rigidity, postural instability and rest tremor) plus the increasingly 
recognized non-motor manifestations.  
Neuropathologically, PD is defined as the selective degeneration of pigmented, 
dopaminergic neurons of the substantia nigra pars compacta (SNc) and other 
brainstem nuclei, with the presence of α-synuclein positive staining cytoplasmatic 
inclusions, (known as Lewy bodies) in the surviving neurons (Gibb & Lees 1988; 
Forno 1996; Spillantini et al. 1997; Bernheimer et al. 1973; Fearnley & Lees 1991).  
The molecular mechanisms which lead to neurodegeneration are gradually 
being elucidated through the combined efforts of epidemiologists, geneticists and 
molecular and cell biologists. In recent years, several genes that cause certain forms 
of inherited PD have been identified, and great progress has been made in revealing 
their molecular mechanisms. However, most cases of PD appear to be sporadic, and 
are likely to represent interplay between both genetic and environmental factors 
(Warner & Schapira 2003). It is the current belief that the neurodegeneration in PD 
occurs in response to a mixture of deleterious mechanisms taking place both inside 
the degenerating neurons (oxidative stress, protein aggregation, defects in the 
ubiquitin-proteasome pathway, autophagy and alteration in mitochondrial function) 
and outside the degenerating neurons. Outside the neurons, mechanisms promoting 
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the spread of α-synuclein, inflammatory processes and loss of trophic support may 
contribute to progressive degeneration of dopaminergic and non-dopaminergic 
neurons, ultimately leading to progression of disease (Hirsch et al. 2013; Foltynie & 
Kahan 2013). 
1.2.1 Determinants of vulnerability 
There is lots of evidence to support that the pathology in PD is distributed 
across both the central and peripheral nervous system. There are several 
morphological and physiological features that appear to determine neural 
vulnerability. PD affects neurons with highly branched axons, which have a common 
physiological type (see section 1.2.1.2 below), Lewy pathology and neurons that 
synthesize a monoamine neurotransmitter. All of these factors are consistent with 
age being the strongest risk factor of PD. Based on the above body of information 
(discussed in detail below), genetic mutations, environmental toxins and proteostatic 
stress (affecting mitochondria) act synergistically in vulnerable cell types, to induce 
a bioenergetics crisis, that evolves into overproduction of misfolded proteins that 
might lead to aggregation and reduced dysfunctional protein degradation and cell 
degeneration that define the pathogenic scenario of PD. 
1.2.1.1 A long, highly branched axon with multiple release sites.  
The axons projecting from the Substantia Nigra pars compacta (SNc), Red 
Nucleus (RN), Pedunculo Pontine Nucleus (PPN), Nucleus Basalis of Meynert 
(NBM) and Locus Coeruleus (LC) are unmyelinated or thinly myelinated and highly 
branched (Orimo et al. 2011). There has been considerable speculation regarding the 
(initially) selective degeneration of dopaminergic neurons in PD. 
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Dopaminergic neurons in the SNc have an incredibly complex structure in 
terms of axon length and number of synapses. Mathematical modelling has shown 
that neuronal energetic demand rises exponentially with axon structure and arbour 
complexity (Bolam & Pissadaki 2012). This potentially makes dopaminergic 
neurons of the SNc more sensitive to energetic stress than other types of 
dopaminergic or indeed non-dopaminergic neurons (Moss & Bolam 2010; Matsuda 
et al. 2009; Bolam & Pissadaki 2012). Their large, complex axonal arbour puts them 
under such a tight energy budget that it makes them particularly susceptible to 
factors that contribute to cell death. 
1.2.1.2 A common physiological phenotype.  
PD is a disease of neurons. Therefore, it seems reasonable to think that features 
distinguishing neurons from other cell types may contribute to PD pathogenesis. One 
of the most characteristic properties of neurons is their excitability, which is energy 
dependent. To be electrically excitable, neurons maintain voltage gradients across 
their membranes by means of metabolically driven ion pumps, which combine with 
ion channels embedded in the membrane to generate intracellular-versus-
extracellular concentration differences of ions such as sodium, potassium, chloride 
and calcium (John Hall 2011). During the waking state the SNc, RN, NBM, PPN, 
LC and Dorsal Motor Nucleus of Vagus (DMV) neurons spike continuously (Aston-
Jones & Cohen 2005; McCann & Rogers 1990; Chan & Chan 1989). Furthermore, 
the SNc, LC, DMV and PPN neurons spike autonomously, i.e.in the absence of 
synaptic input. These neurons spend all their time at relatively depolarized 
membrane potentials (Beal 1998). These physiological features are responsible for a 
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sustained metabolic burden carried mainly by mitochondria in the neurons of SNc, 
LC, DMV and PPN (Nicholls 2009). 
1.2.1.3 Lewy pathology.  
Nearly all neurons that experience cell death in PD also display Lewy 
pathology. Despite this, Lewy pathology has been found in peripheral and central 
neurons without evidence of neuronal death. This fact has led to the hypothesis that 
Lewy pathology could reflect a neuroprotective response to detoxify forms of α 
synuclein (Conway 2001). Despite the fact that Lewy pathology might indicate a 
protective stress response, it might have deleterious effect on neuronal functioning, 
ie axonal transport (Dugger & Dickson 2010). 
1.2.1.4 A common reactive neurotransmitter  
SNc, LC, RN, enteric dopaminergic neurons, and sympathetic postganglionic 
neurons synthesize monoaminergic neurotransmitters. It seems that high levels of 
cytosolic monoamines could underlie the process of neuronal death (K. E. Larsen et 
al. 2002). 
1.2.2 Defective glucose sensing and impaired insulin signalling in the 
brain 
The classic idea that CNS was insulin-insensitive and the hormone was unable 
to cross the blood-brain barrier (BBB) has been challenged in the last decades, due to 
the increasing body of evidence showing that insulin can reach high levels in brain, 
and have long-term neuronal trophic effects (Salkovic-Petrisic & Hoyer 2007; Craft 
et al. 2000; Le Roith et al. 1983; Schulingkamp et al. 2000). 
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Insulin-induced neuronal insulin receptor/insulin-growth-factor-1receptor 
(IR/IGF-1R) activation under oxidative stress and subsequent Phosphatidylinositide 
3-kinases/Protein Kinase B (PI3K/Akt) -mediated signalling prevented Glucose 
transporter 3 (GLUT3) oxidation, restored hexokinase-II expression and glucose 
uptake, therefore recovering neuronal glycolysis and energy levels (Duarte et al. 
2006). Therefore, it has been proposed that insulin may play other roles in the CNS 
rather than metabolic regulation. For example, evidence suggests it has a role in 
neurite outgrowth, regeneration of small myelinated fibers, maintenance of cortical, 
sympathetic and sensory neuronal survival during nervous system development, 
stimulation of neuronal protein synthesis, and improvement of synaptic activity and 
plasticity, memory formation, and storage, as well as neuroprotection (Moreira et al. 
2009; Duarte et al. 2012).  
The disruption of insulin regulation, inflammation, endoplasmic reticulum 
stress and mitochondrial dysfunction are candidates to play a role in the aetiology 
and/or progression of PD (Santiago & Potashkin 2013). 
1.2.2.1 Insulin receptor (IR)  
The IR is a trans-membrane receptor that belongs to a large class of tyrosine 
kinase receptors (Smith et al. 2010) and it is activated by insulin, insulin grow factor 
1 (IGF-1) and IGF-II. Its functions are crucial to glucose homeostasis, a process that 
under degenerate conditions may result in a range of clinical manifestations 
including diabetes and cancer (McKern et al. 2006; Esposito et al. 2013). Insulin 
receptor (IR) and Insulin-like Growth Factor 1 Receptor (IGF1R) are hormone 
receptors made up of two α and two β subunits and are each the product of a single 
gene (IR located on chromosome 19 and IGF1R on chromosome 15 in humans) 
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(Werner et al. 1993). The binding of ligand to the α-chains of the IR ectodomain 
induces structural changes within the receptor leading to auto- phosphorylation of 
various tyrosine residues within the intracellular tyrosine kinase domain of the β-
chain. The proteins that are phosphorylated by the IR include a protein called insulin 
receptor substrate 1 (IRS-1). The cascade of phosphorylation results in translocations 
of glucose transporters from sequestered sites within the cell to locations on the cell 
surface (Schulingkamp et al. 2000). Specifically, the glucose transporter 4 (GLUT4) 
is transported from cellular vesicles to the cell surface, where it then can mediate the 
transport of glucose into the cell.  
1.2.2.1.1 JNK in Insulin Resistance  
Although the mechanisms of insulin resistance are not fully elucidated, recent 
studies suggest that a complex interaction between inflammation, endoplasmic 
reticulum stress, oxidative stress, mitochondrial dysfunction and autophagy 
dysregulation plays an important role in insulin resistance. Obesity-associated 
insulin resistance is consistently associated with elevated levels of pro -inflammatory 
cytokines such as TNFα, IL-6, and IL-1β, and neutralization of TNFα improves 
insulin sensitivity in obese rodents (Hotamisligil 2006). These cytokines activate 
inflammatory pathways that terminate in activation of Jun N-terminal kinase (JNK1) 
and inhibitor of Kb kinase (IKKβ), the products of which alter signalling 
downstream of the insulin receptor and cause insulin resistance (Gao et al. 2002; 
Hirosumi et al. 2002). Knockout of JNK1 in non-hematopoietic cells protected mice 
from high fat diet-induced insulin resistance, in part through decreased adiposity 
(Hirosumi et al. 2002; Solinas et al. 2007). By contrast, mice with JNK1 knocked out 
of hematopoietic cells (macrophage-specific cells) became obese on high fat diet, 
with hepatic steatosis and increased intramuscular triglyceride content, but were still 
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protected against insulin resistance (Solinas et al. 2007). Protection against insulin 
resistance was conferred to these hematopoietic cell-specific Knocked out mice by a 
decrease in adipose tissue macrophages content and reduction in inflammatory 
pathway gene expression (Solinas et al. 2007). This experiment demonstrates that 
obesity and tissue lipid burden may not be sufficient to cause insulin resistance. 
Without the inflammatory component, obesity does not lead to appreciably impaired 
insulin action as demonstrated in macrophage-specific IKKβ and JNK1-knocked out 
mice (Arkan et al. 2005; Solinas et al. 2007).  
The stress-activated c-Jun N-terminal kinase (JNK) has been increasingly 
recognized as a central mediator of insulin resistance and suppression of the JNK 
pathway has been shown to improve insulin resistance and glucose tolerance (Li & 
Yu 2013).  
1.2.2.1.2 . IR and Brain  
Historically, skeletal muscle, adipose tissue, and liver were regarded as key 
insulin-sensitive organs involved in insulin-mediated regulation of peripheral 
carbohydrate, lipid, and protein metabolism. Insulin has conventionally been thought 
to act as the signal that tells these organs’ cells to pull glucose in from the blood so it 
can be used to generate the energy the body needs. 
The consequences of impaired insulin action in those organs were deemed to 
explain the functional and structural abnormalities associated with insulin resistance. 
In contrast, since the discovery of insulin in 1922 (Banting et al. 1922), the brain had 
been generally considered an insulin-insensitive organ. However, evidence of insulin 
actions in the brain emerged more than 30 years ago with the demonstration that 
i.c.v. infusion of insulin decreased food intake in baboons (Woods et al. 1979). This 
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discovery was followed by a number of studies reporting that the hypothalamic 
actions of insulin regulate peripheral energy homeostasis (Marino et al. 2011; 
Scherer et al. 2011). However, the effects of insulin in the brain are not restricted to 
the hypothalamus, as IRs are widely distributed throughout the encephalon ( Zhao et 
al. 2004). The hippocampus, a region that is fundamentally involved in the 
acquisition, consolidation, and recollection of new memories, presents particularly 
high levels of IRs ( Zhao & Alkon 2001), indicating that insulin might have 
additional targets in the CNS outside of the hypothalamus. Indeed, insulin has been 
shown to be neuroprotective (Bomfim et al. 2012; Plum et al. 2005; Ott et al. 2012) 
and to affect synaptic plasticity mechanisms (Wan et al. 1997). Insulin has been 
proposed to regulate neuronal survival and to act as a growth factor (Lin Li & 
Hölscher 2007), possibly by activating IGF receptors (Fernandez & Torres-Alemán 
2012). IR signalling further regulates circuit function and plasticity by controlling 
synapse density (Chiu et al. 2008). 
Nonetheless, knowledge of the precise roles of brain IRs is still limited. It is 
important to take into account that brain insulin receptors differ somewhat from their 
peripheral counterparts. It has been proposed that the role of these receptors exceeds 
mediation of insulin utilization. The distribution of the insulin receptors in the brain 
is neither homogeneous nor a simple function of glucose utilization pattern, and they 
have been shown to be present on synapses (Schulingkamp et al. 2000). Thus it has 
been proposed that Insulin receptors may play a role in CNS development, function, 
or pathophysiology (Schulingkamp et al. 2000). 
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1.2.2.1.3 Insulin Resistance & Alzheimer Disease 
The idea that defective insulin signaling contributes to Alzheimer disease (AD) 
pathogenesis was first proposed by Hoyer more than 20 years ago (Hoyer & Nitsch 
1989). Numerous clinical and epidemiological studies have since established that 
type 2 diabetes increases AD risk, and that targeting insulin levels or modulating 
sensitivity to insulin affects cognitive, imaging, and biochemical parameters in 
adults with AD or its presumed prodromal, amnestic mild cognitive impairment 
(MCI). Evidence regarding the mechanistic underpinnings of these relationships has 
been sparse however, as far fewer studies have systematically characterized insulin 
signaling in animal models of AD or in human brain tissue. 
Two recent studies, published in the Journal of Clinical Investigation, have 
made important contributions in favor (Bomfim et al. 2012; Talbot et al. 2012). In 
one study, Talbot et al. showed that defective insulin signaling is a characteristic 
feature of the AD brain (Talbot et al. 2012). The authors demonstrate convincingly 
that postmortem brain tissue from patients with AD is less responsive to near-
physiological doses of insulin than is tissue from non-AD cases. Neurotoxicity 
mediated by oligomeric amyloid-β has been proposed as possible mechanism 
underlying brain insulin resistance in AD and amyloid load in control, MCI and AD 
cases was negatively correlated with the level of tyrosine phosphorylation of the 
insulin receptor, and showed positive correlation with levels of IRS-1 serine kinases 
(Talbot et al. 2012). Importantly, high levels of insulin resistance markers were 
associated with poor performance on memory tests. 
Bomfim et al. addressed possible therapeutic approaches to block the AD-
promoting effects of insulin resistance. Patients with AD exhibited elevated levels of 
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IRS-1pSer and activated JNK (similar to what occurs in peripheral tissue in patients 
with DM). When neuronal cells from this group were taken in culture, both insulin 
and Exendin-4, prevented the increased serine phosphorylation and decreased 
tyrosine phosphorylation of IRS-1 caused by application of amyloid-β. In vivo, 
intraperitoneal injection of Exendin-4 in amyloid precursor protein/ presenilin 1 
(APP/PS1) mice reduced hippocampal IRS-1 serine phosphorylation and amyloid 
burden, simultaneously improving spatial memory (Bomfim et al. 2012). 
Additionally, intranasal insulin has shown therapeutic benefit in adults with 
early-stage AD in a phase II clinical trial (Craft et al. 2012). 
However in a recent prospective cohort study with multiple assessments of 
glucose intolerance and insulin resistance, measures of glucose and insulin 
homeostasis are not associated with AD pathology (Thambisetty et al. 2013). 
Whether levels of glucose and insulin in peripheral blood parallel levels in the 
central nervous system is a question that should be clarified.  
1.2.2.1.4 Insulin Resistance & Parkinsonism 
Several studies have examined IR in the brain in relation to aberrant glucose 
metabolism associated with Parkinsonism (Peppard et al. 1992; Blum-Degen et al. 
1995). Significant reductions (mean 20.7%) in the regional cerebral metabolic rate of 
glucose (rCMRG) have been found in Parkinson patients compared with the control 
group (Peppard et al. 1992).  
In demented patients with PD, the mean rCMRG was 31.9% less than normal 
and 14.1% less than in non-demented patients. In patients with Parkinsonism there 
was a global decrease in glucose metabolism, with more severe abnormalities in the 
temporo-parietal regions. Insulin receptors distribution in midbrain regions of 
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Parkinsonism patients was examined by Moroo et al. (Moroo et al. 1994) using 
mono- and polyclonal anti-InsR antibody. The neurons in the substantia nigra pars 
compacta, parabrachial pigmental nucleus, tegmental pedunculopontine nucleus, 
supratrocheal nucleus, cuneiform nucleus, subcuneiform nucleus and lemniscus 
medialis, which were positive in non-neurological controls, were not stained by these 
antibodies in Parkinson brains. Specifically, the polyclonal InsR antibody recognized 
a major band of approximately 92 kDa, corresponding to that of the b subunit of the 
InsRb. The monoclonal antibody recognized two bands of 135 and 92 kDa 
corresponding to the α and β subunits, respectively. The results suggest that in PD a 
dysfunction of insulin or IR system might precede death of dopaminergic neurons. 
An upregulation of IR density has been reported for the occipital cortex of Parkinson 
patients (Blum-Degen et al. 1995) and selective neuronal loss in the substantia nigra 
is accompanied by decreased IR immunoreactivity (Takahashi et al., 1996). In the 
latter study, the authors performed semiquantitative mRNA analysis in the brain of 3 
patients (82.0 ±9.5 years) and 6 controls (79.3±3.1years) by reverse transcription– 
polymerase chain reaction (RT–PCR) using specific primers for human IR exon 22, 
which encodes a region of the β subunit of the receptor serving as a tyrosine kinase 
domain. Levels of IR mRNA in patient tissues were markedly reduced compared 
with IR levels in the controls.  
1.2.3 Inflammation  
A growing body of evidence supports the hypothesis that inflammation plays 
an important part of the pathogenesis of PD. This is supported by consistent 
associations between the HLA locus and PD risk in meta-analyses of Genome wide 
association studies (IPDGC, WTCCC2 2011). Furthermore, epidemiological data 
reveal lower rates of PD among patients using non-steroidal anti-inflammatory 
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drugs, inflammatory pathways independent of HLA are associated with PD risk 
(Holmans et al. 2013), the presence of activated microglia seen in PD patients using 
PK11195 PET ligand (Gerhard et al. 2006) and the presence of pro-inflammatory 
mediators seen in the post mortem tissue of PD patients (Lee et al. 2009).  
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1.3 LINKS BETWEEN PD AND T2DM- EPIDEMIOLOGY  
Evidence from prospective epidemiological studies has identified T2DM as an 
independent risk factor for multiple diseases of the nervous system such as diabetic 
neuropathy (Boulton et al. 2005), stroke (Hu et al. 2006b; Tuomilehto et al. 1996), 
and more recently Alzheimer’s disease (Peila et al. 2002; Leibson et al. 1997; Ott et 
al. 1999) . There are also reports of varying associations between diabetes (or 
abnormal glucose tolerance) and sporadic forms of PD from both cross-sectional and 
cohort studies. Survey data reveals that diabetes is established in 8-30% of PD 
patients, consistently in excess of the prevalence found in non-PD individuals 
(Chalmanov & Vŭrbanova 1987; Pressley et al. 2003) . This might be readily 
explained by increased detection of hyperglycaemia through additional medical 
contact/-urine/-blood tests among PD individuals regularly attending hospital 
appointments. However, the association is greatly strengthened by reports that 
identified that 50-80% of PD patients have abnormal glucose tolerance when tested 
(Barbeau et al. 1961; Lipman et al. 1974; Sandyk 1993). This relationship is 
questionable and is explored further in Chapter 6. Nevertheless, in a series of 800 
patients with PD, concurrent diabetes was also shown to accelerate progression of 
both motor and cognitive symptoms (Schaw 1960). In view of the possible 
confounding effects of PD treatment, newly diagnosed, never-treated adults with PD 
have also been studied and been shown to have reduced insulin-mediated glucose 
uptake (Van Woert & Mueller, 1971), inhibition of early insulin secretion, long-term 
hyperinsulinaemia, and hyperglycaemia after glucose loading (Boyd et al. 1971). 
This takes into account the effects of some drugs used to treat PD, such as levodopa, 
which induces both hyperglycaemia and hyperinsulinaemia, whereas others, 
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(including the ergot dopamine agonist- bromocriptine), may increase insulin 
sensitivity (Sirtori et al. 1972; Van Woert & Mueller 1971). 
Neuropathological studies of patients with PD have shown that insulin 
receptors are densely represented on the dopaminergic neurons of the SNc (Unger et 
al. 1991), and loss of insulin-receptor immunoreactivity and mRNA in SNc of PD 
patients coincides with loss of tyrosine hydroxylase mRNA (the rate limiting enzyme 
in dopamine synthesis) (Moroo et al. 1994; Takahashi et al.1996). Indeed abnormal 
glucose utilization has been specifically shown in the brains of PD using magnetic 
resonance spectroscopy (Bowen et al. 1995) or fluorodeoxyglucose positron 
emission tomography (FDG-PET) (Hu et al. 2000), demonstrating increased lactate 
concentrations and glucose hypometabolism, supporting the hypothesis that PD is a 
systemic disorder characterized by an derangement of oxidative energy metabolism. 
Further robust evidence for a positive association between PD and T2DM has 
been obtained from prospective cohort studies. A statistically significant direct 
association between triceps skin fold thickness and the risk of PD has been found in 
the Honolulu Heart Program (Abbott et al. 2012), and both excess weight (Hu, et al. 
2006a) and T2DM itself (Hu et al. 2007) were associated with an increased risk of 
PD in a population- based prospective cohort of Finnish men and women. This 
association was independent of the known modifying factors such as smoking status, 
coffee and alcohol consumption and body weight, tempting speculation regarding 
common pathways underlying the development of these conditions. Nevertheless, a 
recent cohort study could not replicate an association between either T2DM or 
obesity and PD risk, although the authors acknowledge that diagnosis of T2DM was 
entirely based on self-report (Palacios et al. 2011). 
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1.4 INSULIN RESISTANCE AND MITOCHONDRIAL 
DYSFUNCTION 
The development of insulin resistance in humans is closely correlated with 
immune cell infiltration and inflammation, with clear links between the development 
of obesity, T2DM and cardiovascular disease (Hotamisligil 2006). Explicit links 
have also been established between exercise, obesity, insulin resistance and levels of 
IL-6 (Kern et al. 2001). Evidence for mitochondrial dysfunction in the development 
of insulin resistance has been obtained through measuring rates of in vivo 
mitochondrial phosphorylation using proton 1(H) magnetic resonance spectroscopy 
in the relatives of patients with T2DM, finding that rates of mitochondrial ATP 
production are reduced by 30% in the muscle of lean, pre-diabetic insulin resistant 
subjects (Petersen et al. 2004). In addition, there are many specific examples of 
insulin resistance occurring due to mitochondrial mutations; it has been estimated 
that approximately 1.5% of T2DM is attributable to the mitochondrial A3243G 
mutation (the cause of Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-
like episodes - MELAS (Gerbitz et al. 1995).  
The more widespread development of insulin resistance has also been 
proposed to be mediated through mitochondrial dysfunction (Stark & Roden 2007), 
at least to a partial extent through muscle expression of transcriptional regulators 
including the PPARγ receptor coactivator (PGC1α), an important regulator of 
enzymes involved in mitochondrial respiration. Expression of PGC1α is rapidly 
induced following even a single bout of exercise, then reverts to baseline after 
cessation of exercise to enable fine control of the energy demands of skeletal muscle 
(Handschin & Spiegelman 2008). Individuals that undergo regular exercise have 
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chronically elevated levels of PGC1α, in association with a switch in muscle fibre 
type characterized by increased mitochondrial density and function (Lin et al. 2002). 
Direct exploration of patterns of gene expression associated with insulin 
resistance has been studied in skeletal muscle in T2DM patients as well as non-
diabetic individuals with and without a family history of T2DM. The earliest sign of 
insulin resistance was shown to be reduction in expression of PGC1α and the 
mitochondrial gene – nuclear respiratory factor 1 (NRF1) (Patti et al. 2003). In a 
whole genome methylation analysis of skeletal muscle from T2DM and control 
subjects, hypermethylation of PGC1α was found in association with reduced PGC1α 
mRNA and reduced mitochondrial DNA levels in T2DM subjects, suggesting a 
potential mechanism underlying the gene-environment interaction in T2DM risk 
(Barrès et al. 2009). 
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1.5  PD AND MITOCHONDRIAL DYSFUNCTION  
Mitochondria are organelles present in all cells of the body (erythrocytes 
excluded), ranging from a few hundred to many thousands per cell, depending on 
cell type.  
Maternally inherited, they are the locus for many of the body's “housekeeping” 
functions, including the biosynthesis of amino acids and steroids and the beta-
oxidation of fatty acids; they also play a central role in apoptosis.  
However, the function that sets this organelle apart, and which is responsible 
for the cliché that mitochondria are the “powerhouses of the cell”, is the production 
of adenosine triphosphate (ATP) via the combined efforts of the tricarboxylic acid 
cycle and the respiratory chain/oxidative phosphorylation system (OxPhos). The 
respiratory chain is a set of biochemically linked multi-subunit complexes 
(complexes I, II, III, and IV) and two electron carriers (ubiquinone/coenzyme Q and 
cytochrome c). It uses the energy stored in carbohydrates to generate a proton 
gradient across the mitochondrial inner membrane, while at the same time 
transferring electrons to oxygen, producing water. The energy of the proton gradient 
drives ATP synthesis via ATP synthase (complex V), ATP is then distributed 
throughout the cell (Nelson & Cox 2013). 
The earliest link between PD and mitochondrial dysfunction followed the 
observation that individuals injected with heroin contaminated with MPTP (1-methyl 
4-phenyl 1,2,3,6-tetrahydropyridine) acutely developed parkinsonism (Langston et 
al. 1983). Both MPTP and another environmental toxin, rotenone, were subsequently 
shown to cause degeneration of dopaminergic neurons in animal models by selective 
inhibition of complex I (Gerlach et al. 1991)
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impairment may itself be sufficient to cause the disease. Complex I (NADH CoQ 
dehydrogenase) is the first enzyme of the mitochondrial respiratory chain, playing a 
crucial role in ATP generation. 
Complex I dysfunction decreases ATP production, generates free radicals and 
sensitizes cells to the pro-apoptotic protein Bax, leading to apoptosis (Perier et al. 
2005). A direct relation between mitochondrial dysfunction and sporadic PD has 
been demonstrated in post-mortem tissue, revealing complex I deficiency (Mann et 
al. 1994; Schapira et al. 1989) and damage (Keeney et al. 2006) in the substantia 
nigra of patients with PD. However it is likely that neurodegeneration provoked by 
Complex I pathology alone is rare.  
Complex I toxins may however contribute to pathogenesis of PD, acting in 
tandem with other environmental influences and genetic causes (Schapira 2010). 
Although rare, there are numerous reports of parkinsonism occurring in association 
with mitochondrial mutations, including the G11778A mutation (associated with 
Leber’s Hereditary Optic Neuropathy (Simon et al. 1999), polymerase γ mutations 
(Luoma et al. 2007), and more commonly in association with somatic mitochondrial 
deletions (Bender et al. 2006). A common mitochondrial haplotype has also been 
associated with sporadic PD (Pyle et al. 2005). 
Converging evidence suggests that both environmental and genetic factors can 
interfere with the physiological removal of damaged or dysfunctional mitochondria 
known as mitophagy. Healthy mitochondrial turnover through mitophagy and 
mitochondrial biogenesis, as well as ongoing processes of fission, fusion, and 
mitochondrial budding, are essential to maintain normal cellular bioenergetic 
function. This relies on intact mitochondrial DNA (mtDNA), which is particularly 
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vulnerable to damage by free radicals due to its lack of a histone coat and limited 
facilities for repair. Furthermore, mtDNA mutations, whether induced by oxidative 
stress, or ageing, have a further effect on complex I and respiratory chain function 
leading to increased damage, again through the production of reactive oxygen 
species (Cooper et al. 1992). Normal human substantia nigra and striatum exhibit the 
greatest free radical-mediated mitochondrial damage with age (Kraytsberg et al. 
2006). Other cellular pathways essential for normal mitochondrial turnover have 
been identified directly as a result of the identification of specific gene mutations 
causing Mendelian forms of PD (Schapira 2008). 
1.5.1  Parkin  
Parkin mutations have been found to cause juvenile parkinsonism. Intracellular 
localisation studies have reported the association of Parkin and mitochondria (Stichel 
et al. 2000). The function of Parkin is not completely clear but the protein has E3 
ligase activity, and is thought to monitor the quality of mitochondria, and trigger 
mitophagy of dysfunctional mitochondria (Rakovic et al. 2010) by triggering the 
ubiquitin-proteasome system (Chan et al. 2011). 
 Parkin knockout mice have demonstrated alterations in abundance and/or 
modification of a number of proteins involved in mitochondrial function or oxidative 
stress, with reductions in several subunits of complexes I and IV, and functional 
assays showing reductions in respiratory capacity of striatal mitochondria isolated 
from Parkin-/- mice. Furthermore, these mice show a delayed rate of weight gain, 
suggesting broader metabolic abnormalities (Palacino et al., 2004). Mitochondrial 
function has also been shown to be decreased (complex I and IV activities) in 
peripheral blood from patients with Parkin mutations (Muftuoglu et al. 2004). 
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1.5.2 PINK1 (PTEN-induced putative kinase 1)  
PINK1 (PTEN-induced putative kinase 1) mutations also cause autosomal 
recessive juvenile parkinsonism. The gene encoding PINK1 encodes a 63 kDa 
protein with an 8 kDa mitochondrial targeting sequence. In health, this protein is 
imported intact into the mitochondria, where it has been suggested that PINK 1 
recruits parkin from the cytoplasm to the mitochondria to initiate the process of 
mitophagy (Vives-Bauza & Przedborski 2011). 
1.5.3  DJ-1 
DJ-1 is a 23 kDa protein that is expressed in peripheral tissues and parts of the 
brain, including the hippocampus, cerebellum, olfactory bulb, striatum, SNc, and 
Substantia Nigra pars reticulate (SNr), both in cells bodies and dendrites, localized to 
the mitochondrial matrix and intermembrane space (Zhang et al. 2005). One 
candidate pathophysiological mechanism is that the deletion or silencing of DJ-1 
causes parkinsonism possibly by sensitising cells to oxidative stress, while over-
expression of DJ-1 protects cells implying a protective role for the protein (Yokota et 
al. 2003). Substantia nigra neurons from DJ-1 knockout mice have increased 
sensitivity to MPTP and oxidative stress (Kim et al. 2005), and cells derived from 
patients with DJ-1 mutations have abnormal mitochondrial morphology (Irrcher et 
al. 2010). DJ-1 has been shown to associate with the mitochondrial protein Bcl-XL, 
which has a role in down regulating apoptosis (Ren et al. 2011). 
1.5.4 Alpha-synuclein (SNCA)  
 Alpha synuclein is the main component of the neuropathological hallmark of 
PD, the Lewy Body (LB). Alpha synuclein mutations can cause autosomal dominant 
PD. The pathological features of PD, can be replicated by simply overexpressing 
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SNCA in transgenic flies (Feany & Bender 2000), suggesting that one mechanism by 
which neurodegeneration occurs is through a toxic “gain-of-function”. The exact 
function of alpha-synuclein remains unknown, and the relationship between SNCA 
oligomers and aggregates, their degradation by the ubiquitin-proteasome- and 
lysosomal systems, and neuronal toxicity requires further work (Wong & Cuervo 
2010). There are nevertheless indications that SNCA affects various mitochondrial 
pathways (Poon et al. 2005). SNCA co-localises with cytochrome C forming hetero-
oligomers which can prevent apoptosis, but in the process forms complexes with 
prolonged peroxidase activity that induces increased oxidative stress (Bayir et al. 
2009). It has been also shown that phosphorylated SNCA (the dominant form in PD) 
influences normal protein-protein interactions including the “pull down” of protein 
complexes involved in mitochondrial electron transport (McFarland et al., 2008). 
Over-expression of SNCA leads to the protein entering mitochondria and interfering 
with mitochondrial function (Devi et al. 2008; Chinta et al. 2010). 
1.5.5 Leucine rich repeat kinase (LRRK-2)  
Leucine rich repeat kinase (LRRK-2) mutations can also cause autosomal 
dominant PD. LRRK-2 has GTPase and kinase domains and study of its interaction 
with SNCA is ongoing (Greggio et al. 2011).Whether LRRK-2 plays a critical role in 
determining the phosphorylation status of SNCA remains to be determined, however 
it has recently been demonstrated that in the transgenic G2019S mutant LRRK-2 
mouse, there is age-dependent degeneration of dopamine nigrostriatal neurons 
together with damaged mitochondria and an increase in mitophagy (Ramonet et al. 
2011). 
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1.5.6 Glucocerebrosidase (GBA)  
GBA mutations cause Gaucher’s disease and have been identified as a risk 
factor for PD in both the homozygous and in the heterozygous state (E Sidransky et 
al. 2009). There has been shown to be a bidirectional link such that SNCA inhibits 
the lysosomal activity of GBA, and functional loss of GBA leads to accumulation of 
SNCA (Mazzulli et al. 2011), potentially explaining the risk of PD through a positive 
feedback loop. Other potential mechanisms also include lipid accumulation and 
impaired mitophagy or mitochondrial trafficking (Westbroek et al. 2011). 
Researchers from UCL have recently sequenced the GBA gene in a series of 
early-onset PD patients. It has been showed that the frequency of GBA mutations is 
much higher in this series of patients than in typical late-onset patient cohorts, and 
that the most prevalent Parkinson’s disease associated GBA mutation is E326K, a 
variant which does not, when homozygous, cause Gaucher’s disease (GD) (Duran et 
al. 2013). This observation, supported by the presence of many other rare GBA 
variants not associated with GD in the PD group, dissociates the pathogenesis of GD 
from that of PD. This association with PD may not be caused by build up of 
glucosylceramide and consequent lysosomal disruption but rather by some more 
subtle and distinct effect on lysosomal biology. 
In PD there is therefore ample evidence of mitochondrial dysfunction that 
includes complex I inhibition, oxidative stress, PINK1 and DJ1 dysfunction, and an 
interaction between Parkin and PINK1 that influences mitophagy & mitochondrial 
biogenesis. Complex I inhibition initiated by any of a range of environmental toxins 
can increase free radical generation, and thus initiate a vicious cycle of events that 
further impairs mitochondrial function, and may enhance any underlying genetic 
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defects and further impair neuronal activity. Neuro-inflammation leads to further 
mitochondrial stress through the production of reactive oxygen species as well as 
through the activation of microglia and subsequent release of pro-inflammatory 
cytokines such as Nitric Oxide (NO) and tumor necrosis factor α (TNFα) (Tansey et 
al. 2008; Whitton 2007). This can be readily detected through the identification of 
activated microglia on imaging (Gerhard et al. 2006) and neuropathology (McGeer et 
al. 1988). The role of a neuro-inflammatory process in PD is further supported by; 
(1) the association between the HLA locus and PD risk in a meta-analysis of genome 
wide studies (Nalls et al. 2011), and (2), the reported beneficial effects of anti-
inflammatory agents on risk of PD (Wahner et al. 2007). It is likely that multiple 
pathways remain relevant with inter-related and common aspects involving 
mitochondrial function. 
1.5.7 Converging evidence implicating PGC1α 
Converging evidence suggests that cellular pathways leading to either insulin 
resistance or neurodegeneration involve mitochondrial mechanisms. It is well known 
that mutations in mitochondrial DNA can lead to a wide variety of phenotypes that 
commonly involve neurodegeneration and diabetes (Finsterer et al. 2008; Hara et al. 
1994). 
 However, these mutations do not account for a significant proportion of cases 
of sporadic PD. The proteins of the mitochondrial respiratory chain are the product 
of a joint effort between the mitochondrial and nuclear genomes. Normal 
mitochondrial biogenesis, respiration, and metabolism of reactive oxygen species 
(ROS) requires intact expression of both nuclear and mitochondrial encoded 
genomes, now recognised as being regulated by the PPARγ receptor coactivator 
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(PGC1α) (Finck & Kelly, 2006; Lin et al. 2005; St-Pierre et al., 2006). It has 
previously been shown that PGC-1α has a powerful suppressive effect on ROS 
production, in parallel to its effects in elevating mitochondrial respiration. This 
occurs through the PGC1α-mediated expression of genes involved in ROS 
detoxification, as well as PGC1α expression, which is rapidly induced by these 
proteins following a single bout of endurance exercise in vivo (Handschin & 
Spiegelman, 2008). Insulin resistant patients show reduced expression of PGC1α and 
the mitochondrial encoded gene COX1 (Heilbronn et al. 2007) while reduction in 
PGC1α-responsive genes has been shown among patients with T2DM and their 
asymptomatic relatives compared with healthy controls (Petersen et al. 2004). Indeed 
polymorphisms in PGC1α have been associated with an increased risk for T2DM in 
diverse populations (Bhat et al., 2007; Ek et al., 2001; Hara et al., 2002). 
PGC1α has also been implicated in having a major role in PD pathogenesis. 
Meta-analysis of gene expression data using microarrays has utilized post-mortem 
brain homogenates examining gene expression in the SNc of patients with confirmed 
SNCA positive Lewy body PD. Robust three tiered analysis from separate genome 
wide datasets have indicated that “gene sets” involved in mitochondrial electron 
transport, mitochondrial biogenesis, glucose utilization and glucose sensing were 
strongly associated with PD. Included amongst these gene sets were 10 PGC1α 
responsive genes. Furthermore, it was shown that over-expression of PGC1α was 
able to protect dopamine cell loss induced by the mitochondrial toxin rotenone 
(Zheng et al., 2010). 
In parallel with these discoveries was the identification of a zinc finger protein, 
Parkin interacting substrate (PARIS), which is upregulated threefold in the nigra of 
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patients with both Parkin- related parkinsonism and sporadic PD, and is both 
necessary and sufficient for neurodegeneration associated in Parkin animal models 
(Shin et al., 2011). The same group further identified that PARIS suppresses the 
expression of PGC1α and PGC1α target genes, playing an important role in 
mitochondrial function including Nuclear Respiratory Factor 1 (NRF1), and the 
oxidative phosphorylation regulators ATP5b.The site of interaction between PARIS 
and PGC1α is a sequence that is involved in the regulation of transcripts involved in 
insulin responsiveness and energy metabolism (Mounier & Posner, 2006). Although 
other pathways are undoubtedly also relevant, it is clear that parkin, PARIS, PGC1α 
and NRF-1 contribute to the pathogenesis of PD. Loss of expression of PGC-1α 
controlled genes may therefore be a key link between abnormal mitochondrial 
function, abnormal glucose utilization and PD. Further hypermethylation of PGC1α 
during life may follow either genetic or environmental influences that promote 
accumulation of free fatty acids, TNFα and ceramides, (Staiger et al., 2006; 
Summers & Nelson, 2005), which might then lead to dysregulation of mitochondrial 
bioenergetics and the onset of PD. (See Figure 1) 
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Figure, 1, Schematic, overview, of, emerging, pathways, linking, insulin,
resistance,and,neurodegeneration.,,
,
FFAs=,free,fatty,acids;,HLA=,human,leucocyte,antigen;,ILC6=,interleukin,6;,
LRRKC2=, leucine, rich, repeat, kinase, 2;, NO=nitric, oxide;, PGC1α=, PPARɣ,
receptor, coactivator;, ROS=, reactive, oxygen, species;, UPS=, ubiquitin,
proteasome,system;,SNCA=,α,synuclein.,,
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1.5.8 Calcium conductance 
Nigral neurons rely on calcium channels to drive their rhythmic pacemaking 
activity. Comparison of the two subpopulations of dopaminergic neurons from the 
ventral midbrain that are affected differentially inPD, namely, those in the SNc 
(severely affected) and those in the ventral tegmental area (VTA) (mildly affected) 
(Dauer & Przedborski 2003), reveals a compelling difference between these two 
groups of neurons. L-type calcium channel recruitment during normal autonomous 
pacemaking is associated with a high reactive oxygen species (ROS) signal in 
dopaminergic neurons of the SNc, but not in those of the VTA (Guzman et al. 2010). 
Based on recent findings, an intriguing hypothesis has emerged that suggests that the 
singular calcium-dependent pacemaking of nigral neurons is associated with 
increased mitochondrial ROS (Guzman et al. 2010). 
1.5.9 Mitophagy 
It is the current belief that PD pathogenesis might be linked to a defect in 
mitochondrial-control mechanisms. Defects in mitochondrial respiration had 
previously been proposed to contribute to the occurrence of many of the most 
common neurodegenerative disorders (Lodi et al. 2000). However, the discovery of 
genes mutated in hereditary forms of these enigmatic diseases has additionally 
suggested defects in mitochondrial dynamics (morphology and function i.e., 
organellar shape, size, distribution, movement, and anchorage). Such disturbances 
can lead to changes in mitochondrial quality control, mitochondrial trafficking, and 
inter-organellar communication. Mitochondria fuse and divide, fragment, swell and 
extend, and exist in clusters and as individual entities. Importantly, they travel within 
the cell. When static, they periodically anchor themselves on other organelles, such 
as the ER, endocytic vesicles, and the plasma membrane. In summary, mitochondria 
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are dynamic organelles that move from the cell body to regions of the cell to deliver 
ATP and other metabolites where they are most required. This process is seen most 
strikingly in highly elongated cells such as neurons; mitochondria are concentrated at 
presynaptic terminals at the ends of axons, and at postsynaptic terminals at the ends 
of dendrites, where bioenergetic demand is particularly high. When mitochondria 
reach the end of their life they are ultimately disposed of (and their component parts 
recycled) via autophagy (“mitophagy”), or via extrusion of “mitochondria-derived 
vesicles” (Braschi & McBride 2010). It is fully understandable that the inability of 
mitochondria to execute these functions would be expected to disrupt cellular 
physiology and viability. Consequently, the degree of impairment likely corresponds 
to that cell's requirements for well-functioning mitochondria positioned in the right 
place at the right time. PD mutations in either Parkin or PINK1 appear to impair the 
normal turnover of damaged mitochondria (Vives-Bauza et al. 2010). In short, it is 
the current belief that a loss of function of Parkin or PINK1 might prevent damaged 
mitochondria from being eliminated, leading to neuronal dysfunction and neuronal 
death. Thus, it is the current belief that defects in mitochondrial dynamics might play 
a pivotal role in the pathogenesis of neurodegenerative disorders. 
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1.6 THE GLUCAGON SUPERFAMILY OF PEPTIDE 
HORMONES. THE INCRETIN SYSTEM 
The glucagon-like peptides include glucagon, GLP-1, and GLP-2, and exert 
diverse actions on nutrient intake, gastrointestinal motility, islet hormone secretion, 
cell proliferation and apoptosis, nutrient absorption, and nutrient assimilation. 
Normal regulation of insulin secretion and function is driven by the detection of 
glucose in the blood. Pancreatic beta cells detect the increase in blood glucose and 
secrete insulin in an attempt to regulate glucose levels by facilitating the transport of 
glucose into cells for cellular metabolic use. An alternative form of insulin regulation 
originates from gastrointestinal tract cells. Gut hormones facilitate the disposal of 
absorbed glucose through the stimulation of insulin secretion from the endocrine 
pancreas (Drucker & Nauck 2006). The incretin response accounts for approximately 
70% of the total insulin secreted following the administration of oral glucose 
(Baggio & Drucker 2007). 
Oral glucose administration enhances insulin secretion to a greater extent than 
that seen with isoglycemic intravenous (IV) loading (also known as the “incretin” 
effect), leading to the discovery of both glucagon-like peptide-1 (GLP-1) and gastric 
inhibitory peptide (also known as glucose dependent insulinotropic peptide- GIP), as 
incretin hormones (Elrick et al. 1964). The incretin peptides: GIP and glucagon-like 
peptide-1 (GLP-1), integrate nutrient-derived signals to control food intake, energy 
absorption, and assimilation (Baggio & Drucker 2007; Holst et al. 2009; Nauck 
2009).  
Both peptides share common actions on islet beta-cells acting through 
structurally distinct yet related receptors. Therefore, incretin-receptor activation 
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leads to glucose-dependent insulin secretion, induction of beta-cell proliferation, and 
enhanced resistance to apoptosis in pancreatic cells (Drucker & Nauck 2006; Baggio 
& Drucker 2006; Lovshin & Drucker 2009). Both GLP-1 and GIP slow gut 
emptying and modulate postprandrial glucose disposal through glucose dependent 
inhibition of glucagon secretion (GLP-1) (Nauck et al. 2002; Holst et al. 2009), 
delayed gastric emptying (GLP-1) (Nauck et al. 1997), and potentially also through 
increased peripheral insulin sensitivity (GLP-1 and GIP) (Baggio & Drucker 2007). 
A key enzymatic regulator of these hormones is dipeptidyl peptidase-4, which 
rapidly inactivates/degrades the incretin hormones (Nauck, 2009).  
Most GLP-1 is made in enteroendocrine L cells in the distal ileum and colon. 
Plasma levels of GLP-1, like GIP, increase within minutes of eating. The major 
physiological stimulus for GLP-1 and GLP-2 secretion is ingestion of a meal. 
 Despite the predominant localization of the L cell in the distal ileum and colon 
(Eissele et al. 1992), intake of either glucose or fat increases release of GLP-1 and 
GLP-2 within 15–30 min, with a second peak of secretion occurring at 90–120 min 
after a meal (Eissele et al. 1992). Hence a combination of endocrine and neural 
signals probably promotes the rapid stimulation of GLP-1 secretion before digested 
food can directly stimulate the Lcells in the small bowel and colon. (Drucker & 
Nauck 2006). A large number of studies in rodents have now demonstrated that 
placement of either glucose or fat directly into the upper gastrointestinal (GI) tract 
stimulates prompt rises in GLP release (Roberge & Brubaker 1993). Nutrient intake 
is also associated with release of two peripheral hormones with key roles in nutrient 
homeostasis; insulin and leptin. Interestingly, both of these hormones stimulate 
GLP-1 release upon activation of their respective receptors on the L cell (Anini & 
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Brubaker 2003). Consistent with these findings, leptin resistance has been 
demonstrated to decrease the effects of leptin on GLP-1 release (Anini & Brubaker 
2003), and may therefore contribute to the reduced levels of GLP-1 that have been 
observed in obese individuals (Ranganath et al. 1996). Similarly, GLP-1 levels have 
been reported to be low in patients with insulin resistance or T2DM, independent of 
both obesity (Rask et al. 2001; Vilsbøll et al. 2001) and clearance rates (Vilsbøll et 
al. 2003).  
The additional actions of GLP-1 appear to be largely beneficial to metabolic 
control; most notably inhibition of glucagon release, gastric emptying, 
gastrointestinal fat absorption, and appetite reduction (Holst et al. 2009; Nauck 
2009).  
Moreover, GLP-1 reduces glycaemia and haemoglobin A1c (HbA1c) levels in 
patients with T2DM, and the GLP-1 mimetics also reduce body weight (Näslund et 
al. 1999; Rodriquez de Fonseca et al. 2000). The glucagon-like peptides exert a wide 
array of biological actions including; (1) enhancement of digestion and absorption in 
the gastrointestinal (GI) tract, (2) facilitation of insulin secretion and nutrient 
disposal, and (3) promotion of growth of the intestinal epithelium and beta cells in 
the endocrine pancreas. These effects culminate in a positive energy balance.  
The actions of these peptides are mediated by distinct members of the 
glucagon receptor superfamily of G protein-coupled receptors (GPCRs). These 
receptors exhibit unique patterns of tissue-specific expression, exhibit considerable 
amino acid sequence identity, and share similar structural and functional properties 
with respect to ligand binding and signal transduction (Brubaker & Drucker, 2002).  
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GLP-1 receptor (GLP-1R) belongs to the class B family of seven-trans-
membrane spanning, heterotrimic GPCRs. The GLP-1R activation, causes activation 
of adenylylcyclase, leading to increased intracellular cAMP levels (Liu et al. 2011). 
Particularly exciting due to its potential implications to future therapeutic 
approaches, is the expression of GLP-1R in pancreatic α and β cells, heart, pituitary, 
kidney, lung, skin, ganglion of the vagus nerve, the central and peripheral nervous 
systems and gastrointestinal tract (Drucker & Nauck 2006; Baggio & Drucker 2007).  
1.6.1  Exendin-4/Exenatide (GLP-1R agonist) 
Exenatide is a synthetic form of Exendin-4 and is an agonist for the GLP-1 
receptor. It has a circulating half-life of 60-90 minutes (Kolterman et al. 2005) with 
increases in plasma Exenatide concentrations lasting 4-6 hours after a single 
subcutaneous injection (Nielsen & Baron 2003). 
1.6.1.1 The Discovery of Exendin 
The glucagon superfamily consists of a diverse group of biologically active 
peptides that are structurally related, having an amino-terminal histidine residue 
(His1) and a phenylalanine residue at position 6 (Phe6), or one of several variant 
structures such as Tyr1-Phe6, His1-Tyr6, or His1-Leu5. An amino-terminal histidyl 
structure (His1) is characteristic of most peptides in the glucagon superfamily. In 
1990, an assay for amino-terminal amino acid sequencing for His1 peptides was used 
as a chemical marker for biologically active peptides to screen venom from the Gila 
monster lizard, Heloderma horridum (Eng et al. 1990). Gila monster venom was 
chosen for screening because venoms from exocrine secretions of Heloderma lizards 
had been shown previously to contain two biologically active His1-Phe6 peptides, 
Helospectin (Exendin-1) and Helodermin (Exendin-2). A new His1 peptide was 
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identified and named exendin-3 to indicate that it is the third peptide to be found in 
an exocrine secretion of Heloderma lizards. It has endocrine activity, acting as a 
pancreatic secretagogue ( Eng et al. 1990; Vandermeers et al. 1987). 
An amino acid sequencing assay for peptides containing an amino-terminal 
histidine residue (His1) was used to isolate a 39-amino acid peptide, exendin-4, from 
Heloderma suspectum venom in 1992. Exendin-4 differs from exendin-3 by two 
amino acid substitutions, Gly2-Glu3 in place of Ser2-Asp3, at positions 2 and 3 from 
the amino terminus, but is otherwise identical (Eng, et al. 1992). Therefore both 
exendin-3 and exendin-4 are 39 amino acid peptides containing an amino-terminal 
histidine and a carboxyl-terminal serine amide, and are members of the glucagon 
superfamily of peptide hormones. In dispersed pancreatic acini, exendin-4 interacts 
only with the exendin receptor. The intrinsic biological activity of exendin-3 and 
exendin-4, in terms of increasing acinar cAMP, resides in the amino-terminal portion 
of the molecule. The amino acid sequence of exendin-3 and exendin-4 required for 
binding to exendin receptors resides in the middle and carboxyl-terminal portions of 
the molecule (Eng et al, 1992) 
Table,1.,Amino,acid,sequence,of,ExendinC4,and,its,comparison,with,peptide,
sequences,of,other,members,of,the,glucagon,superfamily,
 
1.6.1.2 Exenatide and D.M 
The appreciation that the incretin response is defective in T2DM (Nauck et al. 
1986) led to the development of incretin-based therapies. GLP-1 is a naturally 
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occurring hormone that has an important role in insulin and glucose homeostasis but 
has a circulating half-life of only 1-2 minutes. Exenatide has confirmed beneficial 
effects on glucose control, thought to be mediated by β cell proliferation, glucose-
dependent insulin production, decreased gluconeogenesis, and weight loss that 
follows chronic GLP-1 receptor stimulation in the GI tract. GLP-1 also stimulates 
the differentiation of ductal precursor cells into functional pancreatic beta cells. 
(Buse et al., 2004; DeFronzo et al., 2005; Drucker et al., 2008; Kendall et al., 2005).  
Clinical studies utilizing the administration of Ex-4 in T2DM patients have 
found that patients experience decreases in caloric/food intake, hunger and body 
weight (Drucker & Nauck 2006; Lovshin & Drucker 2009; Vilsbøll et al. 2012). In 
addition, subjects had increased feelings of satiety/fullness and an increased resting 
metabolic rate (Bradley et al. 2010).  
The starting dose of Exenatide is 5µgr twice daily for 4 weeks, followed by an 
increase to 10 µgr twice daily (Fineman et al. 2004). The most common adverse 
events with Exenatide in T2DM patients are gastrointestinal (nausea, vomitting and 
diarrhoea) (Buse et al. 2004; Kendall et al. 2005). In spite of gastrointestinal adverse 
effects, Exenatide is rarely discontinued because of them, and side effects subside 
with prolonged therapy (Buse et al. 2004; Kendall et al. 2005). GLP-1 receptors are 
also distributed throughout the brain, and stimulation of central receptors in the 
hypothalamus is responsible for early satiety. Exenatide was approved by the US 
Food and Drug Administration for the treatment of T2DM in April 2005, and it 
gained its indication as primary monotherapy approved by the FDA in October 2009.  
(http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=
Search.DrugDetails)  
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The consensus algorithm for initiation and adjustment of therapy from the 
American Diabetes Association and European Association for the Study of Diabetes 
classifies the GLP-1agonist in “tier 2” category (less well-validated therapist) in 
2009 (Nathan et al. 2009). Taking into account that long-term data regarding safety 
are lacking for incretin-based therapies, they suggest that GLP-1 agonists should be 
considered when weight gain or hypoglycaemia are particular concerns. The NICE 
guidelines suggest that Exenatide should be added as a third line therapy to first line 
metformin and a second-line sulfonylurea when control of blood glucose remains 
inadequate (HbA1C ≥ 7.5%) and a body mass index ≥ 35.0 Kg/m2 or ≤ 35.0 kg/m2 
and therapy with insulin would have occupational implications.  
(http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf).  
A longer-lasting form of Exenatide (marketed as Bydureon) received Food and 
Drug Administration approval in January 2012. 
1.6.1.3  Exendin-4 and neuronal cell model systems 
The presence of GLP-1R in the brain suggests a possible role in the regulation 
of neuronal activity. A growing body of evidence now exists to support 
neuroprotective functions of GLP-1R stimulation. The fact that GLP-1R are located 
on neurons; pyramidal neurons in the hippocampus and neocortex, on dendrites and 
cell bodies suggests a likely role in neuronal activity and synaptic transmission 
(During et al. 2003; Alvarez et al. 1996; Calvo et al. 1995; Campos et al. 1994;  
Larsen et al. 1997; Hamilton & Hölscher 2009).  
Particularly exciting is the realisation that similarities exist between cellular 
responses to incretins in pancreatic beta cells and neurons. The activation of GLP-1R 
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in neurons can produce cellular protection, proliferation and differentiation of 
precursor cells into neurons. 
It is worth noting the promotion of cell proliferation in the dentate gyrus of the 
hippocampal formation of adult rodents after chronic in vivo treatment with Exendin-
4, indicated by an increase in the marker of immature neuronal tissue, reflected on an 
increased BrdU and doublecortin (DCX) staining. Moreover, the proliferative 
properties of Exendin-4 in adult brain were supported by the elevation of the levels 
of gene transcripts for Ki-67 (Isacson et al. 2011). Furthermore, higher levels of 
proliferation (based upon Ki-67 staining) after long-term administration (21 days) of 
Ex-4 in vivo have been reported in the subgranular zone of adult mouse dentate gyrus 
(Li et al. 2009). Additionally, in mouse models of diabetes, chronic treatment with 
GLP-1 analogues for 4–10 weeks significantly increased the number of progenitor 
cells or DCX-positive young neurons in the dentate gyrus, as measured by BrdU or 
DCX immunohistostaining. This action was confirmed to be due to GLP-1R 
activation as GLP-1 receptor antagonist exendin (9–36) reduced progenitor cell 
proliferation in these mice (Hamilton et al. 2011). 
PC12 cell lines (cells derived from a form of tumour located in the rat adrenal 
tissues), treated with GLP-1 did not show any significant levels of proliferation 
(Perry 2002b). However, the human neuroblastoma cell line, SH-SY5Y cells, treated 
with physiologically relevant doses of either GLP-1 or Exendin-4, showed evidence 
of proliferation (Li, Y et al. 2010) 
In a rat striatal embryonic cell line (ST14A cells) in a primary rodent culture 
system, GLP-1R activation (Ex-4 and GLP-1) significantly increased mouse neural 
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stem cell numbers in vitro, as indicated by BrdU incorporation and ATP level 
measurements (Bertilsson et al. 2008) 
1.6.1.4 Exendin-4 and neuronal cell differentiation 
GLP-1R activators can induce the differentiation of neural stem cells into 
neurons. Immunohistochemistry studies in adult mice treated with Exendin-4 
showed a 1.7-fold increase in DCX-positive cells in the medial striatum, and doubled 
the number of BrdU-positive cells in the subventricular zone, a known pool of 
neuronal stem cells (Bertilsson et al. 2008). The administration of Ex-4 for 2 weeks 
to adult rodent induced an elevation of markers of neurogenesis, e.g. DCX and 
Mash-1 gene transcripts, in the hippocampus (Isacson et al. 2011). In addition, 
chronic treatment of Exendin-4 has been proven to increase cell proliferation and 
neuroblast differentiation in the adult mouse hippocampal dentate gyrus, as mice 
treated with Exendin-4 showed a significant higher number of Ki-67, DXC and 5-
bromo-2-deoxyuridine (BrdU) immunoreacive cells than the control group (Li H, 
2010).  
1.6.1.5  Exendin-4 and production of neurite outgrowth 
Exendin-4 has been shown to increase the numbers of neurite-bearing cells in 
both human SH-SY5Y, and in PC12 cell models of neuronal differentiation (Luciani 
et al. 2010). In addition, GLP-1 and Exendin-4 induced neurite outgrowth in a 
manner similar to nerve growth factor (NGF), which was reversed by coincubation 
with the selective GLP-1 receptor antagonist Exendin (9-39). Furthermore, exendin-
4 could promote NGF-initiated differentiation and may rescue degenerating cells 
after NGF-mediated withdrawal (Perry et al. 2002b).  
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1.6.1.6  Exendin-4 and synaptic plasticity 
GLP-1 receptor stimulation has been shown to promote (long-term potentiation 
(LTP). LTP is defined as a long lasting enhancement in signal transmission between 
two neurons, considered as the cellular correlate of memory formation. Reference 
memory has been improved in rodents treated with Ex-4 when compared with 
controls using a radial maze paradigm (Isacson et al. 2011). Moreover, rats 
overexpressing GLP-1R in the hippocampus showed improved learning and memory 
with an improved fear learning performance on the Morris Water Maze (During et al. 
2003). 
1.6.1.7 Exendin and mitochondria 
More recently, Exendin-4 has been shown to protect beta islet cells from 
apoptosis, to prevent damage to mitochondrial DNA encoded genes and to stimulate 
mitochondrial biogenesis (Fan et al, 2010). Fan and colleagues worked with clonal 
insulinoma (INS-1E) cells using transcriptional and translational assays to evaluate 
cell viability and cell mass as well as western blot to detect protein expression. The 
authors also used transfection of constitutively active protein kinase B (PKB/AKT) 
to examine the role of AKT, and quantification of mitochondrial biogenesis using 
mitogreen staining and RT-PCR. 
To prove the potential protective action of Exendin-4 on beta cells apoptosis, 
the authors used human islet amyloid polypeptide (hIAPP), the major component of 
amyloid, which is 37-amino acid protein co-secreted with insulin by beta cells 
(Cooper et al. 1987). hIAPP spontaneously forms oligomers and causes beta-cell 
death, besides when beta cells are incubated with hIAPP, cell proliferation is 
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inhibited and apoptosis is induced. When given Exendin-4 to the INS-1Ecells, these 
cells were protected of the cell apoptosis induced by hIAPP-mediated AKT 
inhibition. Furthermore the mitogreen staining and RT-PCR revealed enhanced 
mitochondrial biogenesis.  
The signalling pathways activated by GLP-1 in the beta cells are complex, and 
PKB/AKT is one of the key kinases involved (Wang et al. 2004; Li , L et al. 2005). 
With this interesting work, the authors proved AKT involvement in 
downstream signalling pathways of GLP-1, proposing that the protective effects of 
Exendin-4 on beta cells could be facilitated somewhat by setback of impaired AKT 
activity and mitochondrial pathways. 
1.6.1.8  Exendin-4 and animals models of neurodegeneration 
GLP-1R stimulation has proven beneficial in neurotoxin-derived models of PD 
in terms of dopamine cell survival, cell functionality, and the resolution of abnormal 
behaviour. The use of GLP-1R agonists has been shown to protect animals against 
MPTP. The MPTP toxic insult was reversed by Exendin-4, which diminished the 
level of inflammation and increased the number of viable dopaminergic neurons 
(Kim et al. 2009; Li et al 2009). Exendin-4 induced elevation of endogenous TH 
levels (key enzyme for the production of dopamine, that converts tyrosine into L-
DOPA, precursor of dopamine) in primary dopaminergic neurons (Li et al. 2009). 
Exendin-4 significantly elevates TH levels in catecholamine neurons in the area 
postrema, likely mediated by Exendin-4 induction of TH gene expression through 
the TH promoter (Yamamoto et al. 2003).  
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The 6 hydroxydopamine (6-OHDA) and Lipopolysaccharide (LPS) toxic insult 
was similarly reversed in rats treated with Exendin-4. In these rodents the 
apomorphine circling behaviour was alleviated by Exendin-4 in a dose-dependent 
manner (Harkavyi et al. 2008)  
In pyridoxine (vitamin-B6) over-treated rats, which develop a form of 
peripheral neuropathy induced by over-consumption of vitamin B6, Exendin-4 has 
been found to improve functional and behavioural deficits in addition to 
morphological normalization of the sciatic nerve and dorsal root ganglia (Perry et al. 
2007). 
In the toxic model of Huntington Disease (HD), N171-82Q induced an 
improvement of abnormal blood sugar levels and reduced quantities of mutant 
huntingtin protein accumulations in pancreas and brain. Exendin-4-treated animals 
had lower motor function deficits and 18% higher animal survival time compared 
with control N171-82Q mouse life span (Martin et al. 2009). 
Based on the fact that motor neurons express the GLP-1R, a recent study has 
focused on the potential benefits of GLP-1R activation in cellular and mouse models 
of Amyotrophic Lateral Sclerosis (ALS) (Li, Y et al. 2012). These actions largely 
translated to Superoxide dismutase-1 (SOD-1) (G93A) mice, in which subcutaneous 
(s.c). Exendin-4 mitigated the dysregulation of glucose evident in animals. 
 Exendin-4 was also neuroprotective at the level of the spinal cord, preserving 
neuron density and spinal cord structure with a clear decrease in loss of cholinergic 
markers and apoptosis (Li, Y et al. 2012).  
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Exendin-4 can protect neurons against metabolic and oxidative insults. It has 
been shown that administration of Exendin-4 reduced brain damage and improved 
functional outcomes in a transient middle cerebral artery occlusion stroke model (Li 
,Y et al. 2009).  
GLP-1R mRNA expression was detected in cultured embryonic primary 
cerebral cortical neurons, which are vulnerable to hypoxia. Interestingly it was found 
that GLP-1 and EX-4 conferred protection in these cells, but not in cells from GLP-
1R knockout mice (Li, Y et al, 2009). Further effects from central GLP-1 stimulation 
are as yet unclear, but neurotrophic and neuroprotective properties have been 
identified in vitro (Perry et al. 2002a). Exenatide has been evaluated as a 
neuroprotective agent in multiple animal models of PD (Bertilsson et al., 2008; 
Harkavyi et al., 2008; Kim et al., 2009; Li et al., 2009), demonstrating consistent 
benefits. Its mechanism of action however remains unknown and could be due to 
anti-inflammatory effects (Harkavyi et al., 2008; Kim Chung le et al., 2009; S. Kim 
et al., 2009), or related to stimulation of neurogenesis (Belsham et al., 2009; 
Bertilsson et al., 2008; Li, Y et al. 2010). (For further description see section 
1.6.1.9.4.2.Mechanism of action in neurodegenerative animal models). 
1.6.1.9  Pharmacokinetic properties 
1.6.1.9.1 Absorption 
Following subcutaneous administration to patients with T2DM, at 0.02, 0.05, 
and 0.1 µgr/Kg Exenatide doses, Exenatide was detectable in plasma as early as 10-
15 minutes post dose, demonstrating its rapid absorption after s.c. injection. The 
corresponding geometric mean AUC 0-5hr values were 9.364, 23.224, and 1.387 
pg*min/mL, respectively, and the corresponding geometric mean Cmax values were 
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45.109 and 187 pg/mL, respectively. Exenatide reaches peak plasma concentrations 
in 2 hours. Exenatide exposure increased proportionally over the therapeutic dose 
range of 5 µg to 10 µg. Similar exposure is achieved with subcutaneous 
administration of Exenatide in the abdomen, thigh or arm. (Kolterman et al., 2005) 
1.6.1.9.2 Metabolism and Elimination  
Non-clinical studies have shown that Exenatide is predominantly eliminated by 
glomerular filtration, with subsequent proteolytic degradation (Copley et al. 2006). 
However, receptor mediated endocytosis and degradation may be responsible for the 
nonrenal clearance (Gao & Jusko 2012). Exenatide’s elimination half-life ranged 
from 3.3 to 4.0 hours (Yoo et al. 2006). These pharmacokinetic characteristics of 
Exenatide are independent of the dose (Kolterman et al., 2005). 
1.6.1.9.3  Exenatide and Blood Brain Barrier (BBB) 
Up to date, using high-performance liquid chromatography Exendin-4 has been 
proved to cross the blood brain barrier in the mouse. Its high lipophilicity helps it to 
cross the BBB directly at a fast rate (Kastin & Akerstrom 2003). However, no data in 
humans are available so far.  
An interesting approach is the one performed using a recombinant GLP-1-
human serum albumin fusion protein (Albugon) in a combination of cell line studies 
in vitro and both wild –type and GLP-1R-/- (Baggio et al. 2004). Remarkably is the 
fact that GLP-1-albumin protein should exhibit a much more prolonged circulating 
t1/2, given the long circulating t1/2 of albumin linked drugs. This approach was taken 
into consideration when looking for strategies which allow an extension in the 
circulating t1/2 of GLP-1. Albugon was proven to activate GLP-1receptor-dependent 
cAMP formation, decreasing glycaemic excursion and stimulate insulin secretion in 
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wild type but not in the GLP-1R-/- mice, as well as decreasing food intake after 
intracerebroventricular and intraperitoneal administration. What it is really 
outstanding is that after intraperitoneal injection of Albugon, there was an inhibition 
of gastric emptying and more importantly an activation of c-FOS expression in the 
area postrema, the nucleus of the solitary tract, the central nucleus of the amygdala, 
the parabrachial, and the paraventricular nuclei. Therefore this approach constituted 
a good approach to determine the relative importance of peripheral versus central 
GLP-1R networks for control of satiety and gut motility, supporting a model in 
which peripheral activation of GLP-1R-dependent vagal afferents is capable of 
activating CNS centres, consequently transducing the effects of GLP-1 in the brain 
(Wettergren et al. 1998; Imeryüz et al. 1997). 
1.6.1.9.4 Pharmacodynamic properties 
1.6.1.9.4.1 Mechanism of action in diabetic patients  
See section 1.6.1.2  
1.6.1.9.4.2  Mechanism of action in neurodegenerative animal models 
1.6.1.9.4.2.1   Anti-inflammatory 
In MPTP mouse models of PD, peripheral administration of Exendin- 4 boosts 
the survival of dopaminergic neurons by deactivating microglia, attenuating 
nigrostriatal dopaminergic neuron loss. It has been shown to inhibit microglial 
activation and to release microglia-derived pro-inflammatory mediators. The 
systemic administration of Exendin-4 significantly attenuates the loss of SNc 
neurons and the striatal dopaminergic fibres, as it has been seen in mice injected with 
exendin-4 thirty minutes prior to MPTP lesion. These mice preserved the number of 
TH cells and TH fibre density (Kim et al. 2009). Here in UCL, Exendin-4 has been 
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investigated in 2 separate animal PD models, LPS & 6OHDA, showing attenuation 
in the Apomorphine-induced circling behaviour, and higher TH activity in brain 
homogenates, suggesting protection against loss of TH+ cell (Harkavyi et al. 2008). 
Exendin-4 also appears to have neurotrophic properties in vitro: incubation with 
Exendin-4 with PC12 cells promotes neurite outgrowth in a similar manner to NGF, 
and may rescue degenerating cells after NGF withdrawal (Perry et al 2002b). It was 
also shown to protect hippocampal cells against glutamate-induced apoptosis, and 
protect against cholinergic cell degeneration in the rodent model using ibotenic acid 
injection into the basal forebrain cholinergic neurons (Perry et al. 2002a). Exendin-4 
prevents MPTP-induced microglial activation in the SNc and striatum, and the 
expression of matrix metalloproteinase-3 (MMP-3). In addition, exendin-4 also 
suppressed MPTP-induced expression of pro-inflammatory molecules as TNFα and 
interleukin-1b (IL-1b) (Brouckaert et al. 2009; Li, Y et al. 2009). MPTP remarkably 
increases the number of activated microglia in both the SNc and striatum 24h after 
the injection. MMP-3, laminin and α-synuclein, released from damaged 
dopaminergic neurons, activate microglia to produce pro-inflammatory and 
neurotoxic molecules, resulting in neuronal death. This microglia-mediated self-
perpetuating cycle of the neurotoxic activation of microglia in response to neuronal 
injury is one of the principal processes that drives progressive dopaminergic 
neurodegeneration (Liu et al. 2006). GLP-1 could inhibit LPS-induced IL-1b mRNA 
expression and IL-1g production in rat astrocytes (Iwai et al. 2006). Exendin-4 may 
function as a survival factor for dopaminergic neurons by preventing the 
morphological abnormalities induced by MPTP neurotoxicity.  
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1.6.1.9.4.2.2 Neurorestorative 
 Exendin-4 is able to promote adult neurogenesis in vitro and in vivo, 
normalize dopamine imbalance, and increase the number of cells positive for 
markers of dopaminergic neurons in the substantia nigra in a 6OHDA model of PD 
(Bertilsson et al. 2008). When Exendin-4 was given intraperitoneally to naıve 
rodents together with bromodeoxyuridine, a marker for DNA synthesis, both the 
number of bromodeoxyuridine-positive cells and the number of neuronal precursor 
cells expressing doublecortin were increased (Bertilsson et al. 2008). In the adult 
mammalian brain, new neurons and glial cells are continuously generated from a 
proliferating population of neural progenitor/stem cells (NSC) that become 
incorporated into the existing brain by a process, known as adult neurogenesis 
(Emsley et al. 2004). This process occurs mainly in the subventricular zone 
(SVZ)/olfactory bulb and hippocampal dentate gyrus (Palmer et al. 1995; Emsley et 
al. 2005). The existence of active, functional adult neurogenesis raises the possibility 
that pharmacological stimulation of endogenous neural stem/progenitor cells could 
lead to cell regeneration that may be beneficial in central nervous system disorders 
where cell loss occurs, e.g., Parkinson’s disease (PD) (Emsley et al. 2005; Taupin 
2005).  
Exendin-4 was tested in the 6OHDA model of PD to investigate its possible 
functional effects in an animal model with neuronal loss. After unilateral lesion and a 
5-week stabilization period, the rats were treated for 3 weeks with Exendin-4. 
Animals receiving Exendin-4 showed a reduction of amphetamine-induced rotations, 
that persisted for several weeks after drug administration had been terminated. 
Histological analysis showed that Exendin-4 significantly increased the number of 
both tyrosine hydroxylase (TH) and vesicular monoamine transporter 2 (VMAT-2) -
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positive neurons in the substantia nigra. The improvement continued throughout the 
Exendin-4 treatment period and, remarkably, persisted for another 5 weeks in the 
absence of the treatment. Thus, this seems likely to be a plastic, rather than a 
transitory effect, and suggests that Exendin-4 is indeed triggering a stable change in 
the brain by improving the course of the pathology rather than just exerting a 
symptomatic and acute effect. The increase in the number of neurons positive for 
two DA markers, TH and VMAT2, reinforces the hypothesis that Exendin-4 is 
acting as a disease-modifying molecule (Bertilsson et al. 2008). 
1.6.1.9.5  Possible expected serious adverse events 
1.6.1.9.5.1  Exenatide and renal disease 
Exenatide is not recommended for use in patients with end-stage renal disease 
or severe renal impairment (creatinine clearance <30ml/min). There have been 
reports of altered renal function, including increased serum creatinine, renal 
impairment, worsening chronic renal failure and acute renal failure, sometimes 
requiring haemodialysis. Some of these events occurred in patients with altered 
hydration states, (including nausea, vomiting and/or diarrhoea), and/or receiving 
pharmacological agents known to affect renal function/hydration status. Concomitant 
agents included angiotensin converting enzyme inhibitors, angiotensin-II anagonists, 
non-steroidal anti-inflammatory medicinal products and diuretics (López-Ruiz et al., 
2010). Reversibility of altered renal function has been observed with supportive 
treatment and discontinuation of potentially causative agents, including Exenatide 
(Aroda & Ratner, 2011; Macconell et al. 2012). 
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1.6.1.9.5.2  Exenatide and gastrointestinal disease 
Exenatide has not been studied in patients with severe gastrointestinal disease, 
including gastroparesis. Its use is commonly associated with gastrointestinal adverse 
reactions, including nausea, vomiting, and diarrhoea. Therefore, the use of Exenatide 
is not recommended in patients with severe gastrointestinal disease. (Aroda & 
Ratner, 2011).  
The most frequently reported adverse reaction is nausea. In patients treated 
with 5µg or 10µg Exenatide, generally 40-50% reported at least one episode of 
nausea. Most episodes of nausea were mild to moderate and occurred in a dose-
dependent fashion. With continued therapy, the frequency and severity decreases in 
most patients who initially experienced nausea (Macconell et al., 2012). 
1.6.1.9.5.3  Exenatide and pancreatitis 
There have been reported events of acute pancreatitis, although they are rare. 
Resolution of pancreatitis has been observed with supportive treatment, but very rare 
cases of necrotizing or haemorrhagic pancreatitis and/or death have been reported. If 
pancreatitis is suspected, Exenatide and other potentially suspect medical products 
should be discontinued (Dore et al., 2011; Wenten et al., 2012). 
Cohort studies have found no increased risk of acute pancreatitis with current 
or recent use of Exenatide twice daily compared with use of other anti-diabetic 
drugs. In a follow-up study investigating the incidence of acute pancreatitis, after 
adjustments for (1) propensity score, (2) insulin and (3) use of medication potentially 
associated with acute pancreatitis, the odds ratio for Exenatide causing pancreatitis 
twice daily exposure was 0.95 (95% 0.65-1.38). A secondary analysis that examined 
current, recent and past medication exposure found no increased risk of acute 
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pancreatitis with Exenatide twice daily, regardless of exposure category. This study 
indicates that exposure to Exenatide twice daily was not associated with an 
increased risk of acute pancreatitis compared with exposure to other anti-diabetic 
medications (Wenten et al., 2012). 
Exenatide has been shown to promote pancreatic duct hyperplasia in rats 
(Nachnani et al. 2010). Metaplasia and ductal proliferation are well-established 
features of human pancreatitis and risk factors for pancreatic cancer (Jura et al. 
2005). It should be kept in mind that patients with T2DM have greater risk of 
pancreatitis than non diabetic patients (Girman et al. 2010), likely due to increased 
frequency of pancreatic duct replication (Jura et al. 2005). This makes more difficult 
to clarify possible links between increase incidence of pancreatitis and pancreatic 
adenocarcinoma and the use of Exenatide. 
1.6.1.9.5.4 Exenatide and weight loss  
Weight loss greater than 1.5kg per week has been observed in approximately 
5% of clinical trials patients treated with Exenatide for glycemic control. Weight loss 
of this rate may have harmful consequences (Rosenstock et al., 2012; Tina Vilsbøll 
et al. 2012). 
1.6.1.9.5.5 Exenatide and hypoglycemia 
Studies in patients treated with Exenatide and a sulphonylurea (with or without 
metformin) have shown that the incidence of hypoglycaemia was increased 
compared to placebo (23.5% and 25.2% versus 12.6% and 3.3%) and appeared to be 
dependent on the dose of both Exenatide and sulphonylurea. Exenatide has a glucose 
level dependent hypoglycaemia effect, and hypoglycaemia in absence of other anti 
DM agent is very rare. Most episodes of hypoglycaemia were mild to moderate in 
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intensity, and all resolved with oral administration of carbohydrate (Aroda & Ratner, 
2011; Macconell et al., 2012). 
1.6.1.9.5.6 Injection Site Reactions 
Injection site reactions have been reported in approximately 5.1% of subjects 
receiving Exenatide in long-term (16 weeks or longer) controlled trials. These 
reactions have usually been mild and usually did not result in discontinuation of 
Exenatide (Blevins et al., 2011). 
1.6.1.9.5.7   Immunogenicity 
As with all protein/peptide therapeutics, patients may develop anti-Exenatide 
antibodies following treatment with Exenatide. In most patients who develop 
antibodies, antibody titres diminish over time and remain low through 82 weeks. 
Patients who develop antibodies to Exenatide tend to have more injection site 
reactions (redness of skin and itching), but otherwise similar rates and types of 
adverse events as those with no anti-exenatide antibodies. Examination of antibody-
positive specimens from one long-term uncontrolled study revealed no significant 
cross-reactivity with similar endogenous peptides (glucagon or GLP-1)(M S 
Fineman et al., 2012) 
1.6.1.9.5.8  Exenatide and cancer 
Concerns have been raised about GLP-1 trophic effects. Analyses of adverse 
events database suggest higher incidences of pancreatic and medullary thyroid 
carcinoma in patients treated with GLP-1 agonists. A recent article reviewed the 
literature available in the Medline database until March 2012 concluding that it is 
more likely due to stimulation of premalignant lesions, rather that new neoplasms 
induced. On the other hand, data have emerged suggesting beneficial effects of GLP-
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1 on colon and breast cancer. Therefore GLP-1 agonists remain contra-indicated in 
patients with a personal history of multiple endocrine neoplasia type 2 or medullary 
thyroid cancer, but the data do not justify screening for those or other malignancies 
in patients treated with incretin-based therapies (Vangoitsenhoven et al. 2012). 
1.6.1.9.5.9  Overall safety assessment 
Exenatide has been the subject of phase III drug trials investigating the 
efficacy of subcutaneous administration (5 or 10µg twice daily) in the treatment of 
patients with Type 2 Diabetes (Buse et al., 2004; DeFronzo et al., 2005; Drucker et 
al., 2008; Kendall et al., 2005) and was approved by the FDA for the treatment of 
T2DM in April 2005. It received European marketing authorisation for the treatment 
of Diabetes in November 2006. 
Subcutaneous administration of Exendin-4 at the doses used for Diabetes is 
thought to be very safe. The risk of hypoglycaemia among non-diabetic patients is 
negligible. The positive actions of Exendin-4 seen in the animal models of PD were 
achieved at doses equivalent to or lower than those used in the treatment of T2DM. 
Combined with an extensive impressive safety record, backed up by the FDA and 
EMEA regulator websites, a further advantage of Exendin-4 / Exenatide is the ability 
to readily cross the blood brain barrier after peripheral administration, due to its high 
lipophilicity (Banks, During, & Niehoff, 2004; Kastin & Akerstrom, 2003).  
No drug has been shown to slow or reverse the neurodegenerative process of 
PD. All currently licensed therapies act as symptom relieving agents but have a 
limited lifespan of effectiveness because of continued brain cell loss. The preclinical 
work has shown that Exenatide may induce beneficial physiological effects on 
neuronal cell proliferation and neuronal stem cell differentiation. The vast amount of 
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work in laboratory models of PD suggest that Exenatide may work as a 
neuromodulatory agent that may slow or reverse the neurodegenerative process of 
PD. Positive results in these preclinical studies suggest that it will be highly effective 
in the treatment of patients with mild to moderate PD, assuming its physiological 
properties remain in pathological conditions in the human brain.  
1.6.2  Liraglutide  
Liraglutide is an anti-T2DM GLP-1R agonist that only requires once daily 
administration to improve glycaemic control (Campbell 2011). It can be used as 
monotherapy or in combination with metformin, a sulphonylurea but not with insulin 
(Campbell 2011). Interestingly, liraglutide was shown to be more effective than 
Exenatide in decreasing HbA1C, with less nausea and hypoglycaemia episodes, 
although side effects were more severe (Campbell 2011). It has been shown to 
increase proliferation of progenitor cells in the subgranular zone of the dentate gyrus 
in high fat-fed mice and non-obese mice (Hamilton et al. 2011). Intra-hippocampal 
injection of liraglutide in rats also protects against Aβ induced impairment in 
learning and memory in a dose-dependent manner, supporting the idea that it could 
be a potential therapy for memory loss in AD patients (Han et al. 2013).  
Hunter and Holscher have recently measured the kinetics of Liraglutide 
crossing the blood brain barrier (BBB), and effect on the GLP-1R, neuronal stem cell 
proliferation and neurogenesis (K. Hunter & Hölscher 2012). According to these 
authors, Liraglutide crossed the BBB at 25 and 250 nmol/kg ip, but no increase was 
detectable at 2.5 nmol/kg ip. 30 min post-injection, and at 250 nmol/kg ip. at 3 h 
post-injection and such transport may shutdown upon supraphysiologic doses 
(Hunter & Hölscher 2012).  
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1.6.3 Lixisenatide 
Lixisenatide is another GLP-1R agonist. Lixisenatide is under development to 
be used as a once-daily treatment for T2DM (Christensen et al. 2011). Lixisenatide 
crossed the BBB at all doses tested (2.5, 25, or 250 nmol/kg bw ip.) when measured 
30 min post-injection and at 2.5-25 nmol/kg bw ip. 3 h post-injection. Lixisenatide 
also enhanced neurogenesis in the brain (Hunter & Hölscher 2012). The main 
difference between the currently available incretin mimetics and those in clinical 
development besides lixisenatide seems to be in the pharmacokinetic profile 
(Christensen et al. 2010). With liraglutide, the large amount of bound drug confers a 
reservoir that provides stable plasma concentrations, whereas the short half-life of 
lixisenatide (and Exenatide) leads to plasma concentration that varies from very low 
to therapeutic values, leaving less room for development of tachyphylaxis to the 
gastrointestinal side effects (Christensen & Knop 2010).  
1.6.4  Once-weekly dosing GLP-1R agonist 
The novel long-acting incretin mimetics appear as promising antidiabetic drug 
candidates. However, these compounds are not one uniform group, and 
pharmacologic differences could influence the therapeutic achievements of these 
agents (Albiglutide/albugon, CJC-1131, CJC-1134-PC, Exenatide once weekly 
(Bydureon), and Taspoglutide). Only one head-to-head trial has been reported yet 
(Buse et al. 2010; Drucker et al. 2008) demonstrating that the longer acting agonists 
were superior with regard to glycaemic control and produced no difference in terms 
of body weight change. Notably, patient-reported treatment satisfaction and quality 
of life were also improved with the longer-acting agonist. 
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1.7 OTHER ANTI-T2DM WITH POSSIBLE 
NEUROPROTECTIVE FEATURES  
1.7.1 PPAR gamma agonists; thiazolidinediones (rosiglitazone, 
pioglitazone) 
 The thiazolidinediones, (from the class of anti-T2D drugs, the peroxisome 
proliferator-activated receptor ɣ (PPARɣ) agonists) are insulin-sensitizing drugs that 
function by binding the PPAR ɣ in fat cells. Rosiglitazone and pioglitazone are 
known to control neuroinflammation and oxidative stress, and have been proved to 
prevent motor and olfactory dysfunctions in parkinsonian mice (Schintu et al. 2009). 
They were shown to decrease stroke-induced brain damage and neurobiological 
dysfunction in T2DM mice (Tureyen et al. 2007). However, rosiglitazone’s and 
pioglitazone’s side-effects in terms of cardiovascular risk led FDA to pose some 
restrictions for thiazolidinediones prescription Pioglitazone is a licensed treatment 
for patients with T2DM, and reduces insulin resistance via its action on the nuclear 
receptor peroxisome proliferator-activated receptor gamma (PPAR-γ). It modulates 
the transcription of genes involved in insulin sensitivity. Of major interest is the 
recent observation that pioglitazone and other active thiazolidinedione compounds 
bind to the outer mitochondrial membrane protein (mitoNEET) with an affinity 
comparable to its binding to PPAR-γ and there has been a suggestion that many of 
the clinical effects of Pioglitazone are mediated by binding to mitoNEET (Colca et 
al. 2004; Paddock et al. 2007; Wiley et al. 2007). MitoNEET plays a key role in 
electron transport and oxidative phosphorylation, and Pioglitazone binding to 
MitoNeet has been shown to have positive regulatory effects on Complex 1 activity 
in neuronal cells (Ghosh et al. 2007). Pioglitazone has been shown to be protective 
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against neurodegeneration in MPTP mouse models of PD (Breidert et al. 2002). The 
neuroprotective properties of pioglitazone have been suggested to be mediated via a 
sequential action through PPAR activation, iNOS induction and NO-mediated 
toxicity (Dehmer et al. 2004). Pioglitazone has also been shown to be 
neuroprotective against the lipopolysaccharide model of PD through reduction of 
microglial activation and reduction of oxidative stress, enabling restoration of 
mitochondrial function (Hunter et al. 2007). Conflicting data has however suggested 
that the mechanism of action of Pioglitazone in protection against MPTP induced 
neurodegeneration is solely mediated through the inhibition of MAO-B, which 
prevents metabolism of MPTP to the toxic MPP+ (Quinn et al. 2008). In view of this 
uncertainty, but responding to the pressing need to evaluate this agent in patients 
with PD, a randomised trial has been initiated to explore possible neuroprotective 
effects of Pioglitazone among patients already on MAO-B inhibitors (Clinical 
Trials.gov Identifier NCT01280123). 
1.7.2 Dipeptidylpeptidase-4 (DDP-4) inhibitors ( Vildagliptin and 
Sitagliptin)  
The Dipeptidylpeptidase-4 (DDP-4) inhibitors are incretin enhancers; 
improving endogenous GLP-1 levels to the upper limit of the normal physiological 
range (Drucker & Nauck 2006). They are not generally associated with a 
deceleration of gastric emptying or weight loss. Typically, they reduce serum DDP-4 
activity by more than 80% with some inhibition maintained for 24h after one dose or 
with once daily treatment (Herman et al. 2005). 
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2  A TRIAL OF EXENATIDE FOR PD PATIENTS 
2.1  INTRODUCTION 
This study was designed to collect preliminary safety and efficacy data 
regarding the possible long-term biological effects of Exenatide in patients with 
treated PD, this factor being the main driver in the trial design. 
2.1.1  Trial design 
Several clinical trials of putative neuroprotective agents in PD have shown 
positive results. However, it could not be determined with certainty if the benefit was 
due to a neuroprotective effect because of potentially confounding pharmacologic or 
regulatory effects of the study agent. A major hurdle for the confirmation of any 
neuroprotective activity is the use of an appropriate clinical trial design. 
2.1.1.1 Open label versus Placebo control 
Having applied for funding to perform a large placebo controlled evaluation of 
Exenatide, and received feedback advising us to obtain open label data in view of the 
inevitable high expense of a placebo controlled design, because of pen style that 
needs good manufacturing practice (GMP) certification; we were compelled to 
choose an open label trial design for this “pilot” evaluation of Exenatide. 
2.1.1.2  Randomised controlled parallel group versus delayed start 
versus crossover 
There has been great interest in the use of novel trial designs such as the 
delayed start approach used in the TEMPO & ADAGIO trials (Parkinson Study 
Group 2002a; Olanow et al. 2009). These suggest that more prolonged therapy had a 
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positive effect on the underlying disease process. Despite encouraging findings from 
these trials there has been criticism of the delayed start approach. There is likely to 
be differential drop out in the two arms of a delayed-start trial, with more patients 
allocated to delayed treatment requiring symptomatic therapy (Clarke et al. 2011). 
 In a pharmacokinetic model of symptomatic and disease modifying effects in 
delayed-start and wash-out design studies using data from DATATOP and 
ELLDOPA, it has been concluded that delayed-start design is capable of  
differentiating symptomatic from disease modifying effects with sufficient 
power only if the disease modifying effect was larger than 7 total UPDRS units per 
annum (Ploeger & Holford 2009). Such a difference has not been seen in any of the 
three delayed-start trials to date.  
 Given the open label nature of this project, and our wish to try and 
differentiate symptomatic from disease modifying effect, we chose a parallel group, 
randomised controlled design including a prolonged washout period to provide the 
possibility of distinguishing symptomatic from disease modifying effects.  
2.1.1.3  Symptomatic versus Disease modifying 
The 2 months washout period between 12 months follow up and 14 months 
follow up will provide some indication to differentiate symptomatic from disease 
modifying effects. As a substantial amendment to the initial trial design, an 
additional visit for all patients at 24 months was scheduled to collect further data to 
distinguish symptomatic from disease modifying effects (see Chapter 4). 
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2.1.1.4  Outcome measures- Clinical/biomarkers 
Each of the outcome measures that have been used in clinical trials of 
interventions claiming neuroprotective effects in PD to date have been potentially 
confounded by symptomatic or pharmacological effects of the study intervention, so 
that if study results are positive, it cannot be unequivocally determined that the agent 
has an effect on disease progression. Options have been proposed, like the LS-1 
study that enrolled a total of 1741 early treated PD patients that were randomized to 
either 10g of creatine/day or matching placebo. Thus participants were required to be 
receiving dopaminergic therapy before randomization, hoping to target participants 
who were at or near their maximum benefit from such therapy at the time of 
enrolment. Therefore the authors tried to avoid the variable improvement that occurs 
in patients when first being on dopaminergic therapy, and they followed them over a 
sufficiently long period of time, such that progression of features causing disability 
(i.e. balance impairment, and cognitive decline) could be observed (Elm 2012). The 
importance of assessing the natural evolution of treated PD from onset, so that 
relevant outcome measures can be identified for clinical trials, has been pointed out 
by Evans and colleagues. These authors followed a cohort of 132 PD patients from 
diagnosis for up to 7.9 years, finding that axial (gait and postural) symptoms evolved 
more rapidly than other motor features of PD and appeared to be the best index of 
disease progression. Consequently this group suggested that the efficacy of disease 
modifying therapies may be more meaningful assessed in terms of their effects in 
delaying the major milestones of PD, such as postural instability and dementia 
(Evans et al. 2011). Thus, it is very difficult to declare with certainty that an 
intervention is neuroprotective even if there are significant benefits in comparison 
with placebo in a clinical trial. Standard clinical scales including the motor section of 
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the UPDRS in the practically defined “Off” medication state as primary outcome 
measure, were chosen in our trial design. Although there is as yet no reliable and 
validated biomarker of PD progression, a small imaging arm was incorporated into 
the trial design to evaluate whether there was any evidence of a change in pre-
synaptic dopaminergic integrity (DaT SPECT scans). There are well documented 
criticisms of DaT SPECT scans discussed in Chapter 3. 
2.1.1.5 Study population of interest: Stage of disease 
Careful consideration was given to the stage of PD targeted for recruitment. 
Evidence from various sources suggests that the rate of progression in early PD is 
faster than in later disease (Fearnley & Lees 1991; Hilker et al. 2005; Anette Schrag 
et al. 2007). Ideally the study of any novel drug would be performed in patients with 
early disease (de novo, untreated patients) but this approach is difficult as it can risk 
the inclusion of non PD patients, which, in a small study, can greatly limit the ability 
to distinguish positive effects. Given the need to collect useful pilot data in a timely 
fashion before embarking on a larger placebo controlled evaluation, and the longer 
follow up periods of early PD patients required to be able to see positive clinical 
effects in the presence of mild disability, a moderate PD group was chosen.  
We recruited patients with mild-moderate PD who had already received L-
dopa and were aware of “wearing off” effects which would therefore allow us to 
judge the effects of Exenatide on the “off phase” periods of PD (e.g. as in DBS trials 
and GDNF trials) as well as allowing us to judge effects on non-motor symptoms 
including cognition and gait problems. It was also felt that PD patients with a degree 
of disability would be more likely to maintain long term compliance, given that there 
are well recognised common side effects of Exenatide. 
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2.1.1.6 Duration 
Beneficial effects in animal models have been seen over weeks however we 
decided that a minimum period of 12 months exposure to Exenatide would be 
necessary to judge any effect on the neurodegenerative process, in the absence of any 
symptomatic effects, as well as necessary to judge the tolerability of this drug in the 
PD. A washout visit at 14 months (after a 2 month washout period), again repeated at 
24 months (a 12 month washout period) follow up also allowed us to collect long 
term follow-up data. The fact that longer term exposure to the drug if ineffective 
may reduce compliance was also taken into consideration. 
2.1.1.7 Cost and Funding availability (MJFF/CPT) 
 A request was made to the Michael J Fox Foundation (MJFF) to support a 
double blind placebo controlled trial but the advice received was to collect open 
label pilot data to reduce risk and subsequently inform the design of a placebo 
controlled evaluation. This trial was finally supported by The Cure Parkinson’s Trust 
(CPT). 
2.1.1.8 Commercial versus academic led 
This trial is non-commercially supported; it is entirely funded by the Cure 
Parkinson’s Trust. The owners of the Intellectual Property of Exenatide (Amylin) 
were made aware of the trial and requested to be informed of the trial results. 
2.1.1.9 Proof of concept 
Preclinical animal testing of Exendin-4, is incapable of determining whether it 
will have an important clinical effect in PD. Therefore, there is a great need for early 
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studies that will confirm such an effect in a short time period, exposing as few 
patients as possible. Such studies are called “proof of principle trials” (B. Schmidt 
2006). This step of proof-of-principle (or proof-of-concept) often links between 
Phase-I and dose ranging Phase-II studies. These small-scale studies are designed to 
detect a signal that the drug is active on a pathophysiologically relevant mechanism, 
as well as preliminary evidence of efficacy in a clinically relevant endpoint. 
In recent years, drug development has been focused on early identification of 
the viability of candidate molecules for full clinical development to a commercially 
competitive product. The important step of proof-of-principle or proof-of-concept 
studies shifts decisions for continuing development to early, less costly stages of 
development, thereby reducing the cost of failures. Such studies may include proof 
of bioavailability in humans as well as an indication of tolerability and safety. Proof 
of concepts studies are small, brief, scientifically rather than regulatory driven 
designs.  
The current trial design was conceived following feedback from both 
commercial and charitable organizations, which confirmed the impression that the 
risks associated with investment into potential neuroprotective agents need to be 
mitigated via the preliminary collection of cost-efficient (open-label) data in the first 
instance. In this context, the current study was designed as a proof of principle; i.e., 
with the aims of collecting rapid and cost-efficient data regarding the tolerability of 
Exenatide in patients with PD and providing preliminary indications whether the 
major neuroprotective and neurorestorative effects of Exenatide seen in the animal 
models might be replicable in human individuals with PD. 
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2.2 METHODS 
2.2.1 Patients 
All patients considered for the study had (at recruitment visit) a diagnosis of 
Idiopathic PD of moderate severity, with akinesia plus at least one of the following 
signs: muscular rigidity, tremor at rest and postural instability. All patients followed 
Queen Square Brain Bank criteria for the clinical diagnosis of PD (Hughes, Daniel, 
et al. 1992a; Hughes, Ben-Shlomo, et al. 1992b). Patients were between 45 and 70 
years old, male or postmenopausal or surgically sterilised female, with disease onset 
after age 40 years and disease duration > 5 years. 
Patients were on L-dopa treatment, with a history of wearing off phenomena 
and duration of action of single dose of L-dopa <6 hours. 
All patients had improvement in response to levodopa, with improvement of at 
least 33% in the total Unified Parkinson’s Disease Rating Scale (UPDRS) score, 
after a first morning dose of L-dopa. 
The exclusion criteria were chosen to ensure that individuals at risk of the 
known adverse effects of Exenatide were excluded from the trial. 
A full list of the Inclusion and the Exclusion criteria are documented in table 1. 
2.2.1.1 Inclusion criteria 
As stated in Table 1, we included patients with moderate severity of PD with 
UPDRS part III off medication at least 15 points, allowing us to appreciate a possible 
improvement along the 14 month follow up period, and avoiding recruitment of non-
PD patients (e.g. Progressive Supranuclear Palsy (PSP), Multiple System Atrophy 
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(MSA) patients). There are no safety data of Exendin-4 on pregnancy so we included 
women only if sterilised or post-menopausal. We did not include very young PD 
patients to avoid over-representation of the genetic forms of PD, neither did we 
include very old patients who would be more likely to experience severe 
comorbidity. Our patients were all on L-dopa treatment as we wanted to ensure L-
dopa responsiveness. They were also on a stable treatment regimen before inclusion 
to make sure that any changes were not due to delayed responses to medication 
adjustments made before baseline. They must have experienced wearing off when 
included so it would make easier to appreciate possible improvements. We 
anticipated that patients with disability would be more likely to maintain long term 
compliance of injectable treatment. 
2.2.1.2 Exclusion criteria 
We excluded patients that did not meet the Queen square brain bank PD 
diagnostic criteria or had a diagnosis or suspicion of other cause for Parkinsonism 
including Vascular parkinsonism, post traumatic parkinsonism, drug or toxin 
induced parkinsonism, or other neurodegenerative condition. We excluded patients 
having Parkinsonism possibly due to recent neuroleptic intake or having any major 
brain imaging abnormality. We did not include demented patients nor depressive 
patients as it will be more difficult for them and their families to maintain 
compliance. We excluded patients with previous brain surgery or in any other PD 
trial, to avoid confusing outcomes. We excluded diabetic patients or patients on 
diabetic treatment, to make sure any possible change in their PD signs were not 
related to any change in their diabetes control. And finally we excluded conditions 
that may increase the risk or trigger pancreatitis like history of alcoholism or 
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pancreatitis, as well as severe cardiac gastrointestinal or renal disease to minimize 
the associated risk of these with Exenatide. 
Table,2.,Inclusion,and,exclusion,criteria,
 
 
The protocol and a consent form describing the risks and potential benefits of 
the study were approved by REC, Joint Research office of University College 
London, ARSAC, and the MHRA. Written informed consent was requested from all 
the patients. 
All patients had blood glucose, HbA1C and fasting Glucose tests to rule out 
concurrent presence of Diabetes Mellitus. 
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2.2.2 Schematic diagram of overall trial design 
 
Figure,2.,Schematic,diagram,of,overall,trial,design,
 
2.2.2.1 Randomization  
Eligible individuals who have given informed consent were randomized to 
receive active drug (Exenatide on the top of their conventional PD medication) or to 
remain on their conventional PD medications and to act as a PD control. Block 
randomization were used with random block sizes. Separate randomization lists was 
generated for patients of greater (Hoehn & Yahr stage 2.5) or lesser (Hoehn & Yahr 
stage 2.0) disease severity to balance this as a possible prognostic factor, i.e. disease 
severity acts as a stratification variable. Randomization list was created prior to trial 
commencement, and stored by the trial pharmacists. The randomization list was 
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sufficiently long (N=50) to enable continued randomization should any patients drop 
out within the first 3 months. The patients and the examining physician were aware 
of treatment-group assignments throughout the study. The randomization outcome 
was 20 patients allocated in the Exenatide group and 24 patients in the control group. 
2.2.2.2 Screening assessment 
Each patient had a review of their demographics and data regarding their PD 
history, medication history, previous imaging, previous genetic test and previous 
drug compliance issues. Also an ECG, baseline blood test (including blood count, 
renal function, HbA1C, serum amylase,) and clinical observations (Pulse, blood 
pressure and weight) were also performed. 
2.2.2.3 Baseline visit 
Each patient was sent the PDQ 39, NMS Quest, SCOPA Sleep, SCOPA AUT 
and Smell Identification test self-assessment forms to complete and bring with them 
to their baseline evaluation. 
Baseline evaluations comprised the following: 
Blood test to measure Blood count, renal function, liver function, serum 
amylase, HbA1C, fasting serum glucose and lipid profile. The patient was allowed to 
eat and drink after it as they wish. 
MDS-UPDRS, which is the standard validated tool for the assessment of 
patients with PD. This scale includes subsections collecting data regarding the 
impact of PD on a patient’s mood and mental state, (UPDRS part 1), their activities 
of daily living (UPDRS part 2) and examination of the motor features of PD 
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(UPDRS part 3) and complications arising from the use of PD (UPDRS part 4) (C G 
Goetz 2010; Gallagher et al. 2012). Part 3 of the UPDRS was performed twice and 
video recording was taken on each occasion - first at a time when the patient has 
been free of all PD medications for at least 12 hours (including Exendin-4) and free 
of long acting dopamine agonists for at least 24 hours. The first UPDRS part 3 
assessments took place as soon as the patient arrived to minimize the duration of any 
discomfort from not having taken medication. The UPDRS part 3 motor score was 
repeated 1 hour after the patient took his/her regular medication and confirmed that 
they had achieved their best medication response. The scores for the UPDRS part 3 
range from score 0 (normal) to score 132 (worst possible).  
For UPDRS part 3, the state of the patient was defined as “off medication” 
when testing was conducted before the patient had a first morning dose of levodopa 
and at least 12 hours after the administration of levodopa the previous day. The “on 
medication” scores refer to the best test scores recorded during the day while the 
patient was taking medication.  
Assessment of PD severity using MDS-UPDRS part 3 off-medication was 
video recorded to allow objective rating of PD disability by observers blinded to 
randomization outcomes. Each patient video was rated by the same blinded clinician 
at each time point. All clinicians were experienced at evaluating PD patients and had 
successfully completed the official training module of the MDS-UPDRS. 
Timed Motor tests include a hand tapping task to evaluate the number of hand 
taps that an individual can perform between 2 points 30 cm apart and a timed, sit, 
stand up, walk a distance of 7m as fast as possible, turn around and return to their 
chair and sit down task. 
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The Dyskinesia Rating Scale is an objective assessment of the severity of 
involuntary movements in 7 body regions with each region receiving a score of 0 
(none) - 4 (extreme, no completion of the voluntary motor act) that was performed 
during patients on medication phase. 
The PDQ39 is a 39 item quality of life assessment especially designed for 
patients with PD, by the Health Services Research Unit, Oxford 1998. Patients are 
given the questionnaire for self-completion. The completed questionnaire is designed 
to be deconstructed into a score for 8 separate dimensions: mobility, activities of 
daily living, emotional well-being, stigma, social support, cognition, communication 
and bodily discomfort. A summary score from 0 to 100 was calculated for the PDQ-
39. This summary index (SI) is the arithmetic mean of the scores for the individual 
domains (Jenkinson et al. 1997). 
2.2.2.4 One month assessment 
At one month after baseline evaluation, each patient was telephoned to 
complete an adverse report and document their PD medication regime. Patients 
randomised to Exenatide were asked to attend the trial clinic taking their regular PD 
medication (and Exenatide). They were asked not to have eaten and to have drunk 
water only for 6 hours to enable fasting blood sample to be taken. Clinical 
observations including Pulse, Blood pressure and weight was measured and blood 
tests sent to measure renal function, liver function, serum amylase and fasting serum 
glucose. Each patient was given a 2 month supply of Exenatide 10 µg bd and supply 
of needles for the subcutaneous pen injection system. 
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2.2.2.5 Three month assessment 
At three months after baseline evaluation, each patient was telephoned to 
complete an adverse events report and document their anti PD medication regime. 
Appointments were made for each patient on Exenatide to attend the trial clinic. 
They were once again asked not to have eaten and to have drunk water only for 6 
hours to enable fasting blood sample to be taken. 
Attending patients had blood tests to measure renal function, liver function, 
serum amylase and fasting serum glucose. An ECG, and clinical observations; 
weight, pulse, blood pressure was performed. Their current medication regime was 
noted. They were given a further 3 months’ supply of Exenatide 10 µg bd and supply 
of needle for the subcutaneous pen injection system.  
2.2.2.6 Six month assessment  
At six months an appointment to attend the trial clinic for all the patients 
(Exenatide and conventional PD medication only) were made. The patients were 
asked to withhold all PD medications (including Exenatide) for at least 12 hours 
(overnight) and 24 hours for long acting dopamine agonists. They had video 
recording of UPDRS part III score, performed timed motor tests and they took their 
regular medications. The patient was asked to complete UPDRS part 1, 2, 4 and 
when they confirmed they their best on state was achieved, they had a further video 
of UPDRS part III score. During the on phase, the Dyskinesia rating Scale, MADRS 
and Mattis DRS was competed. (Non motor assessments are described in detail in 
Cahpter 5). They were given a further 3 months’ supply of Exenatide 10 µg bd and 
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supply of needle for the subcutaneous pen injection system. (The same supply was 
given for the last time at 9months follow up). 
2.2.2.7 Nine, twelve and fourteen month’s assessments (As described in 
table 3) 
Table,3.,Nine,,12,and,14,month's,assessment,overview,
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9,months ,,X On,medication ● ●
12,months Off,medication Off,medication ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
14,months Off,medication Off,medication ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●  
 
2.2.3 Concomitant medication 
Note was made of L-dopa equivalent doses, at each visit. No routine 
adjustment of PD medications was made at the trial clinic unless clinically urgent, 
under the premises of offering the best medical treatment to the patient. Patients 
were asked not to enroll in any other experimental treatment for PD until the end of 
this trial period. All of the patients were seen in the National Hospital of Neurology 
and Neurosurgery at University College London for three to four hours on five to 
eight occasions during the study: twice before the initiation of the treatment for 
screening and base-line assessments. 
Because the doses of levodopa and other antiparkinsonian drugs are 
individualized for each patient, we are using levodopa equivalent doses (Tomlinson 
et al. 2010) to minimize changes in drug therapy which can confound the 
interpretation of outcomes.  
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2.2.4  Treatment procedures 
Patients allocated in the Exenatide group were taught how to self-administer 
subcutaneous injections of the trial drug using the pre-filled pen devices. Patients 
randomised to active treatment were given supplies of 5 µg bd subcutaneous 
injections for 1 month. Further supplies of pre-filled pens, was given to the patient at 
each follow up visit. 
They then returned for their 1 month assessment and were supplied with 2 
months’ supply of Exenatide 10 µg subcutaneous injections to be continued and 
replenished at subsequent follow up visits. 
Exenatide was provided through the hospital pharmacy of the NHNN. It has a 
shelf life of 2 years if stored at 2-8 degrees. Each pre-filled pen can provide 60 doses 
of drug i.e. sufficient for 1 calendar month. 
2.2.4.1 Starting dose and any dose escalation 
Patients randomized to active treatment were given supplies of 5µg bd 
subcutaneous injections of Exenatide (manufactured as Byetta) for 1 month. They 
then returned for their 1 month visit and patients that tolerated the 5 µg dose were 
supplied with Exenatide 10µgr bd subcutaneous injections to be continued and 
replenished at subsequent follow up visits. Initial introduction of Exenatide using 5 
µg dose prior to using the 10 µg dose has been associated with lower rates of nausea 
and vomiting than immediate introduction of 10 µgr dose (Fineman et al. 2004).  
Patients with adverse reactions to the low dose injection e.g. nausea were given 
a supply of Domperidone 10 mg tablets to be taken orally up to three times daily as a 
 
  
 
90 
 
 
treatment to relieve nausea. No patient has been unable to tolerate the low dose 
injections. 
Bioavailability of Exenatide is comparable following subcutaneous injection 
into abdomen, thigh or arm and the 10 µg dose compares favorably to the plasma 
levels in the rodent models namely 200 pg/ml plasma (Calara et al. 2005). 
The dose of Exenatide chosen for this study has been based on 2 pieces of 
information. 
A. There is extensive safety data regarding the use of Exenatide at a dose 
of 10 µg among patients with Diabetes. The key trials are outlined in the table 4. 
Hypoglycaemia among patients that are not on oral hypoglycaemic occurs at a 
frequency of 1 % (Drucker et al. 2008). 
B. The 10 µg dose of Exenatide compares favourably to the plasma 
levels in the rodent models of Parkinson’s disease namely 200 pg/ml plasma (Calara 
et al. 2005). 
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Table,4.,Exenatide,was,granted,a,license,for,the,treatment,of,patients,with,
DM,based,on,the,following,trials,
 
,
Patients were instructed that Exenatide could be administered at any time 
within 60-minute period before the morning and evening meal (or two main meals of 
the day, approximately 6 hours or more apart). Patients were told that it should not 
be administered after a meal. If an injection was missed, the patients were advised 
that treatment should be continued with the next scheduled dose. 
Each dose was administered as a subcutaneous injection in the thigh, abdomen, 
or upper arm.  
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2.2.5  Assessment of compliance 
 Compliance was optimised by informing all patients randomised to receive 
Exenatide, of the most commonly experienced side effects and ways of minimising 
these. Patients were given adequate instruction regarding administration of injections 
and developing twice daily routine for their administration. Good relationship was 
established with all trial participants to maximise honest reporting of compliance. 
 Compliance was assessed by directly questioning patients, at each visit, with 
carers also asked to provide estimates of compliance. Patient estimates were checked 
against reports of how long each pen (with 60 pre-filled doses) lasted before it 
needed replacing. A compliance score was derived from the estimated number of 
injections actually administered each month and this figure recorded in the patient’s 
clinical file at each visit. 
2.2.6 Safety 
Serious adverse events were defined as illnesses and incidents that necessitated 
prolong hospitalization or caused death. These events were reported to the 
monitoring board within 24 hours. 
2.2.6.1 Serious Adverse Events (SAE), adverse reaction (AR) 
 All SAE and AR were defined and recorded according to standard GCP 
guidelines.  
2.2.6.2 The Trial Management Group (TMG) 
The TMG is a body that has been established to assess at intervals the progress 
of the trial, the safety data and the critical efficacy endpoints. The TMG recommend 
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to the sponsor whether to continue, amend or stop the trial. The TMG reviewed the 
summary of adverse event and the mean change in “off-medication UPDRS score”. 
The TMG met initially at 3 months after the trial initiation and every 3 months after 
it. 
The TMG was made up of; Thomas Foltynie, Iciar Aviles-Olmos, Patricia 
Limousin, Andrew Lees and Linda Taib. 
2.2.7 Data handling and analysis 
2.2.7.1 Data entry 
Case report forms (CRF) were designed according to the sponsor’s CRF 
template. All data were entered legibly in black ink with a ball-point pen. If an error 
were made, the error was crossed through with a single line in such a way that the 
original entry could still be read. The correct entry then was clearly inserted, and the 
alterations were initialled and dated. 
At every visit, the patient CRF was completed, making sure the CRF review 
checklist was completed at the same time to avoid any missing data. Immediately 
after the visit was finished, the data were entered into a Microsoft Access database. 
Every 3 months the data-base was checked to make sure there was no missing data, 
nor data replication, to guarantee the completeness and accuracy of the data.  
2.2.8 Endpoints 
2.2.8.1 Primary endpoint  
Change from baseline to 12 months and 14 months between patients on active 
Exenatide treatment and PD controls in respect of their part 3 UPDRS-off-
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medication blind (excluding rigidity, as it cannot be assessed in a video) motor 
subscore. 
2.2.8.2 Secondary endpoint  
Adverse event profile among patients treated with Exenatide compared with 
matched PD controls. Change from baseline to 12 months/14 months between 
patients on active treatment and PD controls in respect of: 
- Part III MDS UPDRS on medication motor subscore 
-UPDRS ADL (MDS-UPDRS part 2) subscore 
-Dyskinesia rating scale 
-Timed motor test 
-Mattis dementia rating scale (MDRS) 
-Montgomery and Asberg depression rating scale (MADRS) 
-PDQ39 
-NMS Quest 
-SCOPA Sleep scale _Scopa AUT scale _Smell identification test 
-DAT SPECT images. 
2.2.9  Statistical analysis  
2.2.9.1 Statistical Considerations 
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Advice regarding sample size, endpoints and statistical analysis plans was 
sought from both Dr Foltynie & Dr Gareth Ambler of the UCL JRO Biostatistics 
Unit.  
2.2.9.2 Sample size calculation 
 In previous studies involving patients on stable treatment regimens of either 
Pramipexole or L-dopa, there was a UPDRS decline of approximately 3 UPDRS 
points per year (SD of 6.8 points) (Holloway et al. 2004). PD trials that have used 
change in off-medication motor UPDRS scores as an outcome measure have shown 
similar rate of decline (1.7 points after 6 months) among patient on “best medical 
treatment” (Weaver et al. 2009; Follett et al. 2010). 
 Therefore it was considered that the group of conventional PD medication 
would decline at a rate of 3 UPDRS points over the course of the 12 month follow 
up. Using the formula, n=42 x (SD of difference/difference)2, the patient sample size 
(n=40) in this trial would have 90% power to detect a difference of 7 UPDRS points 
between the treated and untreated patients at a significance level of 5% assuming 
normality in distribution of response and a SD of 6.8 points. This translates to a 
mean improvement of 4 UPDRS points in the treated patients. This was considered a 
clinically important effect size. Less optimistically, this sample size would still have 
80% power to detect a difference of 6.1 points, i.e mean improvement of 3.1 points 
in the treated patients. Whether the estimation of the possible magnitude of effect of 
Exenatide was realistic, was only established once pilot data were collected. 
 With 40 patients the treatment effect could be estimated to within +/- 4.2 units 
(1.96 x √(2 x sigma2 /n)). (Unit = UPDRS points). Patients that dropped out within 
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the first three months were replaced by further patients who underwent the same 
randomisation process. 
2.2.9.3 Primary endpoint analysis 
 The difference between UPDRS part 3 off medication score at baseline and at 
12 and 14 months was calculated for each patient. The mean difference and SD for 
patients randomised to treatment and for patients on conventional PD medication 
group was presented. It was anticipated that there would be high correlation between 
the baseline and follow up measures. The analysis was performed on an intention to 
treat basis including all patients who completed at least one follow up assessment. 
“Last observation carried forward” was used for participants with missing data. 
 Every effort was made to ensure that missing data was kept to a minimum. 
Patients dropping out prior to 3 months who refuse follow up assessments had their 
reason for dropping out reported. Additional patients were recruited and randomised 
to replace patients who drop out prior to their first follow up assessment. 
 The distribution of scores was checked for normality using the Schapiro-Wilk 
test. Differences between treated and untreated groups with respect to changes in 
scores from baseline to follow-up were analysed using 2-sided t tests. Data were 
analysed using IBM SPSS Statistics 20.  
2.2.9.4 Secondary endpoints analysis  
The difference between each of the secondary outcome measures at baseline 
and at 12 months was calculated for each patient. The mean difference and SD for 
patient randomised to treatment and for patients acting as controls was presented. 
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The analysis was performed on an intention to treat basis including all patients who 
complete at least one follow up assessment. The distribution of scores was checked 
for normality. As data were normally distributed, a paired t test was used to assess 
the difference between the means.  
 We performed an interim analysis of the primary outcome variable once 
every patient reached 6 months follow up assessment. Only the members of the 
performance and safety monitoring board were informed of the outcome, and they 
allowed the study to continue.  
Exploratory subgroup analyses were performed to try and identify whether 
changes in part 3 MDS UPDRS were different in relation to younger age at baseline 
or lower score in Hoehn & Yahr scale at baseline; as a measure of disease severity, 
using correlation between our primary outcome and age at onset and Hoehn & Yahr 
to find out if younger age could influence a better response to treatment. Correlations 
were performed to explore any relationship between change in weight and change in 
part 3 MDS UPDRS off medication to find out if weight loss could contribute a 
better performance on motor improvement. 
To explore differential effects in different UPDRS symptoms, UPDRS part 3 
scores were subdivided into bradykinesia, tremor, axial signs (using blinded ratings) 
and rigidity (using open label ratings). 
“Bradykinesia” was calculated as the sum of right and left finger tapping plus 
right and left hand movement plus right and left arm movements plus right and left 
foot tapping plus right and left leg movements plus facial expression and body 
bradykinesia. 
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“Rigidity” was calculated as the sum of rigidity on the neck plus right upper, 
left upper, right lower and left lower extremity. 
“Tremor” was calculated as the sum of resting tremor on; the face, right arm, 
left arm, right and left leg and constancy of resting tremor plus postural tremor on 
the right hand and left hand plus kinetic tremor on the right and left hand. 
“Axial signs” was the sum of speech, postural instability, gait, posture, rising 
from the chair. 
2.2.9.5  Imaging analysis (See chapter 3) 
2.2.10  Study Approval 
The trial was conducted at the National Hospital of Neurology and 
Neurosurgery (London, United Kingdom), with trial sponsorship and monitoring by 
University College London. The protocol was approved by a research Ethics 
committee, the Administration of radioactive Substances Advisory Committee 
(ARSAC), and the UK Medicines Health Regulatory Agency, and all patients signed 
informed consent. The trial was registered at www.clinicaltrials.gov (trial ID 
NCT01174810). 
2.3 RESULTS  
Enrolment took place from July 2010 to March 2011. The period in which the 
treated patients started to inject themselves, began in September 2010 and finished 
by the end of March 2012. 
Of the 45 patients recruited, one patient randomized to Exenatide dropped out 
before first follow up, and was therefore replaced per the study protocol and not 
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included in the final analysis (See figure 3). The baseline demographic data for the 
44 participants included in the final analysis are presented in Table 5. Clinical data 
were missing for 2 patients (1 patient per group), both for their 14-month visit. 
 
 
Figure, 3., Random, assignments, to, treatment,, completion, of, the, trial,, and,
reasons,for,not,completing,it.,
Patients withdrawing from the trial prior to the 3-month visit were replaced, 
and new recruits were randomly allocated to the 2 groups. 
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Table,5.,Baseline,characteristics,of,the,study,subjects,
 
2.3.1 Clinical outcomes 
2.3.1.1 Blinded video rating of MDS-UPDRS part 3 in the practically 
defined “off medication” condition 
Patients allocated to the Exenatide group had a mean improvement at 12 
months of 2.7 points (SD, 7.7) on the MDS-UPDRS part 3, while controls had a 
mean decline of 2.2 points (SD, 7.3) for a difference of 4.9 points (95% CI, 0.3-9.4; 
p=0.037; Table 7). At 14 months, the Exenatide group had a mean improvement of 
1.7 points (SD, 7.4), while controls had a mean decline of 2.8 points (SD, 6.7), for a 
difference of 4.4 points (9.5% CI, 0.2-8.7; p=0.042). These scores did not include 
any changes detected in limb or neck rigidity, which cannot be reliably rated on 
video. Addition of open label rating of rigidity scores to the blinded data equated to 
an improvement of 1.8 points (SD,8.7) in the Exenatide group at 12 months, 
compared with a decline of 5.3 points (SD, 8.3) in the control group ( difference, 7.0 
points; 95% CI, 1.8-12.1; p=0.009), and an improvement of 0.8 points (SD, 8.7) in 
the Exenatide group at 14 months, compared with a decline of 6.4 points (SD, 7.8) in 
the control group ( difference, 7.2 points; 95% CI, 2.1-12.2; p=0.006; Table 7).  
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UPDRS part 3 scores were then subdivided into bradykinesia, axial, rigidity 
and tremor. There was a significant improvement in bradykinesia subdomain of 
MDS UPDRS part 3 at 12 months in the Exenatide group in comparison with the 
control group, for a difference of 3.4 points (95% CI, 0.5-6.2, p=0.02) but this was 
less at 14 months, for a difference of 2.6 points (95% CI, 0.3-5.5, p=0.082).  
Similarly, there was an improvement in the rigidity subdomain (open label 
data) favouring Exenatide, with a difference of 2.2 points (95% CI, -0.5-3.9, 
p=0.013) at 12 months and 2.7 points at 14 months (95% CI, -1.0-4.4 p=0.002) 
 As well as the axial subdomain with a difference of 1.4points favouring 
Exenatide (95% CI, -0.3-2.5) at 12 months and a significant trend at 14 months 
p=0.054.  
There was no significant difference in tremor subdomains of MDS-UPDRS 
part 3 between Exenatide and control group at 12 months (p=0.467) neither at 14 
months (p=0.447). 
2.3.1.2 Secondary outcome measures 
• Part 3 MDS UPDRS on medication motor subscore. Open label rating of 
MDS-UPDRS part 3 “on medication” showed a significant difference favouring 
patients treated with Exenatide compared with the control group (p=0.06 at 12 
months, p<0.001 at 14months). The mean improvement in “on medication” scores in 
the Exenatide group (2.7 points) was unchanged between the 12- and 14-month 
visits. In contrast, individuals in the conventional PD medication group deteriorated 
over the total 14-month trial period by 7 points. 
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• There was a significant difference or non-significant trend favouring 
Exenatide in MDS-UPDRS parts 1, 2 (UPDRS ADL), and 4 at both the 12- and 14-
month time points (Table 7). 
• There were also general trends for improvement in the timed tests (Table 9 & 
10) and L-dopa equivalent dose (LED) (Table 8). 
• There was no improvement in PD-39 summary index between the 2 groups 
(Table 8). 
2.3.1.3 Safety and tolerability 
Four patients withdrew / dropped out from the study, 3 from the group 
randomized to Exenatide and one from the conventional PD medication group. Of 
the 3 patients in the Exenatide group, 1 withdrew due to worsening PD (recurrent L-
dopa dose failures) prior to the first follow-up visit. Exenatide is known to cause 
slowing of gastric emptying and is the most likely explanation for this observation in 
this patient. Two further patients withdrew from treatment: the first at 9 months due 
to dysgeusia combined with subjective PD deterioration, and the second at 10 
months due to excessive weight loss (despite reduction to the 5-µg dose). The last 
two were included in final analysis, using an intention to treat protocol. One patient 
randomized to the conventional PD medication group withdrew from the study at 12 
months due to deteriorating PD and incapacity to attend the trial clinic in the “off 
medication” state. All serious adverse events, together with adverse events occurring 
in more than 1 patient, are listed in table 6. No clinically relevant changes in ECG, 
haematological, or biochemical indices were observed. Weight loss and nausea were 
more common in the patient group treated with Exenatide. Patients on Exenatide lost 
a mean of 3.2 kg (SD, 3.9; range, 3.5-kg increase to 12.3-kg decrease) over 12 
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months, necessitating 2 patients to reduce to the 5-µg dose. Control group patients 
lost a mean of 0.8 kg (SD, 3.3; range, 5.5-kg increase to 7.8-kg decrease) over 12 
months, for a difference of 2.4 Kg ( 95% CI, 0.2-4.6; p=0.035). There was a greater 
increase in the mean dyskinesia rating scale score in Exenatide versus control 
patients at both 12 and 14 months. This necessitated lowering of LED in 5 Exenatide 
patients, whereas 8 Exenatide patients had unchanged dopaminergic medication and 
7 patients had increased dopaminergic medication over the period of study. 
 
2.3.1.4  Possible cofounders of clinical outcomes 
To make a preliminary assessment of whether motor outcomes were 
confounded by other variables, simple correlations were sought. There were no 
correlations among change in UPDRS part III blind scores and change in body mass 
index at 12 months (p=0.812) 
No correlation was found among patients suffering more dyskinesia at 12 
months and change in body mass index at 12 months (p=0.119). 
The improvement in MDS UPDRS part 3 at 12 months was not correlated with 
younger age at disease onset (p=0.678) nor younger age at start of the trial 
(p=0.211). There was a significant correlation between age at start of the trial and 
improvement in part 3 MDS UPDRS blind scores at 14 month (p=0.007), although 
age at symptoms onset was not correlated with changes in part 3 MDS UPDRS at 14 
month (p=0.304).  
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Table,6.,Adverse,events,reported,by,trial,participants,
,
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!Table!7.!Changes!in!MDS2UPDRS!between!baseline!and!month!14.!A!=blinded!rating!excludes!rigidity.!B!=open2label!rating!includes!
rigidity!scoring 
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!
Table!8.!Changes!in!the!score!on!LED,!dyskinesia!rating!scale!and!PDQ39!summary!index!between!baseline!and!month!14!
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! ! ! Table!9.!Change!in!the!scores!on!the!hand!taps!timed!test!between!baseline!and!month!14!
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! ! ! Table!10.!Change!in!the!scores!on!the!walking!timed!test,!between!baseline!and!month!14!
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Figure' 4.' Change' from' baseline' in' the' MDS8UPDRS' part' 3' score' by' study'
visit.'Data'present'mean'±'SEM'
  
DISCUSSION 
This is the first trial to report tolerability and pilot data of the possible 
biological effects of Exenatide in patients with a neurodegenerative disease. In view 
of the single-blind design, we cannot exclude placebo effects being responsible for 
the observed differences between patients treated with Exenatide and controls, and 
these data should not be interpreted as evidence of symptomatic efficacy or 
neuroprotection. Given the complex design of the Exenatide pen device, the cost of 
manufacture of a matched placebo, and the absence of commercial sponsorship, this 
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weakness was unavoidable, and these data should be considered as proof of 
principle/proof of concept only. Nevertheless, the trial design allowed the collection 
of data in a very cost-efficient manner, and the results demonstrated that Exenatide 
was generally well tolerated by PD patients and that clinically relevant differences 
emerged between the 2 groups that persisted beyond the 12-month exposure to the 
study drug, which may potentially reflect biological activity. 
In an attempt to improve the cost-efficiency of trials of potential 
neuroprotective agents, previous investigators have used “futility” designs in order to 
compare disease progression in individuals assigned to experimental agents against 
the expected natural history of the disease, based on either historical or 
contemporary control data (NINDS NET-PD Investigators 2006; NINDS NET-PD 
Investigators 2007). These studies have highlighted the difficulties in selecting 
agents for major investment, given the presence of highly variable rates of placebo 
responses that can occur. The variable nature of the placebo response is a particularly 
important issue for complex or invasive interventions in which placebo versions of 
the licensed product are not readily available/represent additional significant 
expense, which can thus hinder the conduct and interpretation of even small phase 2 
double-blind trials. In the current trial, we adopted a proof of principle approach to 
provide preliminary data regarding the tolerability of Exenatide in a small number of 
patients with PD, as well as to collect pilot data with respect to possible biological 
effects, in order to help justify the larger investment required to initiate a larger 
double-blind, placebo-controlled study and assist in sample size calculations. We 
chose not to set any futility threshold a priori, but instead chose to use a 
contemporary group of PD controls and to continue follow-up for a sufficiently long 
period to allow inevitable placebo effects to at least begin to diminish.  
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There are multiple issues in the optimal design of trials that aim to identify 
agents with neuroprotective effects that have been previously highlighted, including 
the prioritization of drugs for study, the optimal trial design and duration, the ideal 
outcome measures, and the optimal group of patients for study (Olanow et al. 2008). 
In the current study, the inclusion and exclusion criteria for patient selection were 
chosen on a pragmatic basis to minimize the risk of including patients with non-PD 
tremor or atypical Parkinsonism, with the understanding that patients with advanced 
disease would be likely to have fewer salvageable dopaminergic neurons. We also 
wished to determine whether this drug was tolerable in moderate-stage PD patients 
on L-dopa, given that it is unlikely that any neuroprotective agent will ever be able to 
entirely replace the need for symptomatic therapy. Since Exenatide is also being 
evaluated as an agent to influence cognitive decline, our inclusion criteria allowed us 
to evaluate the possible influence of Exenatide on cognition. Given that Exenatide 
has not previously been given to patients with PD, the design of this trial included a 
washout period to also allow for preliminary distinctions between possible 
symptomatic effects and possible disease-modifying effects.  
However, the inclusion of a 2-month washout period provided information on 
short-term symptomatic effects only. Long-duration symptomatic effects may persist 
beyond this period and cannot be excluded using the current study design. This is 
particularly relevant given the increase in L-dopa–induced dyskinesia (LID) seen in 
the Exenatide-treated group, which necessitated reduction in L-dopa doses in 5 
patients. The possibility of an interaction between Exenatide and conventional 
dopaminergic replacement must be considered in future study designs.  
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A further caveat must be made in the interpretation of these data given the 
small sample size. Despite randomization, minor differences in the baseline 
characteristics of the treated and control groups can influence subsequent disease 
progression. In a larger sample, randomization would be more likely to balance the 
treated and untreated groups. In the current trial, we attempted to minimize this 
chance variation by stratified randomization according to baseline disease severity. 
While there were no significant differences between the 2 groups at baseline, the 
control group had slightly longer disease duration than that of Exenatide-treated 
patients. 
Weight loss is an important concern and prevented trial completion in 1 
individual. This was fully reversible on cessation of the drug. Gastrointestinal 
symptoms are a common side effect of Exenatide and also in the PD population, but 
did not compromise trial participation in any individual. Patients generally tolerated 
the pen injection device well, and none of the serious adverse events observed were 
considered to be reactions to Exenatide. The frequency of the adverse events in the 
Exenatide group was similar to that seen in the previous clinical trials of Exenatide 
in diabetes patients (Buse et al. 2004; DeFronzo et al. 2005).  
Bearing in mind these limitations, our data provided preliminary information 
about Exenatide tolerability in PD and allowed consideration of the size of the 
biological effects seen in comparison to previous trials of patients on placebo 
medications. The absolute size of the difference in PD severity between the 
Exenatide-treated and untreated groups using blinded rating was modest (4.9 points 
in MDS-UPDRS part 3), although this value excluded the additional effects on 
rigidity scores, which were only evaluated using open-label rating. Inclusion of the 
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rigidity scoring made by the unblinded investigator equated to a 7.0-point difference 
in MDS-UPDRS score at 12 months and a 7.2-point difference at 14 months.  
Adding the blinded video rating of MDS-UPDRS part 3 to the differences seen 
in parts 1, 2, and 4 of the scale equated to a 13.8-point advantage in favour of 
Exenatide at 12 months and a 12.3-point advantage at 14 months. The changes 
detected in MDS-UPDRS scores were also largely reflected in the timed motor tests. 
However, there were no significant changes detected in depression or subjective 
ratings of quality of life (i.e., PDQ39 summary index). 
The data presented herein demonstrated that clinically informative data can be 
obtained in a very cost-efficient manner as part of the process of selecting drugs for 
future study as potential neuroprotective agents in PD. These data support further, 
double-blind trials of Exenatide as a potential disease-modifying drug in PD, which 
will incur substantially greater costs than were required for the current study. It is 
arguable that prevention of deterioration is more achievable in the earlier stages of 
PD, when a greater number of dopaminergic neurons are still viable. While the major 
cohort of interest for future trials may be subjects with early PD, the data presented 
here indicate that further investigation of Exenatide as a treatment in later stages of 
PD may also be warranted. 
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3 123I FP-CIT SPECT in a subgroup of Exenatide treated 
patients. 
3.1 INTRODUCTION 
 The mechanism of action through which Exenatide has beneficial effects in 
the animal models of PD is unproven. One hypothesis is that the drug leads to 
dopaminergic neurogenesis through GLP-1R, stimulating neuronal proliferation. In a 
human, such neuronal proliferation could be accompanied by increases in the activity 
measured by DaTSPECT scan. An alternative is that on-going inflammation leads to 
DA cells adopting a quiescent state and stopping DaT mRNA transcription. GLP-1 
receptor stimulation may reduce inflammation. Another alternative is that GLP-1 
stimualtion stops on-going cell death so there is less decline in DaTSPECT scan in 
patients v controls. 
This hypothesis is based on the work done using immunohistochemical 
methods with stains that label different cell division markers. Different researchers 
have used this approach to study the effects of GLP-1R activation in rodent-based 
models of neuronal proliferation. In vivo work done with adult rodents chronically 
treated with Exendin-4 has shown an incremental cell proliferation in the 
hippocampus dentate gyrus of these animals as reflected by the elevation in BrdU 
and doublecortin (DCX) staining, a marker of immature neuronal tissue.  
Testing Exendin-4 on primary adult mouse hypothalamic cultures, an elevated 
level of bromodeoxyuridine (BrdU) staining, an analog of thymidine/uracil that 
reflects the levels of nuclear DNA, was observed (Belsham et al. 2009). In addition, 
authors report an elevation in the levels of gene transcripts for Ki-67, a specific 
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nuclear protein found only in actively dividing cells (Isacson et al. 2011). Long term 
administration of Exendin-4 in vivo for 21 days induced an elevation of Ki-67 
staining in the subgranular zone of adult mouse dentate gyrus, reflecting higher 
levels of proliferation ( Li, H. et al. 2010).  
It is worth noting that results reporting cellular proliferation in vitro appear to 
be dependent upon the model used. For example, on PC12 cell line, derived from a 
form of tumour located in rat adrenal tissue, it was not possible to prove any 
significant level of proliferation induced by GLP-1 treatment (Perry et al, 2002b). 
However, in SH-SY5Y cells derived from a human neuroblastoma cell line, evidence 
of proliferation was shown at physiologically relevant doses of GLP-1 and Exendin-
4. 
 In primary rodent culture, the effect of Exendin-4 has been investigated on 
neural stem/progenitor cells in the subventricular zone of the adult rodent brain. 
Exenind-4 produced an increase in the number of neural stem/progenitor cells, and 
the number of cells expressing the neuronal markers microtubule-associated protein 
2, beta-III-tubulin, and neuron-specific enolase. This same group of researchers gave 
Exendin-4 intraperitoneally to naïve rodents together with BrdU, showing an 
increase in the number of BrdU positive cells and in the number of neuronal 
precursor cells expressing DXC (Bertilsson et al. 2008). 
3.1.1  Imaging biomarkers in PD 
The well characterized pathophysiological feature of PD is the degeneration of 
dopamine neurons. Based on this, different imaging markers have been developed 
for evaluating PD. In an effort to demonstrate different aspects of dopaminergic 
neuronal function, presynaptic terminal have been targeted. The nigrostriatal 
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degeneration preferentially affects the putamen, which is in agreement with results 
from autopsy studies, which report a more severe depletion of DA in the putamen 
than in the caudate nucleus (Kish et al. 1988). This finding is likely due to the more 
extensive degeneration in PD of subpopulations of substantia nigra cells that project 
primarily to the putamen (Goto et al. 1989). 
Radiolabelled tracer-based neuroimaging techniques, such as SPECT and PET, 
rely on infusing the patient with a radiolabelled molecule with an affinity to a 
molecule/complex that is relevant to the pathophysiology. 
Three key molecular targets for neuroimaging biomarkers in PD are the 
dopamine transporter (DAT), the vesicular monoamine transporter (VMAT), and the 
enzyme dopa decarboxylase, all three targeting presynaptic dopamine functions with 
single photon emission computerized tomography (SPECT) and positron emission 
tomography (PET).  
The detection of the small changes in the signal in a population of progressing 
PD patients demands more rigorous quantitative markers of disease (quantifiable and 
reproducible). Additionally, the most rigorous requirements of the imaging ligand 
are posed by studies which attempt to evaluate interruption in the normal progressive 
loss in PD, which could slow the rate of the expected signal loss of 6-13% per year, 
expressed as percent loss from baseline.  
Radioligands such as 18F-DOPA, 11C-VMAT2, and dopamine transporter 
(DAT) ligands have been used as radiolabeled markers for the dopaminergic system 
to evaluate patients with PD (Morrish et al. 1996; Nurmi et al. 2000; Frey et al. 
1996; Marek et al. 2001).  
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• 18F-DOPA: This ligand is a marker for dopamine synthesis in the neuron. 
Specific uptake with 18F-DOPA depends on the conversion of 18F-DOPA by the 
aromatic amino acid decarboxylase and uptake and trapping of 18F-dopamine into 
synaptic vesicles.  
• 11C-VMAT2: The vesicular monoamine transporter sequesters newly 
synthesized or recovered monoamines (dopamine, norepinephrine, serotonin, and 
histamine) from the cytosol into the synaptic vesicles thereby protecting the 
neurotransmitters from catabolism by cytosolic enzymes and packaging them for 
subsequent exocytoxic release.  
• DAT: The dopamine transporter (DAT) is a protein on the nerve terminal 
responsible for reuptake of dopamine from the synapse, thus is used as a marker of 
DA transport (Brooks 1997).  
 
These three markers have demonstrated reduced uptake in the striatum, the 
location of the presynaptic nigral dopamine terminal projections. Therefore the 
striatum is a region that has a very high density of target sites, thus permitting high 
quality quantitative signal assessment. 
A growing body of evidence has emerged from clinical research performed 
with 18F-DOPA- PET, demonstrating its feasibility of detecting changes in early 
PD, as well as in PD patients studied longitudinally, and interestingly, measuring the 
effects of possible disease-modifying therapies on the neurodegenerative process 
(Morrish et al. 1996; Nurmi et al. 2000).  
Among the DAT tracers, 123I-β CIT, 123I altropane, 123I FP-CIT and 99mTc-
TRODAT have been the most widely used dopamine transporter agents for SPECT, 
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and 18F-CFT for PET (Fischman et al. 1998; Huang et al. 2001; Nurmi et al. 2000; 
Booij, Speelman, et al. 2001). A tropane derivative of cocaine (FP-CIT, 
DATSCAN®) is available as a 123I labelled tracer.  
123-I-labelledN-(3-iodoprop-2E-enyl)-2-β-carbomethoxy-3β-(4-methylphenyl) 
nortropane, named PE2I, is a relatively new radioligand that has about 10-fold 
higher in vitro selectivity for the DAT than for the serotonin transporter (SERT) 
compared 123IFP-CIT (Ziebell 2011) . 
Finally, in terms of the differences among scanners, PET scanners have better 
resolution than SPECT scanners, and may benefit from greater flexibility in the 
range of radiopharmaceuticals that can be tested. Nevertheless, SPECT studies may 
be technologically more feasible for clinical studies and in clinical practice, because 
they have the advantage of longer half-life radiopharmaceuticals and potentially 
lower cost. 
3.1.2 Properties of imaging biomarkers 
The imaging marker should be tailored accordingly to the research question. At 
this point, despite the fact that both 18F-dopa PET and 123I B-CIT SPECT measure 
different features of dopamine function, they have shown a very good concordance 
of imaging findings. Both tracers have shown bilateral reductions in striatal tracer 
uptake in hemiparkinson patients with greater reduction on the site of the brain 
contralateral motor symptoms; around 50% signal loss for contralateral compared 
with 20-30% loss of ipsilateral relative to age-matched healthy control values. 
Several studies using dopamine transporter (DAT) imaging agents in normal 
healthy subjects over a wide age range demonstrate age-related reductions in tracer 
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uptake(van Dyck et al. 2008; van Dyck et al. 1995). In studies of disease 
progression, both tracers consistently demonstrate that subjects imaged serially over 
several years, show a significant reduction of the imaging signal on the order of 5–
11% per annum (Booij et al. 2001; Morrish et al. 1996; Brooks 2000a; Marek et al. 
2001). Because the loss of striatal uptake is small and can vary both between patients 
and within patients over their course of disease, when the purpose of the imaging 
study lies in serially monitoring the progression of disease, the radiotracer should be 
amenable to accurate and reliable quantitation. 
3.1.3 Imaging and clinical assessments of PD progression 
Clinical trials designed to follow progression of disease or establish a disease-
modifying effect of a treatment in PD are very difficult to design and execute. This 
difficulty is due to: (1) different rates of PD progression; (2) extended medication 
washouts necessary to remove symptomatic effects for purposes of accurate clinical 
assessment of patients; (3) duration of the trials need to be long enough to allow 
measures of disease progression or evaluation of potential disease-modifying 
interventions. Therefore biomarkers for disease progression that are unaffected by 
symptomatic treatments and can be assessed repeatedly throughout the duration of 
the study have become an increasingly crucial component for evaluations of 
potential disease-modifying drugs. 
3.1.4 History of neuroimaging trials of PD progression 
In longitudinal studies of PD progression using both PET and SPECT, the 
annual rate of reduction in striatal 18F-DOPA, 18F-CFT, 123I β CIT, and 123I FP-CIT 
uptake is about 6% to 13% in PD patients compared with 0% to 2.5% change in age-
matched healthy controls (Morrish et al. 1998; Staffen et al. 2000; Nurmi et al. 2000; 
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Brooks 2000b; Brücke et al. 2000; Marek et al. 2001). Examples of which include 
the REAL-PET trial using 18F-dopa PET, and the CALMPD study with 123I β-CIT 
SPECT, both of which followed PD patients over 2 and 4 years to study disease 
progression, looking at the effects of dopamine (DA) and levodopa (L-dopa) in early 
PD patients with imaging and clinical outcomes. 
3.1.4.1 The CALM-PD trial 
In the CALM-PD trial, the effects of initial treatment with dopamine agonist 
pramipexole were compared with levodopa, with regard to the development of major 
dopaminergic motor complications in patients with early PD (less than 7 years of 
disease duration)(Parkinson Study Group 2000). To compare the rates of dopamine 
neuron degeneration after initial treatment with pramipexole or levodopa, 82 out of 
the 301 patients entered an imaging study using the percentage change from baseline 
in striatal 123I β-CIT uptake after 46 months, as the primary outcome measure. 
Patients initially treated with pramipexole showed a decline in mean (standard 
deviation) 123I β-CIT striatal uptake from baseline of 20.7% (14.4%) at 46 months, 
compared to 25.5% (14.1%) decline seen in the levodopa group. The relative 
reduction in percent loss from baseline of 123I B-CIT uptake in the pramipexole 
versus levodopa was 37% less at 46 months after initial treatment. A correlation of 
the 123I B-CIT percent reductions with percent change in UPDRS scores was not 
demonstrated at 22 months follow-up, but significant correlation was shown at 46 
months (Parkinson Study Group 2002b). 
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3.1.4.2 The REALPET trial 
In contrast, the REAL-PET trial randomised 162 de novo PD patients with 
symptom duration of 2 years or less to have ropinirole or L-dopa, using reduction in 
putamen 18F-dopa uptake between baseline and 2 year as primary outcome measure 
(Whone et al. 2003). The group treated with the dopamine agonist ropinirole had a 
13% reduction of 18F-dopa over two years, compared with a 20% reduction in the L-
dopa cohort. This represents a relative reduction of 35% less signal loss in the 
ropinirole group than in the levodopa group. However it is important to point out that 
the reduction of 18F-dopa did not correlate with changes in UPDRS scores. 
3.1.4.3 The ELLDOPA trial 
The ELLDOPA trial evaluated a cohort of newly-diagnosed de novo PD 
patients, randomising them to receive either a placebo, or one of three doses of L-
dopa (150mg, 300mg, or 600 mg) and followed over 9 months. The authors 
hypothesised that L-dopa is neurotoxic, therefore it was expected to enhance the rate 
of disease progression despite providing symptomatic benefit (Fahn 1999). After two 
weeks of medication washout, UPDRS scores in all the L-dopa groups increased, but 
did not return to the level of the placebo group, suggesting either that L-dopa is 
neuroprotective or that the two week washout was not long enough. The imaging 
data showed a near significant trend for increased percent loss of 123I β-CIT SPECT 
in the high dose levodopa group compared with placebo.  
Given the comparative design of the REAL-PET and CALM-PD studies, we 
cannot distinguish whether the DA agonists (ropinirole or pramipexole) were acting 
as neuroprotectors, slowing the rate of DA terminal loss, or whether L-dopa was 
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increasing the rate of terminal loss (or a combination of both effects). One possible 
conclusion that could be drawn from these imaging data is that L-dopa is neurotoxic. 
However, an alternative explanation is that the dopamine transporter is regulated by 
L-dopa treatment, causing the observed signal changes. Other issues are the lack of a 
placebo control in all these trials and the poor correlations among imaging and 
clinical scores. On one side this discordance could be explained by difficulty in 
achieving complete medication washout of PD patients, compromising the 
assessment of native disease status. However, the possibility that regulation of the 
imaging target site (dopa decarboxylase for 18F-dopa, dopamine transporter for 123I 
β-CIT) may affect interpretation of neuroimaging data in long-term PD progression 
studies shouldn’t be neglected. 
In light of the recent use of functional imaging to monitor progressive 
dopaminergic degeneration, a small imaging arm was incorporated into the 
Exenatide trial design to evaluate whether there was any evidence of a change in pre-
synaptic dopaminergic integrity (123 I-FP-CIT DaT SPECT scans). 
3.2 METHODS  
3.2.1 3.2.1. Patients  
Due to budgetary constraints, not all trial participants could undergo imaging. 
As a pragmatic compromise, the first 10 (8 males, 2 females; mean age 60.3 years ± 
4.8) of the 20 patients randomised to Exenatide treatment were invited to have a 
DaT-SPECT scan at baseline (before treatment initiation) and after 12 months of 
Exenatide therapy. The disease duration within the cohort ranged from 5 to 14 years 
(mean 8.3 ± 3.1), and the mean UPDRS-III off blind score was 29 ± 11.05. These 10 
patients received an appointment to attend the Nuclear medicine department (UCLH) 
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for the injection of the radio-tracer, followed by the SPECT acquisition. All the 
patients received iodide capsules by post.  
3.2.2 SPECT acquisition 
Subjects received four 60mg oral capsules of potassium iodide; two were taken 
the evening before the tracer was administered, and two were taken in the evening 
following the scan, to block thyroid uptake of free radioactive iodine.  
The scans were performed at the Institute of Nuclear Medicine, University 
College Hospital, London. The radiopharmaceutical was purchased commercially 
123I-FP-CIT, Amersham Health, GE Healthcare). On the day of scanning subjects 
were injected intravenously with a bolus of 123I-FP-CIT (approximately 185 MBq, 
specific activity N 100 TBq mmol-1). Subjects were scanned using a dual detector 
rotating gamma camera (GE Infinia Hawkeye) fitted with a low-energy high-
resolution parallel hole collimators. The optimum time of acquisition was defined as 
the time at which specific radioactivity in the striatum (total striatal counts minus 
counts in the occipital cortex) was at a stable level (Booij et al. 1997); in our cohort, 
this meant scanning started between 180 and 240 minutes after radiotracer injection. 
One hundred twenty projections with a 128 x 128 image matrix were acquired at 40 
seconds per view with the camera heads following a circular orbit, resulting in a total 
scan time of 43 minutes. 
The SPECT data were reconstructed by OSEM iterative reconstruction using 
10 iterations, 10 subsets and a Butterworth post filter cut-off of 0.55 cm-1 and power 
factor 10. The reconstructed images, uncorrected for gamma ray attenuation, were 
subsequently converted to Interfile format for further analysis. This same procedure 
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was repeated at 12 months follow up, the day after the last injection of Exenatide at 
month 12. 
3.2.3 Analysis of SPECT data: Overview 
SPECT data were scrutinised using two separate analysis methods. Data were 
first analysed using a region-of-interest-based approach, where the signal in each 
predefined region was extracted, and the statistical tests performed. The data were 
subsequently analysed using Statistical Parametric Mapping (SPM). 
3.2.3.1 Analysis of SPECT data: Region-of-interest analysis 
The data were first registered to a Tailairach and Tournoux based template 
using a modified version of the Brain Analysis Software (BRASS, version 3.4.4; 
Hermes Medical Solutions). An automated multistep procedure consisting of an 
initial nine-parameter linear fit was used (scale, translation and rotation in each the x, 
y and z planes), and subsequent fine adjustment of a standardized 3D volume-of-
interest (VOI) map (Koch et al. 2005). We hypothesised a priori that we would be 
most likely to find changes within the striatum, as has been demonstrated in previous 
functional imaging studies monitoring PD progression. For this reason, our region of 
interest included the whole striatum. For completeness, the striatum was further 
subdivided in the caudate nucleus and putamen to assess whether changes were 
localised or diffuse. The occipital cortex served as a reference region given it is 
almost devoid of DA transporters (De Keyser et al. 1989). Any activity within this 
region was thus considered ‘non-specific’ activity (noise). 
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The volume of interest (VOI) map included the whole striatum, as well as a 
reference region within the occipital cortex. Sub-masks were able to isolate voxels of 
the caudate nucleus and the putamen separately in each hemisphere. 
Mean counts per voxel within each VOI were calculated, as well as the ‘uptake 
ratio’, that is, the ratio of counts within the striatal regions (striatum, putamen and 
caudate nucleus) to the occipital region, as performed previously by (Koch et al. 
2005). 
The uptake ratio in each region of interest was recorded at each time point 
(baseline and 12 months). The striatal (and indeed caudate or putamen) uptake ratio 
is not a straight ratio. It is e.g. (striatal-occipital)/occipital. This means that the 
striatal region of interest counts has to be adjusted for non-specific binding within 
the region and then divided by the non-specific (occipital) uptake. 
The absolute change in uptake ratio between the two time points were then 
calculated, as well as the percentage change. Correlations between SPECT uptake 
ratios and clinical rating scale scores (UPDRS and Mattis DRS-2- For full 
description of Non motor assessments see Chapter 5) were investigated using a 
Spearmen’s statistical test. A P-value less than 0.05 was considered significant.  
3.2.3.2 Analysis of SPECT data: Statistical Parametric Mapping 
Data were formally interrogated using SPM, version 8 running in Matlab. Data 
were pre-processed in the normal way. Data were first realigned and the data from 
different time points were coregistered. Data were then spatially normalised to a 
standard MNI space, and then spatially smoothed using a Gaussian kernel (10mm 
full-width half maximum). 
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Once the images were spatially normalised and smoothed, the general linear 
model (Chatfield, C., Collins 1980) was employed to perform the appropriate voxel-
wise univariate statistical tests. Image intensity was normalised between subjects to 
prevent inter-subject variability masking the regional changes. This was performed 
using proportional scaling (Frackowiak et al. 1997), which scales each image 
appropriately to a reference region. Total counts in the brain were used for the 
proportional scaling. So proportional scaling was performed by dividing the intensity 
values for each scan by the mean count per voxel for the scan.  
  The analysis threshold was set at the intensity (100%) of the occipital mean 
voxel count as this appeared to remove most of the regions containing little or no 
specific uptake, leaving the striatal uptake for analysis.  
Statistical inference about regional effects was estimated from the 
distributional approximations using Gaussian random field theory (Friston et al.. 
1994). 
Brain regions with increased and decreased FP-CIT binding between subject 
groups were assessed using standard T-contrasts (contrast weights: increased = (1, -
1); decreased = (-1, 1), and examined by superimposing the ensuing maps (SPMs) 
onto an anatomical template image. All statistical maps were threshold for peak 
height at the level P ≤ 0.05. Correction for multiple comparisons was made using 
Family Wise Error rate (FWE). 
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3.3 RESULTS 
3.3.1 Region of interest analysis 
There were no changes in dopamine transporter availability pre- and post- 
Exenatide treatment using VOI analysis. Quantified uptake of 123I-FP-CIT at 
baseline, together with absolute change and percentage change in 123I-FP-CIT uptake 
at 12 months did not show difference for each sub-region of the basal ganglia for 
each individual, as presented in Table 12. All patients had profoundly abnormal 
scans at baseline with some variation in severity of pre-synaptic dopaminergic deficit 
(See Table 11). Two patients with severe baseline pre-synaptic deficits had minor 
improvement in 123I-FP-CIT uptake in all basal ganglia sub-regions at 12 months 
(Patients 2 and 5. Figure 5). One person had deterioration in all sub-regions (Patient 
9). Mean values for absolute and percentage changes in 123I-FP-CIT activity showed 
minimal change in all basal ganglia sub-regions at 12 months. .  
No correlations were found between SPECT uptake ratios and clinical rating 
scale scores (UPDRS and Mattis DRS-2). 
3.3.2 Statistical parametric mapping 
Statistical parametric mapping was performed using baseline UPDRS as 
covariate, no correlations among UPDRS and change in 123I-FP-CIT uptake was 
found.  
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Table'11.'[123I]FP8CIT'Uptake'ratio'of'VOI'to'occipital'cortex'at'baseline'
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Table' 12.' Change' in' striatal' [123I]FP8CIT' Uptake' between' baseline' and'
month'12'for'each'patient.'
Absolute levels of [123I] FP-CIT uptake are presented for each patient, together 
with absolute change and percentage change at 12 months scan (Bold 
type/positive values indicate improvement in [123I]FP-CIT compared with 
baseline scan). 
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Table' 13.' Mean' (SD)' of' change' in' Striatal' [123I]FP8CIT' Uptake' between'
baseline'and'Month'12'
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Figure'5.'[123]FP8CIT'SPECT'pre'and'post8therapy'of'patient'2'and'5'
 
3.3.2.1 DISCUSSION  
In the absence of a placebo group, or any reliable measure that tracks the 
pathology of PD, our trial design incorporated a functional imaging arm that 
theoretically allowed us to get some indication of whether Dat SPECT scan might be 
a useful secondary outcome of effectiveness of Exenatide as disease modifying 
agent. 
Different studies have utilised different functional imaging methods to image 
the dopaminergic pathway. There has been some controversy about the suitability of 
123I-FP-CIT- SPECT for assessing the progressive loss of striatal dopamine nerve 
terminal function (Morrish 2003). The choice of imaging modality is ultimately 
determined by the specific study questions and study design. 18F-dopa PET has been 
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shown to provide reliable measures over a short period of time, but it is extremely 
expensive, therefore it was unavailable due to budget restrictions (this trial was 
charity funded). Thus, our imaging arm subgroup was chosen using 123I-FP-CIT - 
SPECT scans that may lack the sensitivity to detect gradual changes in the 
nigrostriatal pathway once the disease has started, in contrast to 18F-dopa PET 
images, but offer a cheaper and more feasible approach. 
In prior imaging studies, the annual percentage loss of 123I-FP-CIT striatal 
uptake of early PD patients has been reported as declining at 4.5% per year over the 
first 2 years then 3.0% per year over the subsequent 3 years (Pirker et al. 2003). 
However, a smaller reduction in DAT binding per year has been reported by a few 
studies on PD patients with a disease duration of more than 5 years (Marek et al. 
2001; Colloby et al. 2004) suggesting a slowing down of the progression in the case 
of more advanced disease. On the other hand, in a cohort of 139 healthy controls for 
13 different centres, an average age-related decline in [123I]FP-CIT- SPECT 
availability of 5.5% per decade was found for both genders (Varrone et al. 2013). No 
differences were found in SPECT availability in our group when comparing images 
at baseline with the ones at month 12. Moreover, pre- and post-treatment DAT 
availability was assessed using SPM, but again no significant difference was found.  
An interesting point that should be considered is that the majority of the 
patients in these studies were untreated at the time of the baseline scan and started 
antiparkinsonian medication before the follow-up scan. Results of the ELLDOPA 
trial suggest that levodopa may downregulate striatal dopamine transporter binding 
(Fahn 1999).This could be an explanation for the higher rates of progression that 
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have been found in imaging studies with de novo patients (Nurmi et al. 2000; Marek 
et al. 2001). 
Moreover, important criticism have been raised in the past for the use of 123I-
FP-CIT- SPECT in neuroprotection studies, mainly driven by concerns about the 
very strong influence of scan to scan variability, as well as reproducibility of the 123I-
FP-CIT SPECT technique. It has been pointed out that considering that variability of 
SPECT measurement is substantially larger than the average annual decline of 
striatal binding, its suitability for measuring disease progression should be 
questioned.  
The quantification of the radioligand binding in our study was performed 
automatically, using an automated three dimensional quantification on a voxel by 
voxel basis. This observer-independent automated system standardizes the 
semiquantification procedure, avoiding observer bias/dependency. 
Another criticism that should not be forgotten, in progressive stages of 
parkinsonian syndromes, as it was the case of our imaged patients, is the little 
residual activity found in the caudate nucleus and almost none in the putaminal area, 
which might result in incorrect transformation of the data, introducing new sources 
of error. Errors can be introduced when imaging data are exported into mat lab 
software for analysis.  
 On the top of that, despite optimal standardization of manual ROI analyses, 
observer-independent automated systems are required to standardize the 
semiquantification process and to overcome observer dependency. The BRASS 
software allowed us to register the patients’ studies to a tracer-specific template of 
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healthy control subjects and then apply a standardized 3D VOI map for 
semiquantification. Therefore objective and observer-independent semiquantification 
of the ligand binding in the striatum was performed. 
Different outcomes have been published so far in relation to correlations in 
imaging outcomes and clinical outcomes. Longitudinal studies have shown only 
weak correlations at best between the change in imaging outcomes and the change in 
clinical outcomes. The REAL PET study did not find significant correlation, and the 
CALM-PD imaging study, with a much larger cohort, found significant correlation 
between the percentage reduction of striatal β-CIT binding and the change in total 
UPDRS, but only for the longest follow-up group at 46 months from baseline 
(Parkinson Study Group 2002b). Consequently it has been suggested that correlation 
between imaging and clinical outcomes can emerge in larger groups of patients 
followed up for longer enough periods (Pirker et al. 2003). In our group no 
correlations were found among the changes in part III UPDRS (Blinded scores) that 
improved significantly in Exenatide treated patients along the 12 months follow up 
and the difference in DAT availability in the imaged patients.  
There are several explanations for the lack of correlation between [123I]-β-CIT 
or [18F]-dopa uptake and UPDRS in longitudinal studies. To start with, the UPDRS 
is confounded by the effects of the patient’s anti-PD medications both acutely after 
initiation of therapy and with ongoing treatment. The UPDRS “off medication” state 
might be affected by prolonged washout medication period, consequently, some 
symptomatic effect might remain (Seibyl 2003). Another point to consider is that the 
rate of loss of dopamine terminals and the change of UPDRS may not share a simple 
linear relationship. This is reflected by the loss of 40-60% of striatal 123I-β-CIT or 
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18F-dopa uptake at the time of diagnosis (Tissingh et al. 1998), when UPDRS score 
is minimal. As UPDRS scores slowly increase later in the disease (at a rate of 1.34 – 
1.58% a year) (Poewe 2009), imaging markers during this period show the expected 
continued loss of β-CIT or F-dopa uptake (Benamer et al. 2000), again indicating 
that clinical and imaging outcomes provide complementary but not necessarily 
correlative data.  
Therefore DAT availability did not support a neuroprotective action of 
Exenatide in our group of patients. The SPM analysis was repeated using the 
baseline, pre-treatment UPDRS as a covariate, to see if different disease severity at 
baseline could influence the 123I-FP-CIT striatal uptake at month 12, but no 
significant correlation were found either. 
We acknowledge that a weakness of our imaging study is the lack of imaging 
data in the control group and sample size (only half the treated patients had scans). 
This was due to financial restrictions.  
Although our results do not survive statistical testing, there appears to be 
improvements in more regions than decline. This is interesting and the mean change 
in activity and SD, allows future sample size calculations for subsequent studies. 
 
 
 
 
 
  
 
136 
 
 
4 TWO YEARS FOLLOW UP OF TRIAL PATIENTS  
4.1 INTRODUCTION 
Ahead of the last patient reaching the14 month visit, the idea of performing a 
prolonged open label follow up visit at 24 months emerged. This would potentially 
provide further information about the longevity of any effects of the 12 month period 
of Exenatide exposure (biological, placebo or otherwise) in our cohort. A substantial 
amendment of the protocol was REC/ MHRA approved to perform a further detailed 
assessment of all participants at 2 years post baseline assessment. The aim of this 24 
month assessment was to further clarify whether any changes associated with 
Exenatide exposure at 12 and 14 months were sustained over this longer follow up 
period. 
4.2  METHODS  
(See chapter 2.2) 
4.2.1 Patients 
The 44 patients (Exenatide group: 20, Control group: 24) included in the final 
analysis at 12 and 14 months, all then underwent a 24 month clinic assessment using 
the same battery as previously performed. 
4.2.2 Patients who had undergone DBS 
Three out of the 44 patients followed up at 24 months, had clinically 
deteriorated and had needed Deep Brain Stimulation for the treatment of the PD 
symptoms between the 12 and 24 month follow up; 
• One in the Exenatide group, 16months after baseline assessment. 
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• Two in the Control group.  
! One at 14 months follow-up. This patient did not attend the trial clinic at 14 
month due to worsening PD and inability to attend being off medication. 
! One at 16 months follow-up. 
Patients undergoing DBS frequently have substantial lowering of their 
conventional PD medication. This can mean that assessments in the Off medication 
and OFF stimulation setting can be associated with much more profound severity of 
“OFF” symptoms and signs, presumably because of the long duration response to L-
dopa replacement that is not seen in the “practically defined “Off” state after a short 
overnight withdrawal (Piboolnurak et al. 2007). Therefore OFF assessments in these 
3 patients would be a source of bias and not comparable with the rest of the cohort. 
Similarly their On drug and ON stimulation assessments would also be a potential 
bias. For this reason, the decision was taken to use “last observation carried forward” 
(LOCF) for these patients for their motor scores (UPDRS, Dyskinesia rating Scale 
and Timed Test) and L-dopa equivalent dose (LED) at the 24 month assessment. For 
2 patients this was the data collected at 14 months, for 1 patient this was the data 
collected at 12 months. Non motor scales were collected at 24 months from all 
patients. 
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4.2.3 Schematic diagram of 2 years post baseline trial design  
  
Figure'6.'Schematic'diagram'of'2'years'post'baseline'trial'design'
 
4.2.4 Twenty four month assessments  
Patients were sent the PDQ39, to self-complete and bring to the clinic. 
All patients withheld all PD medications as previously described, see section 
2.2.2.iii. baseline visit. They were asked not to have eaten and to have only drunk 
water for 12 hours enable fasting blood samples to be taken. 
Each patient had blood tests to measure fasting serum glucose.  
All patients had a video recording of UPDRS part 3 score, performed timed 
motor test and then took their regular medication. The patients were asked to 
complete UPDRS part 1, 2, 4, and when confirmed that their best on state was 
achieved, they had a further video of UPDRS part 3 score. During their on phase, the 
Dyskinesia rating scale, MADRS, Mattis DRS was completed (Non-motor 
assessments are discussed in Chapter 5). Clinical observations (weight, pulse and 
blood pressure) were also collected and their current PD medication regime was 
noted. The adverse events along the previous year were recorded. 
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4.2.4.1  Blinded Video rating 
Blinded rating of videos was performed by the same individuals trained and 
certified in MDS-UPDRS rating. Individuals were allowed to view videos and their 
previous scores at baseline, 12 months, 14 months while assessing the 24 month 
videos to ensure consistency across timepoints. The treatment status of 1 individual 
had become known to one of the blinded raters and therefore all their videos were 
assigned to a different blinded reviewer for re-scoring at each timepoint. 
4.2.4.2 Analyses 
Comparisons were made between the change at 24 month in primary outcome 
(Part 3 MDS UPDRS) and change at 24 month in secondary outcomes; MDS 
UPDRS part 1, 2 and,4 ,LED, Dyskinesia rating Scale, timed test and PDQ39 using 
2-sided t test. 
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Table'14.'Twenty'four'month's'assessment'overview'
4.3 RESULTS 
 Twenty four months follow up visit started in August 2012, and last patient 
was seen for the 24 month assessment in March 2013. 
 The 44 patients (Exenatide group 20: Control group 24) included in the 
primary analysis at 12 and 14 month had a 24 follow up and were included in 
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primary analysis at 24 month. There were no missing data (allowing for the LOCF 
motor scores for the 3 patients who had undergone DBS surgery). 
4.3.1 Clinical outcomes 
4.3.1.1 Blinded video rating of MDS-UPDRS part 3 in the practically 
defined “off medication” condition 
Patients allocated to the Exenatide group had a mean improvement at 24 
months of 1.1 points (SD, 5.9) on the MDS-UPDRS part 3, while controls had a 
mean decline of 4.5 points (SD, 5.3) for a difference of 5.6 points (95% CI, 2.2-9.0; 
p=0.002; Table 15). These scores did not include any changes detected in limb or 
neck rigidity, which cannot be reliably rated on video. Addition of open label rating 
of rigidity scores to the blinded data equated to a decline of 0.5 points (SD,7.3) in the 
Exenatide group, compared with a decline of 8.5 points (SD, 6.3) in the control 
group ( difference, 8.0 points; 95% CI, 3.8-12.2; p<0.001); (Table 15 & Figure 7) 
There was a significant improvement in bradykinesia subdomain of part 3 
MDS UPDRS at 24 months in the Exenatide group in comparison with the control 
group, for a difference of 4.1 points (95% CI ,1.6-6.6 , p=0.002). Similarly there was 
an improvement in the rigidity subdomain (open label data) favouring Exenatide, 
with a difference of 2.4 points (95% CI, 0.5- 4.2, p=0.014). There were no 
significant differences in the axial and tremor subdomains of MDS-UPDRS part 3 
between Exenatide and control group. 
4.3.1.2 Secondary outcome measures 
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• Part 3 MDS UPDRS on medication motor subscore. Open label rating of 
MDS-UPDRS part 3 “on medication” showed a significant difference (p<0.001) 
favouring patients treated with Exenatide compared with the control group. The 
mean improvement in “on medication” scores in the Exenatide group was 0.9 points, 
SD (6.8) at 24-month visit. In contrast, individuals in the conventional PD 
medication group deteriorated over the 24-month trial period by 7.8 points SD (6.7). 
• There was a significant difference favouring Exenatide in MDS-UPDRS 
parts 1 (p=0.049) and 2 (p=0.009) (UPDRS ADL). 
• There was an advantage in Exenatide group for MDS-UPDRS part IV, LED 
or Dyskinesia Rating Scale (Tables 15 and 16), although this did not reach threshold 
for statistical significance. 
• There was significant improvement in Left hand tapping test on medication 
state (p=0.026). No further significant differences were found in the other tapping 
tasks or walking timed tests (Table 18 &19). 
• There was no improvement in PD-39 summary index between the 2 groups 
(Table 16). There was an advantage in cognition subdomain with a mean 
improvement in the Exenatide group of 3.1points, SD (9.8) at 24-month visit. In 
contrast, individuals in the conventional PD medication group deteriorated over the 
24-month trial period by 0.2 points SD (13.7), although this was not significant 
(p=0.363). There was also an advantage in the communication subdomain with an 
advantage of 2.9 points , SD(18.2) at 24 months in the Exenatide group and a 
deterioration of 2.8 points, SD (16.6)in the control group (Table 19 &20). 
4.3.1.3 Adverse events 
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 There were no serious adverse events at 24 months. No clinically relevant 
changes in haematological, or biochemical indices were observed. 
 Patients allocated to the Exenatide group had a mean weight loss at 24 
months of 1.6 Kg SD(3.1), while controls had a mean weight loss of 1.7 kg SD(5.8) 
for a difference of 0.1 points (95% CI, 3.0-2.8; p=0.93) (Adverse events reported by 
trial participants at month 24 are presented in table 17). 
4.3.1.4 Correlations of clinical outcomes  
Change in MDS UPDRS part 3 at 24 months was not correlated with younger 
age at disease onset, or younger age at start of the trial. No correlation was found 
among change in MDS UPDRS part 3 at 24 months and change in weight at 24 
months. 
No correlation was found among Hoehn and Yahr state (2 vs 2.5) at baseline 
and change in MDS-UPDRS part 3. 
4.4 DISCUSSION  
There is a difference at baseline between groups in terms of age at study 
enrolment with the Exenatide group having an older age 61.4(6.0) years versus 
control group having 59.4 (8.4) years and disease duration with Exenatide having a 
shorter disease duration 9.6 (3.4) years than conventional PD medication 11.0 (5.9) 
years, that could be a source of confounding. It is important to take into account that 
on one hand older age of onset has been associated with more rapid progression (A 
Schrag et al. 2006) but on the other hand it has been proposed that the rate of 
progression in early PD is faster than in later disease (Fearnley & Lees 1991; Hilker 
et al. 2005; Anette Schrag et al. 2007)  
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Inclusion of the rigidity scoring made by the unblinded investigator equated to 
an 8.0 points difference in MDS-UPDRS part 3 score at 24 months. Adding the 
blinded video rating of MDS-UPDS part 3 to the differences seen in parts 1, 2, and 4 
of the scale equated to a 14.5 points advantage in favour of Exenatide at 24 months. 
Significant differences in the primary outcome (part 3 MDS UPDRS) were found 
between groups, favouring Exenatide at 24 months. This advantage favouring 
Exenatide was accompanied by effects seen across a range of other measures; 
MDSUPDRS part 1, 2 and 4, LED and Dyskinesia rating scale. However, looking at 
the MDS UPDRS part 3 “subdomain”, the advantage favouring Exenatide was 
restricted to bradykinesia and rigidity, and was not seen in the tremor or axial signs 
subdomains at 24 month. The possibility that these observations might be due to 
placebo effect cannot be completely ruled out. Due to the open label design of the 
trial is not possible to elucidate if the nature of this effect is real or placebo driven. 
Nevertheless no reports on placebo effect, lasting 24 months have been reported to 
date to my knowledge. 
A decision of extending the follow up for a sufficiently long period was taken 
to allow inevitable placebo effects to at least begin to diminish. The initial 
improvement in the main outcome (MDS-UPDRS part 3 blinded ratings) was 
sustained in the long term follow up. Despite the fact that a possible placebo driven 
effect could not be completely ruled out, the 24 month data support the idea that 
perhaps a real biological effect of Exenatide should not be completely ruled out 
either, reinforcing the possibility that open label trial designs with long wash out 
periods may provide preliminary indications of clinically relevant biological effects 
and thus provide a cost efficient means of providing further support for future study 
of Exenatide in PD patients. 
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The adverse events at 24 months are well in keeping with what would be 
expected in moderate severity PD patients. Weight loss was reversible upon stopping 
Exenatide injections, and there were no difference in change in body mass index at 
24 months among patients on Exenatide and control group. No correlation was found 
among change in part 3 MDS UPDRS at 12, 14 and 24 months and weight loss, 
making it less likely that Exenatide patients had improved motor scores as their BMI 
was reduced along the first 12 month trial period. 
There is a discrepancy between the improvement in MDS UPDRS part 2; 
activities of daily living (ADL) and the lack of improvement in PDQ39 Summary 
Index and PDQ39 ADL subdomains separately. Surprisingly, there were quite 
marked differences between some of the PDQ39 subdomains comparing Exenatide 
patients with controls at baseline. These differences at baseline, despite the 
randomisation process can be seen in small trials and may contribute to observed 
differences over the subsequent 2 years. The relative sensitivity of, the MDS-
UPDRS part 2 scale, in comparison to the PDQ39 ADL subdomain to detect change 
in ADL has not been directly compared.  
The increase in Dyskinesia Rating Scale and reduction in LED seen at 12 and 
14 months in the Exenatide group were no longer significantly different from 
controls at 24 months. This was explicable in part by 4 patients in the Exenatide 
group who had worsening of peak dose dyskinesia at 12 and 14 months that 
necessitated lowering the LED, subsequently went on to have their LED re- 
increased at 24 months. Although not reaching significance, Exenatide patients still 
had slightly more dyskinesias than controls despite lower increases in LED overall, 
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therefore it remains possible that Exenatide may worsen dyskinesia particularly 
during the period of exposure. 
 
 
Table'15.'Changes'in'MDS8UPDRS'score'between'baseline'and'month'24.'
A='Blinded'rating,'excludes'rigidity.'B'='Open'label,'includes'rigidity'
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Figure' 7.' Change' from' baseline' in' the' MDS8UPDRS' part' 3' score' by' study'
visit.'(Data'represent'mean'±'SEM)'
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Table'16.'Changes'in'the'score'on'LED,'dyskinesia'rating'scale,'and'PDQ39'
summary'index'between'baseline'and'month'14'
 
 
 
Table'17.'Adverse'events'reported'by'trial'participants'at'month'24'
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Table'18.'Change'in'the'score'on'hand'tapping'timed'test'between'baseline'
and'month'24'
 
 
Table'19.'Change'in'the'score'on'walking'timed'test'between'baseline'and'
month'24'
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Table'20.' Change' in' the'PDQ39' summary' index'and' subdomains'between'
baseline' and' month' 24
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5 EXENATIDE AND NON MOTOR SYMPTOMS OF PD 
5.1 INTRODUCTION 
Patients with PD can present with a wide array of non-motor symptoms 
(NMS), in addition to the typical parkinsonian motor syndrome. NMS are mainly 
neuropsychiatric manifestations (e.g. depression, and apathy), cognitive impairment , 
sleep disorders (e.g. rapid eye movement (REM) behaviour disorder (RBD), and 
excessive daytime sleepiness), autonomic dysfunctions (e.g. intestinal constipation, 
postural hypotension and micturitional disorders) and others, such as fatigue and 
pain. In their various combinations, NMS may eventually become the main 
complaints of patients with PD, as NMS are frequently an untreated part of the 
disease. 
NMS may be related to the neurodegenerative changes affecting several neural 
systems and/or caused by drugs employed in the treatment of PD. The main neural 
systems related to NMS are: (1) non-motor frontostriatal circuits, (2) serotoninergic 
nuclei of median raphe, (3) noradrenergic nuclei (locus coeruleus and subcoeruleus), 
(4) autonomic centres (hypothalamus and dorsal motor of vagus nucleus) and (5) 
olfactory system (Braak et al. 2006). The NMS in PD may be present in all the 
clinical phases of the disease: pre-motor phase, the initial phase (when the motor 
symptoms appear and the diagnosis is made), the honeymoon phase and in the 
advanced phase. In the pre-motor phase, the most common NMS symptoms are: 
hyposmia, depression, intestinal constipation and RBD. During the initial and 
honeymoon phases, several autonomic and neuropsychiatric manifestations may be 
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present, and in the advanced phase, the most important NMS is PD dementia 
(Chaudhuri et al. 2006).  
The presence of NMS impacts on disability and quality of life, mainly in 
advanced disease and might limit the ability to prescribe other drugs (Chaudhuri et 
al. 2006) .  
5.1.1 Measuring NMS 
Full understanding of the patient’s condition requires not only the 
consideration of symptoms and disabilities, but also patient’s perspective and 
preferences, in what has been described as a holistic approach; trying to treat the 
whole person rather than just the physical symptoms of the disease (Martinez-Martin 
2013). According to this, information coming from patient him/herself 
(questionnaires) should be considerably helpful in combination with rating scales to 
achieve a holistic assessment of PD. 
5.1.1.1 Mattis dementia Rating Scale  
The Mattis dementia Rating Scale is a widely used scale to evaluate cognitive 
functioning in older adults. A total score ranging from 0 to 144 is based on 
performance from five subscales; Attention (37 points), Initiation/Perseveration (37), 
Constructional ability (6), Conceptualisation (39) and Memory (25) with higher 
scores conferring better cognitive function (Schmidt, KS. et al. 2006).  
5.1.1.2 Montgomery and Asberg Depression Rating Scale  
A number of scales have been used to screen or measure the severity of 
depression. For screening purposes, The Montgomery and Asberg depression rating 
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scale (MADRS), has been shown to be valid for screening purposes and for 
measurements of severity of depressive symptoms (Aarsland et al. 2009). 
The Montgomery and Asberg Depression Rating Scale is a 10 item physician 
rated depression severity scale constructed to be sensitive to change with treatment. 
Each question had six responses to rate severity from zero to six, thus the total score 
ranges from 0-60. The time frame is the past week, with higher scores representing 
worse depression scores (Montgomery & Asberg 1979). 
5.1.1.3 NMS Quest  
The NMS Quest is a 30-item self-completed screening tool, with a ‘‘yes/no’’ 
response to the questions about the presence of symptoms. These are grouped in nine 
domains:  
Digestive/urinary/apathy/attention/memory/hallucinations/delusions/ 
depression/anxiety/sexual function/cardiovascular/sleep disorders/ 
and miscellany. 
The sum of positive responses indicates the number of NMS perceived by the 
patient, and the time frame is the last month (Martinez-Martin et al. 2007) . To 
obtain a standardized ranking of prevalence for each domain, the sum of each item 
for every domain was transformed to percentage on the maximum possible number 
of “yes” responses in the domain. 
5.1.1.4 SCOPA Sleep  
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The SCOPA Sleep is a 12 item questionnaire enquiring about day time (six 
items) and night time sleepiness (five items) plus a question related to the overall 
sleep quality. It has demonstrated internal consistency and test-retest reliability 
(Marinus et al. 2003; Martinez-Martin et al. 2008). Each question has four responses 
to rate severity from zero “not at all” to three “a lot”, and total score ranging from 0-
33. The time frame is the past month, with higher scores representing increased sleep 
dysfunction. It is recommended for rating overall sleep problems both to screen and 
to measure severity, and for rating daytime sleepiness in a recent review of scales to 
assess sleep impairment in PD (Högl et al. 2010). Thus the SCOPA Sleep includes 
three subscales: a night time scale (NS), a single-item quality of sleep scale and a 
daytime sleepiness scale (DS). 
The NS is a five-item scale with four response options that address night time 
disturbances that occurred in the previous month. Subjects indicate the extent to 
which they were disturbed on a scale of 0 (not at all) to 3 (very much). The five 
items include sleep initiation, sleep fragmentation, sleep efficiency, sleep duration, 
and early wakening. The maximum score is 15, with higher scores reflecting more 
severe sleep problems. 
In addition, quality of sleep is assessed using an additional question that 
evaluates overall sleep quality on a seven-point scale (ranging from slept very well 
to slept very badly). The score on this item is not included in the score of the NS but 
is used separately as a global measure of sleep quality. 
The DS subscale evaluates daytime sleepiness in the past month and includes 
six items with four response options, ranging from 0 (never) to 3 (often). Subjects 
indicate how often they fell asleep unexpectedly, fell asleep in particular everyday 
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situations, how often they had difficulty staying awake, and whether falling asleep in 
the daytime was considered a problem. The maximum score is 18, with higher scores 
reflecting more severe sleepiness.  
5.1.1.5 SCOPA AUT 
  The SCOPA AUT is a 25 item questionnaire enquiring about the existence of 
symptoms involving the autonomic nervous system often seen in PD patients, 
assessing gastrointestinal symptoms (7 items), urinary symptoms (6 items), 
cardiovascular symptoms (3 items), thermoregulatory function (4 items), 
pupillomotor symptoms (1 item), and sexual function (2 items for men and 2 items 
for women) giving a total of 23 items for men and women. Each question has four 
responses to rate frequency from zero “never” to three “often”, and total score 
ranging from 0-69, with higher scores representing increased autonomic dysfunction. 
To obtain a standardized ranking of prevalence for each domain, the sum of each 
item of every domain was transformed to percentage on the maximum possible 
number of “often” responses in the domain. 
5.1.1.6 Smell Identification Test (SIT) 
The SIT is a standardized forced-choice test comprised of four booklets 
containing 10 odorants per booklet, (1 odorant per page). The stimuli are embedded 
in “scratch and sniff” microcapsules fixed and positioned on strips at the bottom of 
each page. A multiple-choice question with four response alternatives for each item 
is located above each odorant strip. The maximum score is 40 that equals normal 
smell sense (Doty et al. 1984) 
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5.1.2 Prevalence of NMS in PD 
In a multicentre, international, cross-sectional study involving 545 PD patients 
(mean disease duration: 6.96 year) using the NMS Quest, it was reported 10.3 points 
(out of a maximum of 30) as the mean total NMS, and 98.4% of the cohort reported 
some NMS (Martinez-Martin et al. 2007). 
In the PRIAMO study 1,072 patients with PD were assessed to determine the 
prevalence of NMS. It was found that 98.6% of patients with PD reported the 
presence of NMS and the mean number of NMS per patient was 7.8, ranging from 0 
to 32. The frequency of NMS was found to increase along with the disease duration 
and severity, and cognitive dysfunction (Barone et al. 2009). 
Consentino and colleagues determined the prevalence of NMS in a cohort of 
300 Peruvian patients with PD patients using the Spanish version of NMS Quest. 
The mean total non-motor symptoms was 12.41, ranging from 0 to 27 of a 
maximum of 30. A progressive increase in mean total score was observed across 
each 5-year interval (Cosentino et al. 2013). Thus, the authors propose that the 
mean total NMS increases significantly with disease duration.  
5.2 METHODS 
5.2.1 5.2.1. Baseline visit 
Each patient was sent the PDQ 39, NMS Quest, SCOPA Sleep, SCOPA AUT 
and Smell Identification test self-assessment forms to complete 1 week prior to their 
clinic assessment to be brought to the clinic with the patient for their baseline 
evaluation. Patients were requested to fill the smell identification test while being on 
medication. Questionnaires left at home were replaced and completed at the time of 
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the visit. During the patients on medication phase, Mattis DRS and MADRS were 
completed. 
5.2.2 Flowchart of study assessments 
Appointment M
AD
RS
Ma
ttis
/DR
S
NM
S
SC
OP
A
AU
T
SIT
Baseline ● ● ● ● ● ●
6/months ● ● ● ● ●
12/months ● ● ● ● ● ●
14/months ● ● ● ● ●
24/months ● ● ● ● ●  
Table'21.'Flowchart'of'study'Non8motor'symptoms'assessments'
 
5.2.2.1 Endpoints 
5.2.2.1.1 Secondary endpoint. Change from baseline to 12 /14 and 24 months between 
patients on active treatment and PD controls for the following scales: 
-Mattis dementia rating scale (MATTIS DRS-2) 
-Montgomery and Asberg depression rating scale (MADRS) 
-NMS Quest 
-SCOPA Sleep scale 
-SCOPA Aut scale 
-Smell identification test (SIT) 
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5.2.2.1.2 Statistical analysis  
The difference between each of the secondary outcome measures (MATTIS 
DRS-2, MADRAS, NMS Quest, SCOPA Sleep, SCOPA AUT) at baseline and at 12, 
14 and 24 months, and the difference between smell test at baseline and 12 month 
was calculated for each patient. The mean difference and SD for patients randomised 
to treatment and for patients on conventional PD medication group was analysed. It 
was anticipated that there would be high correlation between the baseline and follow 
up measures. The analysis was performed on an intention to treat basis including all 
patients who completed at least one follow up assessment. “Last observation carried 
forward” was used for participants with missing data. 
The distribution of scores was checked for normality using the Shapiro-Wilk 
test. As data were normally distributed, a paired t test was used to assess the 
differences between treated and untreated groups with respect to changes in scores 
from baseline to follow-up. Data were analysed using IBM SPSS Statistics 20.  
Correlations were used to generate hypotheses regarding the relationship 
between treatment effects and possible confounding factors like age and Hoehn & 
Yahr at baseline. 
5.3 RESULTS 
5.3.1 Patients 
Retention of patients has been previously stated in the results of Chapter 2. In 
brief, of the 45 patients recruited, four patients withdrew / dropped out from the 
study, 3 from the group randomized to Exenatide and one from the conventional PD 
medication group. Of the 3 patients in the Exenatide group, 1 withdrew due to 
worsening PD (recurrent L-dopa dose failures) prior to the first follow-up visit; this 
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patient was replaced as per protocol and excluded for final analysis. Two further 
patients withdrew from treatment: the first at 9 months due to dysgeusia combined 
with subjective PD deterioration, and the second at 10 months due to excessive 
weight loss. These patients continued follow up assesstments and data collection as 
per protocol. Their data were included in final analysis, under our intention to treat 
protocol. One patient randomized to the conventional PD medication group 
withdrew from the study at 12 months due to deteriorating PD and incapacity to 
attend the trial clinic in the “off medication” state at 14 month. For this individual, 
last observation carried forward was used. The 44 patients (Exenatide group: 20, 
Control group: 24) included in the final analysis at 12 and 14 months underwent a 24 
month visit assessment. NMS assessments were collected in parallel with motor 
assessments. 
5.3.2 Clinical outcomes 
5.3.2.1 Mattis DRS-2 
At both 12 and 14 months, a significant advantage in the Mattis dementia 
rating scale-2 (Mattis DRS-2) was seen in patients treated with Exenatide, with a 
mean improvement of 2.2 points at 12 months compared with deterioration by mean 
of 2.8 points in the control patients (difference, 5 points; 95% CI, 5.2-0.8; p=0.006; 
and a mean improvement of 2.8 points at 14 months compared with deterioration by 
mean of 3.5 points in the control patients (difference, 6.3 points; 95% CI, 2.7-9.9; 
p=0.001) (Figure 8 and Table 22).  
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At 24 months there was a mean improvement of 1.8 points compared with 
deterioration by mean of 3.5 points in the control patients (difference, 5.3 points; 
95% CI, 9.3-1.4; p=0.009). 
Figure' 8.' Change' from' baseline' in' the' Mattis' DRS82' score' by'
study'visit.'Data'represent'mean'±'SEM 
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Table&22.&Changes&in&the&score&on&Mattis&DRS72&and&MADRS&between&baseline&and&month&14 
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Changes in Mattis DRS-2 subdomains are represented in the following figures. 
(Figure 9 to 13). There were a tendency favouring Exenatide in all the subdomains 
but construction.  
Figure'9.'Changes'from'baseline'in'MEMORY'subdomain'by'study'visit.'
Mean'±'SEM'
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Figure' 10.' Change' from' baseline' in' CONSTRUCTION' subdomain' by' study'
visit.'
Mea±'SEM'
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'
Figure' 11.' Change' from' baseline' in' CONCEPTUALIZATION' subdomain' by'
study'visit.'Mean'±'SEM'
 
Figure' 12.' Change' from' baseline' in' INITIATIONJPERSEVERATION'
subdomain.''
Mean''±'SEM'
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Figure'13.'Change'from'baseline'in'ATTENTION'subdomain'by'study'visit.''
Mean'±'SEM'
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5.3.2.2 MADRAS 
There were no significant difference in Montgomery- Asberg depression rating 
scale (MADRS) score between baseline and 12 and 14 months. At 24 month there is a 
non-significant change favouring Exenatide, with a mean improvement of 1.9 points in 
the Exenatide SD (5.2), and a mean deterioration in the control group of 1.5 points SD 
(7.0) (difference, 3.4 points; 95% CI, 0.4, 7.2;p= 0.2). Table 22. 
5.3.2.3 NMS Quest 
Questions regarding sexual dysfunction were omitted by many of the female PD 
patients (44.4%). In total, 60% of the women in the Exenatide group and 25% of the 
women in the control group scored “not applicable” on these items, compared to 0% of 
the male patients in the Exenatide group and 5% of the men in the control group.  
The mean total NMS at baseline was 10.4 ± 3.6 (SD), ranging from 4 to 17 of a 
maximum of 30 in the Exenatide group and 10.4 ± 5.5 (SD), ranging from 0 to 23 in the 
control group. 
At 24 months there was a non-significant difference (p= 0.4) favouring Exenatide, 
with a mean improvement of 0.8 ± 3.8 (SD), at 24 month in the Exenatide group and a 
mean deterioration of 0.2 ± 4.3 (SD), in the control group. 
The NMSQuest has nine domains and among these, the most frequents were 
digestive and miscellaneous. The mean of the digestive domain scored 0.19 ± 0.1 (SD), 
and the miscellaneous domain score 0.16 ± 0.0 (SD), in the Exenatide group at baseline. 
Similarly digestive 0.17± 0.01 (SD) and miscellaneous 0.13 ± 0.0 (SD), were most 
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prevalent in the control group. Therefore digestive and miscellaneous subdomains had 
the most “positive” answers at baseline in both groups. 
At 24 months the digestive domain was the one having the most prevalent 
complaint in both the Exenatide group 0.17 ± 0.1 (SD), and the control group 0.13 ± 0.1 
(SD). 
5.3.2.4 SCOPA sleep 
The mean total sleep night time at baseline was 6.3 points ± 3.6 (SD), ranging 
from 0 to 14 of a maximum of 15 in the Exenatide group and 5.6 ± 3.6 (SD), ranging 
from 0 to 15 in the control group. At baseline the mean total sleep night time in the 
Exenatide group was 5.4 points ± 3.0 (SD), ranging from 1 to 13 and 5.7 ± 4.3 (SD), 
ranging from 0 to 15 in the control group. 
At 24 months, patients treated with Exenatide showed non-significant benefits in 
night time sleepiness, with a mean improvement of 0.9 points compared with 
deterioration by mean of 0.2 points in the control patients , although it was not 
significant (difference, 1.1 point; 95% CI, 0.8-2.9; p=0.8); and a mean improvement of 
0.3 points at 12 months compared with deterioration by mean of 0.7 points in the control 
patients (difference, 1.0 points; 95% CI,1.1,3.3; p=0.3) . Figure 14. 
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Figure'14.'Change' from'baseline' in'SCOPA'sleep'nightime'sleepiness'by'study'
visit.'Mean'±'SEM'
 
At 12 months, patients treated with Exenatide showed improvements in day time 
sleepiness, with a mean improvement of 0.3 points compared with deterioration by mean 
of 0.6 points in the control patients, although this too was not significant (difference, 0.9 
point; 95% CI, 0.6-2.4; p=0.2); Figure 15. 
Figure' 15.' Change' from'baseline' in' SCOPA' sleep' daytime' sleepiness' by' study'
visit.'Mean'±'SEM'
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The overall sleep quality favoured Exenatide along the trial period, with a mean 
improvement of 0.1 points compared with a deterioration of 0.4 points in the control 
group at 24 months, although this was only trend significant (difference 0.5 points, 95% 
CI, 0.2,1.3; p=0.1). Figure 16. 
Figure'16.'Change'in'overall'sleep'quality'by'study'visit.'Mean'±'SEM'
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5.3.2.5 SCOPA AUT 
There were few missing data, except for the questions regarding sexual 
dysfunction, which had the most missing values, especially in female PD patients 
(44.4%). In total, 60% of the women in the Exenatide group and 25% of the women in 
the control group scored “not applicable” on these items, compared to 0% of the male 
patients in the Exenatide group and 5% of the women in the control group, paralleling 
the missing data in the NMSQuest.  
At 14 months, an advantage in the total SCOPA-Aut score was seen in patients 
treated with Exenatide, with a mean improvement of 0.9 points at 14 months compared 
with deterioration by mean of 1.0 points in the control patients (difference, 1.9 points; 
95% CI,-5.5,1.1; p=0.2); This effect was not present at 12months and it was not 
sustained at 24 months, with a mean deterioration of 1.0 points at 24 months in the 
Exenatide group compared with deterioration by mean of 0.5 points in the control group 
(difference, 0.5 points; 95% CI,-2.9, 3.9; p=0.7- Figure 17). The gastrointestinal domain 
deteriorated at 12 months, although it was nearly back to baseline levels at 14 months. 
The urinary domain got worse in both groups along the 24 months, with a slight 
improvement in both groups at 6 months. At 12 months the urinary subdomain 
deteriorated 1.1 points (SD 8.5) in the Exenatide group and 2.5 (SD 18.6) in the control 
group, although it was not significant p=0.754. The cardiovascular subdomain got better 
at 12 and 14 month in the Exenatide group, with an improvement of 0.7 points (SD2.8) 
favoring Exenatide and a deterioration of 0.6 (SD 4.0) in the control group although non-
significant p=0.228. There was an advantage favoring Exenatide in the sexual 
dysfunction  domain at 12 months, and a trend at 14 months. With an improvement of 
7.5(SD 19.1) in the Exenatide group and a deterioration of 10.4 (SD25.0) in the control 
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group at 12 month p=0.12, and an improvement of 15.8 (SD 27.8) in the Exenatide 
group and a deterioration of 1.4 (SD 34.7) in the control group at 14 months p= 0.081, 
that was sustained at 24 months for a difference among both groups of 7.4 points p= 
0.293.  
Figure'17.'Change'in'total'SCOPAJAUT'by'visit'time.'Mean'±'SEM'
 
 
 
 
 
'
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Figure'18.'Change'in'score'on'SCOPAJAUT'subdomains'by'study'visit'
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5.3.2.6  Smell test 
There was no significant difference in the smell test among both groups at 12 
months 
Figure'19.'Change'in'smell' identification'test'between'baseline'and'month'12.'
Mean'±'SEM'
 
 
5.3.3 Correlations Exenatide group  
NMS: There were no significant correlations between change in PDQ39 SI at all 
the time points and the NMSquest at the correspondence time point. There was no 
correlation between the prevalence of NMS measured with the NMSQuest at any time 
points and age of patients at disease onset nor with age at start of the trial. 
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SLEEP: There were no correlations between changes in LED and sleep scales 
(Neither Sleep night time, sleep daytime nor overall quality of sleep) at any time point 
along the trial. There were no correlation among change in sleep and change in 
MADRAS along the trial. 
Mattis: There were no correlations between changes in Mattis DRS-2 and age at 
onset of the trial, neither age at symptoms onset. There was no correlation among 
changes in Mattis DRS-2 and Hoehn & Yahr state.  
MADRAS: There were no correlations among changes in Mattis DRS-2 and 
MADRAS. No correlation was found among changes in activities of daily living 
UPDRS part1 and MADRAS. 
5.4 DISCUSSION 
5.4.1 Exenatide and Cognition. MATTIS DRS-2.  
In the past 30 years, numerous studies that have explored in more detail the 
epidemiology of cognitive impairment and dementia in PD, have concluded that 
cognitive deterioration is a common, progressive and clearly disabling feature of 
Parkinson's disease. In an early review on the variable reported prevalence of 
Parkinson’s disease dementia (PDD), among 4336 patients included from 27 studies, the 
mean prevalence was 40%. Aarsland et al. found a prevalence of PDD of 31.3% among 
1767 patients included from 13 studies (Aarsland et al. 2005). These numbers indicate 
that PD patients have a 4- to 6-fold increased risk of developing dementia compared to 
age-matched general population (Aarsland et al. 2010). 
Two longitudinal, community-based studies following PD patients for >15 years 
have reported very similar prevalences. In the Sydney study, that included 136 patients 
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with pathologically defined PD, the prevalence of dementia increased from 28% after 5 
years of follow-up, to 48% at 15 years, and up to 83% after 20 years (Hely et al. 2008).  
It has been proposed that the efficacy of disease modifying therapies may be more 
meaningfully assessed in terms of their effects in delaying the major milestones of PD, 
such as postural instability and dementia, since it is these that have the greatest impact 
on patients (Evans et al. 2011). Evans and colleagues proposed that understanding 
progression in PD enables the identification of relevant outcome measures for clinical 
trials of putative disease modifying agents. For that reason the authors followed a cohort 
of 132 PD patients from diagnosis for up to 7.9 years, finding that clinical presentation 
with a tremor dominant phenotype offered relative protection from progression, although 
the relevant factor was probably a lower burden of axial symptoms in these patients 
rather than the presence of tremor. In the “Milestone model” of PD progression proposed 
by Evans (Evans et al. 2011), the efficacy of disease modifying therapies is evaluated in 
their ability to postpone the onset of levodopa induced dyskinesia, reaching a higher 
H&Y state, developing Freezing or dementia. In this model the authors included 
olfactory dysfunction to illustrate that this concept can be extended to encompass 
premotor milestones.  
To date, the design of trials of putative disease modifying agents has focused on 
the demonstration of sustained symptomatic effects (Olanow et al. 2009). However it 
has been proposed that identifying effects which translate into clinically meaningful 
benefits for patients would be a more useful approach. In our trial, cognitive decline was 
measured with Mattis DRS-2 scale during the on medication state at every time point. 
There was divergence in cognitive performance between the groups, with a 5-point 
advantage in the Mattis DRS-2 at 12 months that persisted as a 6.3-point advantage at 14 
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months and 5.3-points at 24 months. To date no reports have been found on Mattis DRS-
2 being affected by placebo effect. We cannot however exclude placebo effect as a 
possible explanation for these observations. Nevertheless, an alternative interpretation is 
that the significant change in Mattis DRS-2 score favouring Exenatide that was 
sustained at 24 months, (12 months after stopping Exenatide injections) may be that the 
drug has modulated the natural history of the disease. 
Muslimovic and colleagues followed 89 patients diagnosed at baseline with PD, 52 
with established PD with a disease duration of 6.5 years and 64 healthy controls in a 
prospective study for 3 years, finding that the clinical features that best predicted 
cognitive change were age at disease onset and axial impairment (Muslimović et al. 
2009). 
In our trial there was a correlation between axial symptoms off medication (Blind 
assessment) at baseline and changes in Mattis DRS-2, although it was not significant; at 
12 months (p=0.072) at 14months (p=0.068) and at 24months (p=0.104).  
Fronto-striatal executive deficits with impairment of attention and memory search 
strategies, slower visuomotor processing, reduced verbal fluency, impairment of 
organizational and constructional strategies, and motor programming disturbances are 
characteristic and develop over the course of the disease (Pagonabarraga & Kulisevsky 
2012). Up to 20% of non-demented PD patients also exhibit visuospatial and memory 
deficits more typical of posterior cortical functioning and fail performing tasks such as 
naming or copying. Major differences in the overall rate of cognitive decline among PD 
patients support the co-existence of at least two patterns of involution, differentiating a 
relatively slow (frontostriatal deficits) from a more rapid (posterior-cortical deficits) 
decline with different pathophysiological substrates, genetics, prognosis and response to 
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drugs used to treat the motor symptoms of PD. While frontostriatal defects appear more 
related to dopaminergic defects and reactive to dopaminergic manipulation, degeneration 
of cholinergic projection fibers from the basal forebrain is a highly probable correlate of 
posterior cortical defects and pivotal for the development of PDD (Kehagia et al. 2013). 
The Mattis DRS-2 has high sensitivity (92.7%) and high specificity (91.4%) for a 
diagnosis of PDD versus PD cases without dementia (Docherty & Burn 2010). It 
involves 5 subdomains (Attention, Initiation/perseveration, Construction, 
Conceptualization and memory), most of them depending on frontostriatal related 
functions. Attention, construction and memory were the domains that had the most 
significant and sustained improvement along the 24-month trial period. However, no 
correlation was found among changes in these domains and changes in the DaT SPECT 
scans among the patients in the imaging substudy, as previously reported in Chapter 3. 
Following the Braak hypothesis (Braak et al. 2003) to address the pathological 
correlates of cognitive dysfunction, a pivotal longitudinal clinico-pathological study that 
followed patients for >20 years (Halliday et al. 2008b) showed that cognitive 
pathological correlates are clearly different and dependent on the age of onset of PD. In 
patients with PD onset before 60 years, the progressive deterioration of cognitive 
function was seen to be associated with the progression of Lewy bodies from the 
brainstem to the limbic system, and finally to associative neocortical areas (Halliday 
2008a). A trans-synaptic spread of the pathological process with presynaptic aggregation 
of α-synuclein, causing neurotransmitter deficiencies rather than Lewy bodies and cell 
death has recently been proposed to explain clinical-pathological inconsistencies in the 
progression of the neurodegeneration according to the Braak model (Schulz-Schaeffer 
2010). In our group no correlations were found between Mattis DRS-2 baseline and age 
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at disease onset, or between change in Mattis DRS-2 at 12 (p=0.991), 14 (p=0.663) and 
24 months (p=0.944) and age at disease onset. 
Given the importance that synaptic dysfunction rather than neuronal loss seems to 
have in the development of clinical symptoms in PD (Plowey & Chu 2011), greater 
preservation of grey matter in PDD may indicate a potential reversibility of cognitive 
symptoms if the mechanisms leading to synaptic dysfunction could be treated. If the 
changes found in the Mattis DRS-2 in the Exenatide group are true biological effect 
rather than placebo effects, this might be an indication that Exenatide could play a role 
as stabiliser of synaptic function. 
5.4.1.1 Exenatide and mood. MADRAS 
Of the behavioural disorders in PD, mood disorders are amongst the most common 
and can occur in both early and late stages of PD (Tan 2012). Depression has been 
strongly associated with PD. The cause of depression in PD remains unknown. Two 
primary and not mutually exclusive hypotheses exist. The first argues that depression in 
PD represents a reactive state, resulting from the perception of progressive and social 
disabilities associated with the disorder. The other suggests that the cause of depression 
is intrinsic to PD itself, accounting for the occurrence of depressive PD patients prior to 
or at the onset of motor symptoms. In both instances, the induced neurochemical 
alterations are complex and probably include dopaminergic, serotonergic, and 
noradrenergic mechanisms. These findings have been supported by post-mortem studies, 
cerebrospinal fluid examinations and functional imaging (Aarsland, et al, 2009b). In our 
group there was a non-significant change in mood measure with MADRAS favouring 
Exenatide at 24 month. However, this change was not present at 12 or 14 months, thus 
there is little evidence from this data that Exenatide has a major effect on mood.  
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5.4.1.2 Exenatide and non-motor symptoms. NMSQuest 
In previous studies describing the prevalence of non-motor symptoms, urinary 
symptoms have been among the most commonly present, scoring over 55%. Other 
symptoms particularly prevalent were cognitive, perceptual, autonomic (postural 
dizziness), sexual, and sleep problems all scoring over 30% (Martinez-Martin et al. 
2007). In our Exenatide arm, gastrointestinal symptoms were the most prevalent in the 
first 12months, during the injections period. This is absolutely in keeping with the most 
frequent expected adverse event of Exenatide that is gastrointestinal disturbance. 
5.4.1.3 Exenatide and sleep. SCOPA Sleep 
With the intention of evaluating night time sleep problems and daytime sleepiness 
in PD patients, 420 PD patients (mean age (SD) 61.1 (11.5) years and 150 controls 
(mean age (SD) 60.9 (9.9) years) were assessed using SCOPA sleep questionnaire 
(Verbaan et al 2008). It was found that night time sleep problems were related to 
dopamine-agonist and levodopa dose, whereas daytime sleepiness was related to age, 
dopamine-agonist dose, and disease severity. The authors also reported that excessive 
daytime sleepiness (DS) is most commonly reported than excessive night time sleep 
problems (ENSP).  
In our sample a non-significant difference in the NTSP was found favouring 
Exenatide throughout the trial period, while an improvement in the DS was just found at 
12 months, but not sustained at 12 and 24 months. A significant correlation was found 
among changes in LED at 12 months in the Exenatide group and changes in EDS at 12 
months (p=0.02), but no correlation was found with age at trial onset, or Hoehn & Yahr.  
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Thus it is likely that the lowering of LED in 5 Exenatide patients at 12 months 
(See chapter 2), explaining the proportional reduction in the LED in comparison with the 
patients in the control group (LED at 12 months (mean (SD)) was 997(446) in the 
Exenatide group versus 1121 (620) in the control group), could explain the improvement 
in the EDS at 12 months in the Exenatide group. 
5.4.1.4  Exenatide and autonomic symptoms. SCOPA Aut 
To date it has been concluded that SCOPA-AUT is a good tool for quantifying the 
dysautonomia in PD. However, the intensity of the autonomic symptoms as measured 
using this scale do not seem to correlate with any of the variables of clinical severity or 
progression of the disease (Berganzo et al. 2012). In our group there was a general 
improvement in the autonomic symptoms measured with total SCOPA-Aut, with modest 
non-significant improvement in the cardiovascular, temperature, pupillo motor and sex 
domain. A clear deterioration in the gastrointestinal domain at 12 month paralleled the 
NMSQuest scores and reflecting the main expected adverse event that was lessened once 
the injection period was finished. The urinary domain got worse along the trial period, 
but there were no differences among both groups during the 14 months. 
5.4.1.5 Exenatide and smell sense. SIT 
The purpose of this study was to determine if an association exists between 
performance on an odor identification task and subsequent risk of reaching milestones of 
clinically meaningful disease progression, particularly non motor complications 
including cognitive impairment (Evans et al. 2011). There was no significant change in 
the smell test between both groups at 12 months. Therefore perhaps a different 
pathology from motor and cognitive symptoms should be involved. 
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In conclusion, aside from the changes in MDS-UPDRS scores, there was also 
divergence in cognitive performance between the groups, with significant differences 
represented by advantage in the Mattis DRS-2, which were sustained along the trial 
period, beyond the injection period. Divergent results were found as well in the 
MADRAS, NMS Quest, SCOPA-Sleep and SCOPA-AUT favouring Exenatide along 
the 24 months trial follow up period, although these trends failed to reach significance. 
Despite the lack of change in the smell test at 12 month, the rest of non-motor symptoms 
scales and questionaires favoured Exenatide along the 24 months follow up period, 
further than the active drug injection period. Although it could not be completely rule 
out the possibility that this results could be placebo driven, the fact that the scores 
remained sustained in time are consistent with the possibility of a real disease modifying 
effect of Exenatide.  
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6 EXENATIDE AND ORAL GLUCOSE TOLERANCE TESTS 
6.1 INTRODUCTION 
6.1.1 Insulin resistance 
Insulin resistance is a condition in which cells fail to respond to the normal actions 
of the hormone insulin, with reduced sensitivity or responsiveness to the metabolic 
actions of insulin; namely, insulin-mediated glucose disposal, and inhibition of hepatic 
glucose production. The body produces insulin, but the cells in the body become 
resistant to insulin, mainly due to changes in their surface receptors. One of insulin’s 
main functions is to regulate delivery of glucose into cells, providing them with a source 
of energy. Therefore insulin resistant cells cannot take in glucose, amino acids and fatty 
acids. If insulin resistance exists, more insulin needs to be secreted by the pancreas as 
compensatory mechanism, finally evolving into the appearance of Type 2 DM. 
 At the same time, the liver that in health regulates glucose levels by reducing its 
secretion of glucose, continues secreting glucose to the blood stream, further 
contributing to hyperglycaemia. “Insulin responsiveness”, is defined as the maximal 
effect of insulin, whereas “insulin sensitivity” is defined as the insulin concentration 
required for a half-maximal response (Muniyappa et al. 2008). 
Insulin resistance normally refers to reduced insulin actions, such as glucose 
disposal and reduction of the inhibition of hepatic glucose production. However, other 
functions of insulin can also be affected. Insulin resistance in adipose cells results in 
reduced uptake of circulating lipids and increased hydrolysis of stored triglycerides. 
Increased mobilization of stored lipids in these cells elevates plasma levels of free fatty 
acids, producing the “metabolic syndrome”. 
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6.1.2 Impaired glucose tolerance 
Impaired glucose tolerance is a pre-diabetic state of hyperglycaemia that is 
associated with insulin resistance and increased risk of cardiovascular pathology.  
6.1.2.1 Epidemiology  
The association among PD and DM is strengthened by reports suggesting that up 
to 50–80% of patients with Parkinson's disease have abnormal glucose tolerance when 
tested (although these figures are from non-contemporary papers and we are unaware of 
confirmatory data from more recent cohorts) (Barbeau et al. 1961; Elner & Kandel 1965; 
Lipman et al. 1974; Sandyk 1993). However, in a series of 800 patients with Parkinson’s 
disease, concurrent diabetes was indeed shown to accelerate progression of both motor 
and cognitive symptoms (Schwab 1960). In view of the possible confounding effects of 
Parkinson’s disease treatment, newly diagnosed, never-treated adults with Parkinson’s 
disease have also been studied and been shown to have reduced insulin-mediated 
glucose uptake (Van Woert & Mueller 1971), inhibition of early insulin secretion and 
long-term hyperinsulinaemia and hyperglycaemia after glucose loading (Boyd et al. 
1971). This takes into account the effects of some drugs used to treat Parkinson’s 
disease, such as levodopa, which induces both hyperglycaemia and hyperinsulinaemia, 
whereas others (including the ergot dopamine agonist bromocriptine) may increase 
insulin sensitivity (Van Woert & Mueller 1971; Sirtori et al. 1972). Nevertheless, a 
recent cohort study could not replicate an association between either type 2 diabetes 
mellitus or obesity and Parkinson’s disease risk although the authors acknowledge that 
diagnosis of type 2 DM was entirely based on self-report (Palacios et al. 2011). There 
has also been a review of cohort studies and case control studies that has looked at 
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relationship between PD and DM that did not found conclusive evidence on this 
association (Cereda et al. 2011). 
6.1.3 Glucose tolerance test in Exenatide trial 
PD patients with confirmed Type 2 DM, or previously unconfirmed Type 2 DM 
were excluded from participation in this Exenatide trial (n= 1 of a total of 51 screened), 
but at baseline, we had not previously formally quantified the frequency of impaired 
fasting glucose or impaired glucose tolerance. Based on the published epidemiology 
suggesting links between PD and glucose homeostasis, the decision was taken to further 
explore the frequency of impaired fasting glucose and impaired glucose tolerance in PD 
patients by performing oral Glucose Tolerance tests (OGTT) in several groups of 
individuals to crudely explore whether the high rates of abnormal glucose homeostasis 
previously reported (as an indirect measure of insulin resistance) also existed in our 
patients. 
OGTT was performed at 24 months follow up visit in: 
1. PD patients previously treated with Exenatide (n= 20). 
2. PD patients recruited to the Exenatide trial but allocated to the control 
arm (n= 24). Data from these individuals was added to that from a random sample of PD 
patients not included in the trial and not previously diagnosed with DM (n=10). 
3. Spouses of patients with PD and not previously diagnosed with DM 
(n=15). 
The sample size was extended to PD patients not included in the trial and willing 
to take part and their spouses, to be able to increase the sample size. We included 
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spouses due to the higher prevalence of impaired glucoregulation with advanced age to 
be able to compare with a group of population of the same age without PD. 
6.2 METHODS 
The individuals were instructed not to have anything to eat or drink (other than 
plain water) after 22.00h on the evening prior to the test or on the day of the test, until it 
was completed. Individuals were informed what the GTT involves, and were given a 
patient information sheet at least 24 hours before the test. During the test, the subjects 
were at rest. 
The first fasting venous blood test was performed immediately after the individual 
signed the consent form. This first fasting blood sample was labelled with number 1 with 
the individual’s details and the time it was taken.  
Immediately following the first sample, the individual was requested to drink 394 
mL of new formulation of Lucozade Energy original (70 Kcal per 100ml), ensuring it 
was consumed within 5 minutes. The time the patient started to drink the Lucozade was 
noted. To avoid excessive fizziness, the bottle was opened 30 minutes before the test 
began. The second blood test was performed exactly 2 hours after the Lucozade was 
consumed. The 2nd venous blood sample was labelled with number 2 and the patient’s 
details and time it was taken. The individuals were then advised to eat and drink as they 
wished. A test was considered as impaired fasting glucose when the level of glucose in 
the fasting blood test was higher than 6.0mmol/L. A test was considered as impaired 
glucose tolerance when the glucose level 2h after Lucozade intake was higher than 
7.7mmol/L (Bartoli et al. 2011). A test was considered as T2DM when the glucose level 
2h after Lucozade intake was higher than 11.1 mmol/L (American Diabetes Association 
2013). 
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6.2.1 Analysis 
Mean and standard deviation of the fasting glucose levels and the glucose levels 2 
hours after the Lucozade intake were calculated for the Exenatide patients, PD patients 
never exposed to Exenatide and the spouses group. 
6.3 RESULTS 
6.3.1 Patients 
Twenty PD patients in the Exenatide arm (age (SD), 63.2 (5.9)years), 34 PD 
patients receiving best medical therapy (59.1 (8.7) ears) and 15 healthy age-matched 
controls (60.7 (8.5) years had an OGTT.  
6.3.2 GTT in Exenatide patients 
The mean (SD) fasting glucose was 5.0 (0.5) mmol/L. The mean glucose level 2 
hours later was 5.6 (1.4) mmol/L. One patient exhibited impaired glucose intolerance. 
There were no patients meeting criteria for DM. Normal range was considered 3.9-6.0 
for the fasting test and 3.9-7.7 for the glucose tolerance sample. 
6.3.3 GTT in PD patients 
The mean (SD) fasting glucose was 5.2 (1.5) mmol/L. The mean glucose level 2 
hours later was 5.6 (1.3) mmol/L. There were 2 patients with impaired fasting glucose, 
one of them with a fasting glucose in the diabetic range. There were three patients that 
were glucose intolerant.  
6.3.4 GTT in spouses 
The mean (SD) fasting glucose was 4.9 (0.4) mmol/L. The mean glucose level 2 
hours later was 6.0 (2.0) mmol/L. There were two spouses that were glucose intolerant. 
There were no new cases of diabetes among the spouses.  
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6.4 DISCUSSION 
Our data do not support the high prevalence of Glucose intolerance in PD patients 
previously described by other groups. We deliberately excluded patients with PD and 
previously confirmed DM (n=1 out of a total of 51 screened for inclusion). Furthermore 
no higher incidence of Glucose Intolerance was found in the Exenatide group in 
comparison with the other PD patients. While we acknowledge that we have only 
recruited small numbers of individuals that may be subject to several possible biases, our 
small sample does not lend any support to the previous observation that up to 80% of PD 
patients have impaired glucose tolerance. 
The gradual decline in physiological reserve that is characteristic of aging results, 
in part, from insulin homeostasis. Impairment of gluco-regulatory mechanisms, which is 
characterized by altered glucose tolerance and features of insulin resistance, occurs 
frequently in the elderly and the prevalence of DM increases with age. 
Approximately 40% of individuals 65 to 74 years old and 50% of individuals older 
than 80 years have impaired glucose tolerance or DM, and nearly half of elderly diabetes 
are undiagnosed (Harris 1990). For that reason our study performed OGTTs in spouses, 
which acted as a control match population, non-diabetic and without PD. In our spouses’ 
sample, although the mean age was slightly younger than the Exenatide group we found 
a higher mean of glucose levels in the sample taken 2 hours after the Lucozade intake. 
Mean glucose levels 2hours after Lucozade in the Exenatide group was 5.6 (1.4) mml/L, 
almost identical to the figures in the PD group 5.6 (1.3) mmol/L, while in the spouses 
the mean glucose 2 hours after Lucozade was 6.0 (2.0) mmol/L. 
This study used GTTs an indirect measure of insulin resistance. To date different 
methods have been used to measure insulin resistance. 
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Some methods rely on steady-state analysis of glucose and insulin, whereas others 
rely on dynamic testing. Each of these methods has distinct advantages and limitations, 
and optimal choice and employment of a specific method depends on the nature of the 
studies being performed. The hyperinsulinemic euglycemic glucose clamp and the 
insulin suppression test directly assess insulin-mediated glucose utilization under steady-
state conditions that are both labour and time intensive. A slightly less complex indirect 
method relies on minimal model analysis of a frequently sampled intravenous glucose 
tolerance test. Finally, simple surrogate indexes for insulin sensitivity/resistance are 
available (e.g., Quantitative insulin sensitivity check index (QUICKI), Homeostasis 
model assessment (HOMA), 1/insulin, Matusda index) that are derived from blood 
insulin and glucose concentrations under fasting conditions (steady state) or after an oral 
glucose load (dynamic). 
We elected not to use a glucose clamp approach because (1) it is an expensive test, 
and (2) requires an experienced operator to manage the process. Similarly, we did not 
use surrogate indexes due to budget limitations. 
One important point to be considered is the plausible physiological role for 
dopamine in the regulation of insulin secretion. There is plenty of evidence suggesting 
that the components necessary for dopamine synthesis and secretion are all present in the 
β-cell (Lundquist et al. 1991; Lindström 1986; Saisho et al. 2008). More outstandingly, 
the presence of dopamine receptors has been found using reverse transcription-PCR in 
INS-1E insulin secreting cells as well as in rodent and human isolated islets (Rubí et al. 
2005). These authors also showed that exogenous dopamine can inhibit glucose-
stimulated insulin secretion from isolated cells likely due to distal steps in metabolism 
secretion coupling (Rubí et al. 2005).  
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It has been proposed that dopaminergic signalling can down-regulate glucose-
stimulated insulin secretion from pancreatic islets. Activation of AKT/PKB mediated by 
GLP-1 was partially reversed by the addition of exogenous dopamine in the rodent β-cell 
line INS-SE (Ustione et al. 2013). In this model, dopamine would serve as an 
“antiincretin” signal that antagonises the stimulatory effect of GLP-1 (Ustione et al. 
2013). This potential “antiincretin” effect of dopamine could be partially responsible for 
the difference incidence of DM and Glucose intolerance reported to date. With the 
intention of removing potential cofounding effects of dopamine, the OGTT was 
performed at 24 month visit when the patients were free of all PD medications for at 
least 12 hours (including Exendin-4) and free of long acting dopamine agonists for at 
least 24 hours. The rest of PD patients who took part in the OGGT attending the trial 
clinic also being off medication to be able to establish formal comparisons. 
In conclusion our results do not confirm the high incidence of glucose intolerance 
reported in previous PD samples, although we have to acknowledge that our sample is 
small and the age is a bit younger than previously reported. Furthermore, we did not find 
evidence in our data that glucose tolerance is different in PD patients who received 
Exenatide for 12 months in addition to best medical therapy when compared to PD 
patients who only received best medical therapy, or when compared to a healthy age-
matched control sample. Based on these results, we find little to suggest that any 
biological effects of Exenatide in PD are solely related to improvement in peripheral 
glucose metabolic control. Central mechanisms of glucose sensing and insulin signalling 
warrant further explorations. 
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7 SUMMARY & CONCLUSIONS 
7.1 Summary of research findings 
The management of PD consists of therapies that aim to relieve the symptoms of 
the condition at its various stages. There are no approaches universally accepted to 
modify the progressive course of the disease. A major obstacle to the development of a 
neuroprotective drug for PD is the duration and the cost of the development program. 
The average drug development program for a CNS drug is approximately 15 years from 
the laboratory until the time the drug is first introduced to the clinic then licensed, and 
the cost is approximately $1.2 billion (Sherer et al. 2012). 
In the face of the obstacles outlined, it is reasonable to question why anyone would 
make the investment required for the development of a neuroprotective therapy for PD. 
The increased risk of Alzheimer’s disease, Parkinson’s disease and stroke in 
people with Type 2 DM suggests that shared mechanisms/pathways of cell death, 
possibly related to insulin dysregulation, may underlie all of these disorders. It seems 
conceivable a wide range of genetic and environmental triggers result in activation of 
similar biochemical pathways in all of them, suggesting a complex network of 
biochemical events that feed in to a final common path towards cellular dysfunction and 
death. GLP-1 receptor agonist itself appears to be a promising strategy in the prevention 
and/or amelioration of a variety of neurodegenerative diseases. To date only preliminary 
in vitro and animal studies have investigated the potential neuroprotective functions of 
GLP-1-based therapies (Holst et al. 2011). 
The current trial design was conceived following feedback from both commercial 
and charitable organizations, which confirmed the impression that the risks associated 
with investment into potential neuroprotective agents need to be mitigated via the 
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preliminary collection of cost-efficient (open-label) data in the first instance. In this 
context, the current study was designed as a proof of principle (Schmidt 2006); i.e., with 
the aims of collecting rapid and cost-efficient data regarding the tolerability of Exenatide 
in patients with PD and providing preliminary indications whether the major 
neuroprotective and neurorestorative effects of Exenatide seen in the animal models 
might be replicable in human individuals with PD. 
Repurposing a drug for treating a novel disease is difficult, particularly with an 
injectable therapy. However, given the large body of safety data already gathered from 
its use in the DM patients, we moved to Phase II testing to also assess efficacy, and in 
the present study, we were challenged to explore whether Exenatide might modify the 
progressive course of PD, rather than simply have some direct symptomatic effect. 
To date there is no reliable outcome measure that accurately reflects the 
underlying disease state and is not potentially confounded by symptomatic or 
pharmacological effects of the study intervention. Each of the outcome measures that 
have been used in clinical trials to date have been potentially confounded by 
symptomatic or pharmacological effects of the study intervention, so that even if study 
results are positive, it cannot be unequivocally determined that the agent has an effect on 
disease progression. For that reason we chose to include a longer follow up, 2 and 12 
months after drug discontinuation to try to differentiate ongoing symptomatic effects and 
allow placebo effects to further diminish. 
 In chapter 2 and 4 our data provided preliminary information about the absolute 
size of the difference in PD severity between the Exenatide treated and untreated groups 
using blinded rating. At 12 month this difference was modest (4.9 points in MDS-
UPDRS part 3), although this value excluded the additional effects on rigidity scores. 
These figures were sustained at 14 months (4.4 points) and at 24 months (5.6 points). 
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The study saw a sustained benefit twelve months after the Exenatide was discontinued, 
including in a number of motor measures as well as non-motor measures. 
In chapter 5, cognitive scores were notably improved in the Exenatide group and 
this improvement remained sustained 12 month after drug discontinuation. Although a 
sustained symptomatic effect potentially could explain the improvement after Exenatide 
was discontinued, the observations are also consistent with the possibility that Exenatide 
may have slowed disease progression.  
7.2 Main Criticisms 
One criticism of this study is the possibility of placebo effect in the Exenatide 
group. The variable nature of the placebo response is a particularly important issue for 
complex or invasive interventions in which placebo versions of the licensed product are 
not readily available/represent additional significant expense, which can thus hinder the 
conduct and interpretation of even small phase 2 double-blind trials. 
Any treatment (physical, pharmacological, or psychological) for a medical 
condition can potentially have a dual effect for the patient: that related to the treatment 
itself (eg, the intrinsic pharmacological property of an active drug) and that inherent in 
the perception that the treatment is being received. The latter is known as the placebo 
effect (Oh 1991). 
Essentially, any sort of treatment can act as a placebo, but what determines 
whether there is a placebo effect is the response of the patient to the intervention. There 
is extensive clinical evidence for a prominent placebo effect in PD (Diamond et al. 1985; 
Shetty et al. 1999; Goetz et al. 2000; Hauser et al. 2007). The experience of being 
enrolled in a clinical trial includes numerous factors besides taking a new medication or 
undergoing a new surgical procedure. Added clinic visits, regular laboratory 
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assessments, increased contact with physicians and research staff, and the anticipation of 
change are experiences that may influence patient outcomes in both the study and 
control population. 
Because of dopamine activation in neural pathways involved with motivation, 
reward and the response to novelty and change, attention has been particularly focused 
on changes in PD during placebo treatment (Schultz 1998).This effect is biochemically 
mediated by the activation of the nigrostriatal dopaminergic pathway, which leads to the 
release of dopamine in the striatum. Within [11C] raclopride PET scans of a patient with 
PD, the lower radioactivity observed in the striatum after placebo (saline injection) 
reflects increased occupancy of striatal D2 receptors by dopamine (ie, placebo-induced 
dopamine release).  
The biochemical placebo effect in Parkinson’s disease is as powerful as the effect 
of an active drug (apomorphine)(de la Fuente-Fernández et al. 2001), and also similar in 
magnitude to the effect of amphetamine in healthy people and patients with 
schizophrenia (Breier et al. 1997) .There is some indication that physical placebos may 
be even more powerful than oral placebos (Kaptchuk et al. 2000; Freeman et al. 1999). 
PD is a disorder in which the response to treatment can be assessed directly by the 
examiner. This direct measurability might allow a better evaluation of the placebo effect. 
Objective changes in motor function during placebo treatment in PD were examined in a 
placebo treated group from a randomized, multicentre, placebo-controlled clinical trial 
of monotherapy with ropinirole in 105 patients. A prominent placebo effect was reported 
in all domains of parkinsonian disability (although there was a trend for a greater effect 
on bradykinesia and rigidity than on tremor and gait/balance)(Goetz et al. 2000). 
However, the clinical scales of motor function are also subjective measurements. 
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Rates and timing of placebo responses were examined using a strict definition of 
placebo-associated improvement in order to identify patient and study-based 
characteristics, predicting positive placebo response in several PD clinical trials (Goetz 
et al. 2008). Individual patient data from the placebo groups of 11 medical and surgical 
treatment trials involving PD patients with differing PD severities and placebo-
assignment likelihoods were examined. They defined a positive placebo response as 
50% improvement in total UPDRS motor score or a decrease by 2 points on at least two 
UPDRS motor score items compared to baseline. The overall placebo response rate was 
16% (range: 0–55%). Patients with higher baseline UPDRS motor scores and studies 
that focused on PD with motor fluctuations, surgical interventions, or those with a higher 
probability of placebo assignment showed increased odds of positive placebo response. 
The greatest proportion of placebo-related improvements occurred in the patients with 
motor fluctuations. The only subject characteristic that increased the odds of a positive 
placebo response was the baseline UPDRS motor score, with higher scores associated 
with higher likelihood of placebo-related improvement. This association was driven 
primarily by tremor and bradykinesia scores and not by rigidity or gait impairments. The 
most likely driving factor for differences in placebo response rates across studies to be 
the greater overall severity of PD, as evidenced by the higher rates in the group with 
motor fluctuations and as demonstrated by the link between placebo-related 
improvement and baseline UPDRS motor score (Goetz et al. 2008). 
Another studied looked at the placebo-treated group from a randomized, 
multicentre, placebo-controlled clinical trial of monotherapy with ropinirole in PD 
patients without motor fluctuations. In 105 patients, they evaluated placebo-associated 
effects on the motor section of the Unified Parkinson’s Disease Rating Scale (UPDRS), 
dividing the motor examination into four categories: tremor, bradykinesia, rigidity, and 
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gait/balance/midline functions. Again they applied a rigorous definition of placebo-
associated improvement as an improvement over baseline score in motor UPDRS of at 
least 50% or a change in at least two motor items at any one visit by 2 points. During the 
6-month study, 16% of subjects improved on placebo treatment. The prevalence of 
response was steady (8 to 9%) at any one visit without a predominance of an early 
effect. No patient showed a placebo-associated improvement on all visits. All domains 
of parkinsonian disability were subject to placebo-associated improvement, with a trend 
toward more response in bradykinesia and rigidity than in tremor or gait/balance/midline 
function. Gender, age, disease duration, and baseline disability score did not influence 
the likelihood of improvement in association with placebo treatment (Goetz et al. 2000). 
The sample size was relatively small in this study, but old and young patients, both men 
and women, experienced placebo-associated improvement (Goetz et al. 2000).  
In another earlier an smaller double-blind trial of Pergolide for PD it was 
documented that both drug and placebo groups improved compared with baseline 
(Diamond et al. 1985). 
Because placebo-associated improvements occur throughout a 6-month trial, 
placebo-controlled studies in PD should be at least 6 months to capture early as well as 
late improvements. 
To date, no data on how the UPDRS motor scores vary in open-label assessments 
over 6 months in patients with mild PD, have been published to my knowledge. 
Furthermore, the natural progression of disability as measured by the UPDRS motor 
score over 6 months in open-label conditions compared with placebo treatment has not 
been determined. 
The persistence of the response to placebo may be difficult to evaluate because the 
fear of exposing patients to placebo over long periods has often resulted in trial designs 
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that limit placebo periods. However, relatively long placebo periods have been 
infrequently used. For instance, in a long-term trial of placebo as the only antianginal 
medication for a cohort of 35 patients, the number of angina attacks decreased by 48 
percent during titration (eight weeks), and by 77 percent during the entire six-month 
period (Boissel et al. 1986).The conflicting literature may be entirely expected 
considering the complex elements that make up the placebo response, including 
continued interaction between subjects and treatment team, monitoring of treatment 
effects by both subjects and researchers, and changes in disease processes over the 
course of the study. We have analysed the different subdomains of UPDRS, to look at 
differences in improvement in the gait and rigidity subdomain in comparison to tremor 
and bradykinesia subdomains, finding no improvements on tremor subdomain. No 
correlation was found among Hoehn and Yahr state (2 vs 2.5) at baseline and change in 
MDS-UPDRS part 3 in our trial.!
In the current trial, we chose not to set any futility threshold a priori, but instead 
chose to use a contemporary group of PD controls and to continue follow up for a 
sufficiently long period to allow inevitable placebo effects to at least begin to diminish. 
However, without a placebo injectable study arm, one cannot entirely exclude that there 
was a protracted placebo effect after cessation of the drug therapy. Indeed, protracted 
placebo effects have been seen in some gene therapy trials while patients have still been 
blinded (Calara et al. 2005; Tomlinson et al. 2010). In the present study, one would 
predict that if a placebo effect played a major role, it ought to have waned during the 
final twelve months, when the patients were aware that they were no longer receiving 
injections of the active drug. 
In the absence of a placebo group or any reliable peripheral measure that tracks the 
pathology of PD, the imaging substudy was incorporated to get some indication of 
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whether exenatide might have a disease-modifying effect. There was no change in 
[123I]FP-CIT SPECT scan appearances over a 12-month period. Given the quite 
advanced stage of disease suggested by the baseline levels of [123I]FP-CIT uptake, this 
may simply reflect a slower rate of decline of PD than occurs in the first few years. The 
small mean improvements in [123I]FP-CIT uptake in 2 patients is out of keeping with the 
natural history of PD. These patients both experienced LID during the course of the trial 
that responded to lowering of LED. Whether this is due to a possible biological effect of 
Exenatide or not, could not be completely ruled out due to the lack of [123I]FP-CIT 
SPECT scan in the control group. 
At the same time, NMS were assessed looking for differences outcomes in 
cognition, mood, smell sense, sleep, and autonomic symptoms scales between both 
groups. Differing results were found in these tests between both groups, remarkable are 
the divergent result in cognitive tests and although could not be completely rule out the 
possibility that could be placebo driven, the sustainability of the results along the 24 
month trial period is consistent with a possible real biological effect of Exenatide as 
disease modifying drug in PD. 
Nevertheless we should take into account the possibility of further different biases 
affecting our results: 
• Randomization at baseline. 
Despite randomization, minor differences in the baseline characteristics of the 
treated and control groups can influence subsequent disease progression. In a larger 
sample, randomization would be more likely to balance the treated and untreated groups. 
In the current trial, we attempted to minimize this chance variation by stratified 
randomization according to baseline disease severity. While there were no significant 
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differences between the 2 groups at baseline, the control group had slightly longer 
disease duration than that of Exenatide-treated patients.!!
• Weight loss influence in motor response!
No correlation was found among change in part 3 MDS UPDRS at 12, 14 and 24 
months and weight loss, making it less likely that Exenatide patients had improved 
motor scores as their body mass index was reduced along the first 12 month trial period. 
• Blinded videos 
In an effort to reduce investigator bias, we used an established procedure in which 
participants are videotaped and assessed by a blinded third party (Galpern et al. 2012). 
Blinded rating of videos was performed by the same individuals trained and certified in 
MDS-UPDRS rating. Individuals were allowed to view videos and their previous scores 
at baseline, 12 months, and 14 months while assessing the 24 month videos to ensure 
consistency across time points. This was decided upon to reduce intraobserver variability 
however is a further potential source of bias given that raters were aware that the 12 
month and 14 month data overall favoured Exenatide treated patients, they may have 
kept their scores in the same direction.!
7.3 Interpretation of statistical tests 
The aim of this trial was to collect pilot data upon which to design a further 
placebo control randomised trial, we analysed differences between treated and untreated 
groups with respect to change in scores from baseline to follow-up using 2-sided t tests. 
The statistical tests performed in this study have been provided to help in the judgement 
of which outcomes are most clearly changed in the context of this pilot trial, and thus to 
help guide planning of future placebo controlled trials and are thus restricted to the main 
outcomes of interest, not with the idea of proving efficacy. Multiple statistical tests have 
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been performed therefore the reader should not interpret a p value of 0.05 as evidence of 
efficacy.  
7.4 Further work 
A thorough understanding of how the brain integrates the feedback signals coming 
from the periphery to maintain normal brain function and metabolic homeostasis, as well 
as how this homeostasis is disrupted by dietary and environmental factors, will be key to 
better disease treatment and prevention. Our decision to perform OGTT in our trial 
patients and in PD patients not included in the trial, was an attempt to verify in our PD 
patients higher incidence of glucose intolerance, as previously described. However we 
did not see obvious evidence of impaired fasting glucose or impaired glucose tolerance 
in our small sample therefore the relationship between PD, dopamine, normal brain 
function, insulin signalling and peripheral metabolic homeostasis is clearly not a 
straightforward one. The interaction between peripheral and central effects of Exenatide 
in metabolism and neurodegeneration needs further clarification. 
7.5 Concluding remarks 
This is the first trial to report tolerability and pilot data of the biological effects of 
Exenatide in patients with a neurodegenerative disease. Our study clearly shows that the 
group receiving Exenatide improved over 24 months and that the patients not receiving 
the drug declined. This could be due to an acute treatment effect or, as discussed above, 
a placebo effect. Obviously, these data should not be interpreted as evidence of 
symptomatic efficacy or neuroprotection and can only be seen as providing initial pilot 
clinical data in order to help to justify the larger investment required initiating a larger 
double-blind, placebo-controlled study and assist in sample size calculations. 
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We decided to adopt a pragmatic approach to the problems of taking established 
drugs to new areas of therapy in a neurodegenerative disorder and have done so with a 
study design that is informative and affordable. In so doing we have provided further 
reassurance and to some extent mitigated against the risk associated with the sizeable 
investment required to further investigate the role of Exenatide in the treatment of PD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
200 
 
 
Bibliography 
 
Aarsland, D et al., 2010. Mild cognitive impairment in Parkinson disease: a multicenter 
pooled analysis. Neurology, 75(12), pp.1062-9. 
Aarsland, Dag, Marsh, L. & Schrag, Anette, 2009. Neuropsychiatric symptoms in 
Parkinson’s disease. Movement disorders!: official journal of the Movement 
Disorder Society, 24(15), pp.2175-86. 
Aarsland, Dag, Zaccai, J. & Brayne, C., 2005. A systematic review of prevalence studies 
of dementia in Parkinson’s disease. Movement disorders!: official journal of the 
Movement Disorder Society, 20(10), pp.1255-63. 
Abbott, R.D. et al., 2002. Midlife adiposity and the future risk of Parkinson’s disease. 
Neurology, 59(7), pp.1051-7. 
Alvarez, E. et al., 1996. Expression of the glucagon-like peptide-1 receptor gene in rat 
brain. Journal of neurochemistry, 66(3), pp.920-7. 
American Diabetes Association. 2013. Diagnosis and classification of diabetes mellitus. 
Diabetes care, 36 Suppl 1, S67-74.  
Anini, Y. & Brubaker, Patricia L, 2003. Role of leptin in the regulation of glucagon-like 
peptide-1 secretion. Diabetes, 52(2), pp.252-9. 
Arkan, M.C. et al., 2005. IKK-beta links inflammation to obesity-induced insulin 
resistance. Nature medicine, 11(2), pp.191-8. 
Aroda, V.R. & Ratner, R., 2011. The safety and tolerability of GLP-1 receptor agonists 
in the treatment of type 2 diabetes: a review. Diabetes/metabolism research and 
reviews, 27(6), pp.528-42. 
Aston-Jones, G. & Cohen, J.D., 2005. An integrative theory of locus coeruleus-
norepinephrine function: adaptive gain and optimal performance. Annual review of 
neuroscience, 28, pp.403-50. 
Baggio, L.L. et al., 2004. A recombinant human glucagon-like peptide (GLP)-1-albumin 
protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent 
pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. 
Diabetes, 53(9), pp.2492-500. 
Baggio, L.L. & Drucker, Daniel J, 2007. Biology of incretins: GLP-1 and GIP. 
Gastroenterology, 132(6), pp.2131-57. 
Baggio, L.L. & Drucker, Daniel J, 2006. Therapeutic approaches to preserve islet mass 
in type 2 diabetes. Annual review of medicine, 57, pp.265-81. 
 
  
 
201 
 
 
Banks, W.A., During, M J & Niehoff, M.L., 2004. Brain uptake of the glucagon-like 
peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol 
Exp Ther, 309(2), pp.469-475. 
Banting, F.G. et al., 1922. Pancreatic Extracts in the Treatment of Diabetes Mellitus. 
Canadian Medical Association journal, 12(3), pp.141-6. 
Barbeau, A., Giguere, R. & Hardy, J., 1961. [Clinical experience with tolbutamide in 
Parkinson’s disease]. L’unión médicale du Canada, 90, pp.147-51. 
Barone, P. et al., 2009. The PRIAMO study: A multicenter assessment of nonmotor 
symptoms and their impact on quality of life in Parkinson’s disease. Movement 
disorders!: official journal of the Movement Disorder Society, 24(11), pp.1641-9. 
Barrès, R. et al., 2009. Non-CpG methylation of the PGC-1alpha promoter through 
DNMT3B controls mitochondrial density. Cell metabolism, 10(3), pp.189-98. 
Bartoli, E., Fra, G.P. & Carnevale Schianca, G.P., 2011. The oral glucose tolerance test 
(OGTT) revisited. European journal of internal medicine, 22(1), pp.8-12. 
Bayir, H. et al., 2009. Peroxidase mechanism of lipid-dependent cross-linking of 
synuclein with cytochrome C: protection against apoptosis versus delayed oxidative 
stress in Parkinson disease. J Biol Chem, 284(23), pp.15951-15969. 
Beal, M.F., 1998. Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis. 
Annals of neurology, 44(3 Suppl 1), pp.S110-4. 
Belsham, D.D. et al., 2009. Ciliary neurotrophic factor recruitment of glucagon-like 
peptide-1 mediates neurogenesis, allowing immortalization of adult murine 
hypothalamic neurons. FASEB J, 23(12), pp.4256-4265. 
Benamer, H.T. et al., 2000. Correlation of Parkinson’s disease severity and duration with 
123I-FP-CIT SPECT striatal uptake. Movement disorders!: official journal of the 
Movement Disorder Society, 15(4), pp.692-8. 
Bender, A. et al., 2006. High levels of mitochondrial DNA deletions in substantia nigra 
neurons in aging and Parkinson disease. Nat Genet, 38(5), pp.515-517. 
Berganzo, K. et al., 2012. SCOPA-AUT scale in different parkinsonisms and its 
correlation with (123) I-MIBG cardiac scintigraphy. Parkinsonism & related 
disorders, 18(1), pp.45-8. 
Bernheimer, H. et al., 1973. Brain dopamine and the syndromes of Parkinson and 
Huntington. Clinical, morphological and neurochemical correlations. Journal of the 
neurological sciences, 20(4), pp.415-55. 
Bertilsson, G. et al., 2008. Peptide hormone exendin-4 stimulates subventricular zone 
neurogenesis in the adult rodent brain and induces recovery in an animal model of 
Parkinson’s disease. J Neurosci Res, 86(2), pp.326-338. 
 
  
 
202 
 
 
Bhat, A., Koul, A., Rai, E., Sharma, S., Dhar, M. K., & Bamezai, R. N. 2007. PGC-
1alpha Thr394Thr and Gly482Ser variants are significantly associated with T2DM 
in two North Indian populations: a replicate case-control study. Hum Genet, 121(5), 
609-614.  
Blevins, T. et al., 2011. DURATION-5: exenatide once weekly resulted in greater 
improvements in glycemic control compared with exenatide twice daily in patients 
with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 96(5), 
pp.1301-10. 
Blum-Degen, D. et al., 1995. Altered regulation of brain glucose metabolism as a cause 
of neurodegenerative disorders? Journal of neural transmission. Supplementum, 46, 
pp.139-47. 
Boissel, J.P. et al., 1986. Time course of long-term placebo therapy effects in angina 
pectoris. European heart journal, 7(12), pp.1030-6. 
Bolam, J Paul & Pissadaki, E.K., 2012. Living on the edge with too many mouths to 
feed: why dopamine neurons die. Movement disorders!: official journal of the 
Movement Disorder Society, 27(12), pp.1478-83. 
Bomfim, T.R. et al., 2012. An anti-diabetes agent protects the mouse brain from 
defective insulin signaling caused by Alzheimer’s disease- associated Aβ 
oligomers. The Journal of clinical investigation, 122(4), pp.1339-53. 
Booij, J., Bergmans, P., et al., 2001. Imaging of dopamine transporters with [123I]FP-
CIT SPECT does not suggest a significant effect of age on the symptomatic 
threshold of disease in Parkinson’s disease. Synapse (New York, N.Y.), 39(2), 
pp.101-8. 
Booij, J., Speelman, J.D., et al., 2001. The clinical benefit of imaging striatal dopamine 
transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic 
parkinsonism from those with other forms of parkinsonism. European journal of 
nuclear medicine, 28(3), pp.266-72. 
Booij, J. et al., 1997. [123I]FP-CIT SPECT shows a pronounced decline of striatal 
dopamine transporter labelling in early and advanced Parkinson’s disease. Journal 
of neurology, neurosurgery, and psychiatry, 62(2), pp.133-40. 
Boulton, A.J.M. et al., 2005. Diabetic neuropathies: a statement by the American 
Diabetes Association. Diabetes care, 28(4), pp.956-62. 
Bowen, B.C. et al., 1995. Proton MR spectroscopy of the brain in 14 patients with 
Parkinson disease. AJNR. American journal of neuroradiology, 16(1), pp.61-8. 
Boyd, A.E., Lebovitz, H.E. & Feldman, J.M., 1971. Endocrine function and glucose 
metabolism in patients with Parkinson’s disease and their alternation by L-Dopa. 
The Journal of clinical endocrinology and metabolism, 33(5), pp.829-37. 
 
  
 
203 
 
 
Braak, H. et al., 2003. Staging of brain pathology related to sporadic Parkinson’s 
disease. Neurobiology of aging, 24(2), pp.197-211. 
Braak, H. et al., 2006. Stanley Fahn Lecture 2005: The staging procedure for the 
inclusion body pathology associated with sporadic Parkinson’s disease 
reconsidered. Movement disorders!: official journal of the Movement Disorder 
Society, 21(12), pp.2042-51. 
Bradley, D.P., Kulstad, R. & Schoeller, D.A., 2010. Exenatide and weight loss. Nutrition 
(Burbank, Los Angeles County, Calif.), 26(3), pp.243-9. 
Braschi, E. & McBride, H.M., 2010. Mitochondria and the culture of the Borg: 
understanding the integration of mitochondrial function within the reticulum, the 
cell, and the organism. BioEssays!: news and reviews in molecular, cellular and 
developmental biology, 32(11), pp.958-66. 
Breidert, T. et al., 2002. Protective action of the peroxisome proliferator-activated 
receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. 
Journal of neurochemistry, 82(3), pp.615-24. 
Breier, A. et al., 1997. Schizophrenia is associated with elevated amphetamine-induced 
synaptic dopamine concentrations: evidence from a novel positron emission 
tomography method. Proceedings of the National Academy of Sciences of the 
United States of America, 94(6), pp.2569-74. 
Brooks, D.J., 2000a. Monitoring neuroprotection and restorative therapies in Parkinson’s 
disease with PET. Journal of neural transmission. Supplementum, (60), pp.125-37. 
Brooks, D.J., 2000b. Morphological and functional imaging studies on the diagnosis and 
progression of Parkinson’s disease. Journal of neurology, 247 Suppl, pp.II11-8. 
Brooks, D.J., 1997. PET and SPECT studies in Parkinson’s disease. Baillière’s clinical 
neurology, 6(1), pp.69-87. 
Brouckaert, O. et al., 2009. Short-term outcome of primary operated early breast cancer 
by hormone and HER-2 receptors. Breast Cancer Res Treat, 115(2), pp.349-358. 
Brücke, T. et al., 2000. SPECT and PET imaging of the dopaminergic system in 
Parkinson’s disease. Journal of neurology, 247 Suppl, pp.IV/2-7. 
Buse, J B et al., 2004. Effects of exenatide (exendin-4) on glycemic control over 30 
weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 27(11), 
pp.2628-2635. 
Buse, John B et al., 2010. DURATION-1: exenatide once weekly produces sustained 
glycemic control and weight loss over 52 weeks. Diabetes care, 33(6), pp.1255-61. 
 
  
 
204 
 
 
Calara, F. et al., 2005. A randomized, open-label, crossover study examining the effect 
of injection site on bioavailability of exenatide (synthetic exendin-4). Clinical 
therapeutics, 27(2), pp.210-5. 
Calvo, J.C. et al., 1995. Glucagon-like peptide-1(7-36)amide induces the release of 
aspartic acid and glutamine by the ventromedial hypothalamus of the conscious rat. 
Brain research bulletin, 38(5), pp.435-9. 
Campbell, R.K., 2011. Clarifying the role of incretin-based therapies in the treatment of 
type 2 diabetes mellitus. Clinical therapeutics, 33(5), pp.511-27. 
Campos, R.V., Lee, Y.C. & Drucker, D J, 1994. Divergent tissue-specific and 
developmental expression of receptors for glucagon and glucagon-like peptide-1 in 
the mouse. Endocrinology, 134(5), pp.2156-64. 
Cereda, E. et al., 2011. Diabetes and risk of Parkinson’s disease: a systematic review and 
meta-analysis. Diabetes care, 34(12), pp.2614-23. 
Chalmanov, V. & Vŭrbanova, M., 1987. [Diabetes mellitus in parkinsonism patients]. 
Vŭtreshni bolesti, 26(1), pp.68-73. 
Chan, J.Y. & Chan, S.H., 1989. Passive electrical properties of spontaneously active 
neurons in the nucleus reticularis gigantocellularis of the cat. Neuroscience letters, 
97(1-2), pp.169-74. 
Chan, N.C. et al., 2011. Broad activation of the ubiquitin-proteasome system by Parkin 
is critical for mitophagy. Hum Mol Genet, 20(9), pp.1726-1737. 
Chatfield, C., Collins, A.J., 1980. Introduction to Multivariate Analysis, London: 
Chapman & Hall. 
Chaudhuri, K.R., Healy, D.G. & Schapira, A.H.V., 2006. Non-motor symptoms of 
Parkinson’s disease: diagnosis and management. Lancet neurology, 5(3), pp.235-
45. 
Chinta, S.J. et al., 2010. Mitochondrial α-synuclein accumulation impairs complex I 
function in dopaminergic neurons and results in increased mitophagy in vivo. 
Neuroscience letters, 486(3), pp.235-9. 
Chiu, S.-L., Chen, C.-M. & Cline, H.T., 2008. Insulin receptor signaling regulates 
synapse number, dendritic plasticity, and circuit function in vivo. Neuron, 58(5), 
pp.708-19. 
Christensen, M. et al., 2010. Glucagon-like peptide-2, but not glucose-dependent 
insulinotropic polypeptide, stimulates glucagon release in patients with type 1 
diabetes. Regulatory peptides, 163(1-3), pp.96-101. 
Christensen, M. et al., 2011. Lixisenatide for type 2 diabetes mellitus. Expert opinion on 
investigational drugs, 20(4), pp.549-57. 
 
  
 
205 
 
 
Christensen, M. & Knop, F.K., 2010. Once-Weekly GLP-1 Agonists: How Do They 
Differ from Exenatide and Liraglutide? Curr Diab Rep, 10, pp.124-132. 
Clarke, C.E. et al., 2011. Should treatment for Parkinson’s disease start immediately on 
diagnosis or delayed until functional disability develops? Movement disorders!: 
official journal of the Movement Disorder Society, 26(7), pp.1187-93. 
Colca, J.R. et al., 2004. Identification of a novel mitochondrial protein (“mitoNEET”) 
cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol 
Endocrinol Metab, 286(2), pp.E252-60. 
Colloby, S.J. et al., 2004. The application of statistical parametric mapping to 123I-FP-
CIT SPECT in dementia with Lewy bodies, Alzheimer’s disease and Parkinson's 
disease. NeuroImage, 23(3), pp.956-66. 
Consortium, I.P.D.G.C. (IPDGC); W.T.C.C. & (WTCCC2), 2011. A two-stage meta-
analysis identifies several new loci for Parkinson’s disease. PLoS genetics, 7(6), 
p.e1002142. 
Conway, K. a., 2001. Kinetic Stabilization of the alpha -Synuclein Protofibril by a 
Dopamine-alpha -Synuclein Adduct. Science, 294(5545), pp.1346-1349. 
Cooper, G.J. et al., 1987. Purification and characterization of a peptide from amyloid-
rich pancreases of type 2 diabetic patients. Proceedings of the National Academy of 
Sciences of the United States of America, 84(23), pp.8628-32. 
Cooper, J.M., Mann, V.M. & Schapira, A.H., 1992. Analyses of mitochondrial 
respiratory chain function and mitochondrial DNA deletion in human skeletal 
muscle: effect of ageing. J Neurol Sci, 113(1), pp.91-98. 
Copley, K. et al., 2006. Investigation of exenatide elimination and its in vivo and in vitro 
degradation. Current drug metabolism, 7(4), pp.367-74. 
Cosentino, C., Nuñez, Y. & Torres, L., 2013. Frequency of non-motor symptoms in 
Peruvian patients with Parkinson’s disease. Arquivos de neuro-psiquiatria, 71(4), 
pp.216-9. 
Craft, S et al., 2000. Insulin effects on glucose metabolism, memory, and plasma 
amyloid precursor protein in Alzheimer’s disease differ according to 
apolipoprotein-E genotype. Annals of the New York Academy of Sciences, 903, 
pp.222-8. 
Craft, Suzanne et al., 2012. Intranasal insulin therapy for Alzheimer disease and 
amnestic mild cognitive impairment: a pilot clinical trial. Archives of neurology, 
69(1), pp.29-38. 
Dauer, W. & Przedborski, Serge, 2003. Parkinson’s disease: mechanisms and models. 
Neuron, 39(6), pp.889-909. 
 
  
 
206 
 
 
DeFronzo, R.A. et al., 2005. Effects of exenatide (exendin-4) on glycemic control and 
weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes 
Care, 28(5), pp.1092-1100. 
Dehmer, T. et al., 2004. Protection by pioglitazone in the MPTP model of Parkinson’s 
disease correlates with I kappa B alpha induction and block of NF kappa B and 
iNOS activation. Journal of neurochemistry, 88(2), pp.494-501. 
Devi, L. et al., 2008. Mitochondrial import and accumulation of alpha-synuclein impair 
complex I in human dopaminergic neuronal cultures and Parkinson disease brain. 
The Journal of biological chemistry, 283(14), pp.9089-100. 
Diamond, S.G., Markham, C.H. & Treciokas, L.J., 1985. Double-blind trial of pergolide 
for Parkinson’s disease. Neurology, 35(3), pp.291-5. 
Docherty, M.J. & Burn, D.J., 2010. Parkinson’s disease dementia. Current neurology 
and neuroscience reports, 10(4), pp.292-8. 
Dore, D.D. et al., 2011. A cohort study of acute pancreatitis in relation to exenatide use. 
Diabetes, obesity & metabolism, 13(6), pp.559-66. 
Doty, R.L., Shaman, P. & Dann, M., 1984. Development of the University of 
Pennsylvania Smell Identification Test: a standardized microencapsulated test of 
olfactory function. Physiology & behavior, 32(3), pp.489-502. 
Drucker, D J, Buse, J B, et al., 2008. Exenatide once weekly versus twice daily for the 
treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. 
Lancet, 372(9645), pp.1240-1250. 
Drucker, D J & Nauck, M A, 2006. The incretin system: glucagon-like peptide-1 
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 
368(9548), pp.1696-1705. 
Duarte, A.I. et al., 2006. Insulin restores metabolic function in cultured cortical neurons 
subjected to oxidative stress. Diabetes, 55(10), pp.2863-70. 
Duarte, A.I., Moreira, P.I. & Oliveira, C.R., 2012. Insulin in central nervous system: 
more than just a peripheral hormone. Journal of aging research, 2012, p.384017. 
Dugger, B.N. & Dickson, D.W., 2010. Cell type specific sequestration of choline 
acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta 
Neuropathologica, 120(5), pp.633-639. 
Duran, R. et al., 2013. The glucocerobrosidase E326K variant predisposes to 
Parkinson’s disease, but does not cause Gaucher's disease. Movement disorders!: 
official journal of the Movement Disorder Society, 28(2), pp.232-6. 
During, M J, Cao, L, et al., 2003. Glucagon-like peptide-1 receptor is involved in 
learning and neuroprotection. Nat Med, 9(9), pp.1173-1179. 
 
  
 
207 
 
 
van Dyck, C H et al., 1995. Age-related decline in striatal dopamine transporter binding 
with iodine-123-beta-CITSPECT. Journal of nuclear medicine!: official 
publication, Society of Nuclear Medicine, 36(7), pp.1175-81. 
van Dyck, C H et al., 2008. Striatal dopamine transporters correlate with simple reaction 
time in elderly subjects. Neurobiology of aging, 29(8), pp.1237-46. 
Eissele, R. et al., 1992. Glucagon-like peptide-1 cells in the gastrointestinal tract and 
pancreas of rat, pig and man. European journal of clinical investigation, 22(4), 
pp.283-91. 
Ek, J., Andersen, G., Urhammer, S. A., Gaede, P. H., Drivsholm, T., Borch-Johnsen, K., 
Hansen, T., et al. 2001. Mutation analysis of peroxisome proliferator-activated 
receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid 
polymorphisms to Type II diabetes mellitus. Diabetologia, 44(12), 2220-2226.  
Elm, J.J., 2012. Design innovations and baseline findings in a long-term Parkinson’s 
trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials 
in Parkinson's Disease Long-Term Study-1. Movement disorders!: official journal 
of the Movement Disorder Society, 27(12), pp.1513-21. 
Elner, A.M. & Kandel, E.I., 1965. Studies on the carbohydrate metabolism in 
parkinsonism. (Relation of carbohydrate metabolism disorders to the clinical 
picture of the disease). Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova 
(Moscow, Russia!: 1952), 65, pp.46-50. 
Elrick, H. et al., 1964. Plasma insulin response to oral and intravenous glucose 
administration.. The Journal of clinical endocrinology and metabolism, 24, 
pp.1076-82. 
Emsley, J.G. et al., 2005. Adult neurogenesis and repair of the adult CNS with neural 
progenitors, precursors, and stem cells. Progress in neurobiology, 75(5), pp.321-41. 
Emsley, J.G., Arlotta, P. & Macklis, J.D., 2004. Star-cross’d neurons: astroglial effects 
on neural repair in the adult mammalian CNS. Trends in neurosciences, 27(5), 
pp.238-40. 
Eng, J. et al., 1992. Isolation and characterization of exendin-4, an exendin-3 analogue, 
from Heloderma suspectum venom. Further evidence for an exendin receptor on 
dispersed acini from guinea pig pancreas. The Journal of biological chemistry, 
267(11), pp.7402-5. 
Eng, J. et al., 1990. Purification and structure of exendin-3, a new pancreatic 
secretagogue isolated from Heloderma horridum venom. The Journal of biological 
chemistry, 265(33), pp.20259-62. 
Esposito, D.L. et al., 2013. Novel insulin receptor substrate 1 and 2 variants in breast 
and colorectal cancer. Oncology reports. 
 
  
 
208 
 
 
Evans, J.R. et al., 2011. The natural history of treated Parkinson’s disease in an incident, 
community based cohort. Journal of neurology, neurosurgery, and psychiatry, 
82(10), pp.1112-8. 
Fan, R., Li, X., Gu, X., Chan, J. C. N., & Xu, G. (2010). Exendin-4 protects pancreatic 
beta cells from human islet amyloid polypeptide-induced cell damage: potential 
involvement of AKT and mitochondria biogenesis. Diabetes, obesity & 
metabolism, 12(9), 815-24.  
Fahn, S., 1999. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. 
Earlier vs Later L-DOPA. Archives of neurology, 56(5), pp.529-35. 
Feany, M.B. & Bender, W.W., 2000. A Drosophila model of Parkinson’s disease. 
Nature, 404(6776), pp.394-398. 
Fearnley, J.M. & Lees, A.J., 1991. Ageing and Parkinson’s disease: substantia nigra 
regional selectivity. Brain!: a journal of neurology, 114 ( Pt 5, pp.2283-301. 
Fernandez, A.M. & Torres-Alemán, I., 2012. The many faces of insulin-like peptide 
signalling in the brain. Nature reviews. Neuroscience, 13(4), pp.225-39. 
Finck, B. N., & Kelly, D. P. (2006). PGC-1 coactivators: inducible regulators of energy 
metabolism in health and disease. J Clin Invest, 116(3), 615-622.  
Fineman, M.S. et al., 2004. Effectiveness of progressive dose-escalation of exenatide 
(exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. 
Diabetes/metabolism research and reviews, 20(5), pp.411-7. 
Fineman, M. S., Mace, K. F., Diamant, M., Darsow, T., Cirincione, B. B., Booker 
Porter, T. K., Kinninger, L. A., et al. 2012. Clinical relevance of anti-exenatide 
antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes, 
obesity & metabolism.  
Fischman, A.J. et al., 1998. Rapid detection of Parkinson’s disease by SPECT with 
altropane: a selective ligand for dopamine transporters. Synapse (New York, N.Y.), 
29(2), pp.128-41. 
Follett, K.A. et al., 2010. Pallidal versus subthalamic deep-brain stimulation for 
Parkinson’s disease. The New England journal of medicine, 362(22), pp.2077-91. 
Foltynie, T. & Kahan, J., 2013. Parkinson’s disease: an update on pathogenesis and 
treatment. Journal of neurology. 
Forno, L.S., 1996. Neuropathology of Parkinson’s disease. Journal of neuropathology 
and experimental neurology, 55(3), pp.259-72. 
Frackowiak, R.S., Friston, K.J., Frith, C.D., Dolan, R.J., Mazziotta, J.C., 1997. Human 
Brain Function A. Press, ed., 
 
  
 
209 
 
 
Freeman, T.B. et al., 1999. Use of placebo surgery in controlled trials of a cellular-based 
therapy for Parkinson’s disease. The New England journal of medicine, 341(13), 
pp.988-92. 
Frey, K.A. et al., 1996. Presynaptic monoaminergic vesicles in Parkinson’s disease and 
normal aging. Annals of neurology, 40(6), pp.873-84. 
Friston, K.J., Worsley, K.J., Frackowiak, R.S.J., Mazziotta, J.C., E. & A.C., 1994. 
Assessing the significance of focal activations using their spatial extent. In Hum. 
Brain Mapp. pp. 214-220. 
de la Fuente-Fernández, R. et al., 2001. Expectation and dopamine release: mechanism 
of the placebo effect in Parkinson’s disease. Science (New York, N.Y.), 293(5532), 
pp.1164-6. 
Gallagher, D.A. et al., 2012. Validation of the MDS-UPDRS Part I for nonmotor 
symptoms in Parkinson’s disease. Movement disorders!: official journal of the 
Movement Disorder Society, 27(1), pp.79-83. 
Gao, W. & Jusko, W.J., 2012. Target-mediated pharmacokinetic and pharmacodynamic 
model of exendin-4 in rats, monkeys, and humans. Drug metabolism and 
disposition: the biological fate of chemicals, 40(5), pp.990-7. 
Gao, Z. et al., 2002. Serine phosphorylation of insulin receptor substrate 1 by inhibitor 
kappa B kinase complex. The Journal of biological chemistry, 277(50), pp.48115-
21. 
Gerbitz, K.D. et al., 1995. Mitochondrial diabetes mellitus: a review. Biochimica et 
biophysica acta, 1271(1), pp.253-60. 
Gerhard, A. et al., 2006. In vivo imaging of microglial activation with [11C](R)-
PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis, 21(2), pp.404-412. 
Gerlach, M. et al., 1991. MPTP mechanisms of neurotoxicity and their implications for 
Parkinson’s disease. European journal of pharmacology, 208(4), pp.273-86. 
Ghosh, S. et al., 2007. The thiazolidinedione pioglitazone alters mitochondrial function 
in human neuron-like cells. Mol Pharmacol, 71(6), pp.1695-1702. 
Gibb, W.R. & Lees, A.J., 1988. The relevance of the Lewy body to the pathogenesis of 
idiopathic Parkinson’s disease. Journal of neurology, neurosurgery, and psychiatry, 
51(6), pp.745-52. 
Girman, C.J. et al., 2010. Patients with type 2 diabetes mellitus have higher risk for 
acute pancreatitis compared with those without diabetes. Diabetes, obesity & 
metabolism, 12(9), pp.766-71. 
Goetz, C G et al., 2000. Objective changes in motor function during placebo treatment in 
PD. Neurology, 54(3), pp.710-4. 
 
  
 
210 
 
 
Goetz, C G, 2010. [Movement Disorder Society-Unified Parkinson’s Disease Rating 
Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson's disease]. Revue 
neurologique, 166(1), pp.1-4. 
Goetz, Christopher G et al., 2008. Placebo response in Parkinson’s disease: comparisons 
among 11 trials covering medical and surgical interventions. Movement disorders!: 
official journal of the Movement Disorder Society, 23(5), pp.690-9. 
Goto, S., Hirano, A. & Matsumoto, S., 1989. Subdivisional involvement of nigrostriatal 
loop in idiopathic Parkinson’s disease and striatonigral degeneration. Annals of 
neurology, 26(6), pp.766-70. 
Greggio, E. et al., 2011. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting 
pathways in the pathogenesis of Parkinson’s disease? Molecular 
neurodegeneration, 6(1), p.6. 
Guzman, J.N. et al., 2010. Oxidant stress evoked by pacemaking in dopaminergic 
neurons is attenuated by DJ-1. Nature, 468(7324), pp.696-700. 
Halliday, G., 2008a. Clarifying the pathological progression of Parkinson’s disease. Acta 
neuropathologica, 115(4), pp.377-8. 
Halliday, G. et al., 2008b. The progression of pathology in longitudinally followed 
patients with Parkinson’s disease. Acta neuropathologica, 115(4), pp.409-15. 
Hamilton, A et al., 2011. Novel GLP-1 mimetics developed to treat type 2 diabetes 
promote progenitor cell proliferation in the brain. Journal of neuroscience research, 
89(4), pp.481-9. 
Hamilton, A & Hölscher, C., 2009. Receptors for the incretin glucagon-like peptide-1 
are expressed on neurons in the central nervous system. Neuroreport, 20(13), 
pp.1161-6. 
Han, W.-N. et al., 2013. Liraglutide protects against amyloid-β protein-induced 
impairment of spatial learning and memory in rats. Neurobiology of aging, 34(2), 
pp.576-88. 
Handschin, C. & Spiegelman, B.M., 2008. The role of exercise and PGC1alpha in 
inflammation and chronic disease. Nature, 454(7203), pp.463-469. 
Hara, K., Tobe, K., Okada, T., Kadowaki, H., Akanuma, Y., Ito, C., Kimura, S., et al. 
2002. A genetic variation in the PGC-1 gene could confer insulin resistance and 
susceptibility to Type II diabetes. Diabetologia, 45(5), 740-743.  
Harkavyi, A, Abuirmeileh, A, et al., 2008. Glucagon-like peptide 1 receptor stimulation 
reverses key deficits in distinct rodent models of Parkinson’s disease. J 
Neuroinflammation, 5, p.19. 
 
  
 
211 
 
 
Harris, M.I., 1990. Epidemiology of diabetes mellitus among the elderly in the United 
States. Clinics in geriatric medicine, 6(4), pp.703-19. 
Hauser, R.A. et al., 2007. Ten-year follow-up of Parkinson’s disease patients 
randomized to initial therapy with ropinirole or levodopa. Mov Disord, 22(16), 
pp.2409-2417. 
Hely, M.A. et al., 2008. The Sydney multicenter study of Parkinson’s disease: the 
inevitability of dementia at 20 years. Movement disorders!: official journal of the 
Movement Disorder Society, 23(6), pp.837-44. 
Herman, G.A. et al., 2005. Pharmacokinetics and pharmacodynamics of sitagliptin, an 
inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two 
randomized, double-blind, placebo-controlled studies with single oral doses. 
Clinical pharmacology and therapeutics, 78(6), pp.675-88. 
Hilker, R. et al., 2005. Nonlinear progression of Parkinson disease as determined by 
serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. 
Archives of neurology, 62(3), pp.378-82. 
Hirosumi, J. et al., 2002. A central role for JNK in obesity and insulin resistance. 
Nature, 420(6913), pp.333-6. 
Hirsch, E.C., Jenner, P. & Przedborski, Serge, 2013. Pathogenesis of Parkinson’s 
disease. Movement disorders!: official journal of the Movement Disorder Society, 
28(1), pp.24-30. 
Holloway, R.G. et al., 2004. Pramipexole vs levodopa as initial treatment for Parkinson 
disease: a 4-year randomized controlled trial. Arch Neurol, 61(7), pp.1044-1053. 
Holmans, P. et al., 2013. A pathway-based analysis provides additional support for an 
immune-related genetic susceptibility to Parkinson’s disease. Human molecular 
genetics, 22(5), pp.1039-49. 
Holst, Jens Juul, Vilsbøll, Tina & Deacon, C.F., 2009. The incretin system and its role in 
type 2 diabetes mellitus. Molecular and cellular endocrinology, 297(1-2), pp.127-
36. 
Holst, J. J., Burcelin, R., & Nathanson, E. 2011. Neuroprotective properties of GLP-1: 
theoretical and practical applications. Current medical research and opinion, 27(3), 
547-58.  
Hotamisligil, G.S., 2006. Inflammation and metabolic disorders. Nature, 444(7121), 
pp.860-867. 
Hoyer, S. & Nitsch, R., 1989. Cerebral excess release of neurotransmitter amino acids 
subsequent to reduced cerebral glucose metabolism in early-onset dementia of 
Alzheimer type. Journal of neural transmission, 75(3), pp.227-32. 
 
  
 
212 
 
 
Hu, G., Jousilahti, P., Nissinen, A., et al., 2006a. Body mass index and the risk of 
Parkinson disease. Neurology, 67(11), pp.1955-9. 
Hu, G., Jousilahti, P., Sarti, C., et al., 2006b. The effect of diabetes and stroke at 
baseline and during follow-up on stroke mortality. Diabetologia, 49(10), pp.2309-
16. 
Hu, G. et al., 2007. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care, 
30(4), pp.842-847. 
Hu, M.T. et al., 2000. Cortical dysfunction in non-demented Parkinson’s disease 
patients: a combined (31)P-MRS and (18)FDG-PET study. Brain!: a journal of 
neurology, 123 ( Pt 2, pp.340-52. 
Huang, W.S. et al., 2001. Evaluation of early-stage Parkinson’s disease with 99mTc-
TRODAT-1 imaging. Journal of nuclear medicine!: official publication, Society of 
Nuclear Medicine, 42(9), pp.1303-8. 
Hughes, A.J., Daniel, S.E., et al., 1992a. Accuracy of clinical diagnosis of idiopathic 
Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of 
neurology, neurosurgery, and psychiatry, 55(3), pp.181-4. 
Hughes, A.J., Ben-Shlomo, Y., et al., 1992b. What features improve the accuracy of 
clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology, 
42(6), pp.1142-6. 
Hunter, K. & Hölscher, C., 2012. Drugs developed to treat diabetes, liraglutide and 
lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC 
neuroscience, 13, p.33. 
Hunter, R.L. et al., 2007. Inflammation induces mitochondrial dysfunction and 
dopaminergic neurodegeneration in the nigrostriatal system. Journal of 
neurochemistry, 100(5), pp.1375-86. 
Högl, B. et al., 2010. Scales to assess sleep impairment in Parkinson’s disease: critique 
and recommendations. Movement disorders!: official journal of the Movement 
Disorder Society, 25(16), pp.2704-16. 
Imeryüz, N. et al., 1997. Glucagon-like peptide-1 inhibits gastric emptying via vagal 
afferent-mediated central mechanisms. The American journal of physiology, 273(4 
Pt 1), pp.G920-7. 
International Parkinson’s Disease Genomics Consortium (IPDGC); Wellcome Trust 
Case, & (WTCCC2). (2011). A two-stage meta-analysis identifies several new loci 
for Parkinson’s disease. PLoS genetics, 7(6),  
Irrcher, I. et al., 2010. Loss of the Parkinson’s disease-linked gene DJ-1 perturbs 
mitochondrial dynamics. Hum Mol Genet, 19(19), pp.3734-3746. 
 
  
 
213 
 
 
Isacson, R. et al., 2011. The glucagon-like peptide 1 receptor agonist exendin-4 
improves reference memory performance and decreases immobility in the forced 
swim test. European journal of pharmacology, 650(1), pp.249-55. 
Iwai, T. et al., 2006. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production 
in cultured rat astrocytes. Neuroscience research, 55(4), pp.352-60. 
Jenkinson, C. et al., 1997. The Parkinson’s Disease Questionnaire (PDQ-39): 
development and validation of a Parkinson's disease summary index score. Age and 
ageing, 26(5), pp.353-7. 
John Hall, 2011. Guyton and Hall Textbook of Medical Physiology, 12th Edition 12th 
ed., Saunders Elsevier. 
Jura, N., Archer, H. & Bar-Sagi, D., 2005. Chronic pancreatitis, pancreatic 
adenocarcinoma and the black box in-between. Cell research, 15(1), pp.72-7. 
Kaptchuk, T.J. et al., 2000. Do medical devices have enhanced placebo effects? Journal 
of clinical epidemiology, 53(8), pp.786-92. 
Kastin, A.J. & Akerstrom, V., 2003. Entry of exendin-4 into brain is rapid but may be 
limited at high doses. International journal of obesity and related metabolic 
disorders!: journal of the International Association for the Study of Obesity, 27(3), 
pp.313-8. 
Keeney, P.M. et al., 2006. Parkinson’s disease brain mitochondrial complex I has 
oxidatively damaged subunits and is functionally impaired and misassembled. J 
Neurosci, 26(19), pp.5256-5264. 
Kehagia, A.A., Barker, R.A. & Robbins, T.W., 2013. Cognitive impairment in 
Parkinson’s disease: the dual syndrome hypothesis. Neuro-degenerative diseases, 
11(2), pp.79-92. 
Kendall, D.M. et al., 2005. Effects of exenatide (exendin-4) on glycemic control over 30 
weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. 
Diabetes Care, 28(5), pp.1083-1091. 
Kern, P.A. et al., 2001. Adipose tissue tumor necrosis factor and interleukin-6 
expression in human obesity and insulin resistance. Am J Physiol Endocrinol 
Metab, 280(5), pp.E745-51. 
De Keyser, J. et al., 1989. [3H]GBR 12935 binding to dopamine uptake sites in the 
human brain. Journal of neurochemistry, 53(5), pp.1400-4. 
Kim, R.H. et al., 2005. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S 
A, 102(14), pp.5215-5220. 
 
  
 
214 
 
 
Kim, S., Moon, M. & Park, S., 2009. Exendin-4 protects dopaminergic neurons by 
inhibition of microglial activation and matrix metalloproteinase-3 expression in an 
animal model of Parkinson’s disease. J Endocrinol, 202(3), pp.431-439. 
Kis, B. et al., 2002. Novel three-stage ascertainment method: prevalence of PD and 
parkinsonism in South Tyrol, Italy. Neurology, 58(12), pp.1820-5. 
Kish, S.J., Shannak, K. & Hornykiewicz, O., 1988. Uneven pattern of dopamine loss in 
the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and 
clinical implications. The New England journal of medicine, 318(14), pp.876-80. 
Koch, W. et al., 2005. Clinical testing of an optimized software solution for an 
automated, observer-independent evaluation of dopamine transporter SPECT 
studies. Journal of nuclear medicine!: official publication, Society of Nuclear 
Medicine, 46(7), pp.1109-18. 
Kolterman, O.G. et al., 2005. Pharmacokinetics, pharmacodynamics, and safety of 
exenatide in patients with type 2 diabetes mellitus. American journal of health-
system pharmacy!: AJHP!: official journal of the American Society of Health-
System Pharmacists, 62(2), pp.173-81. 
Kraytsberg, Y. et al., 2006. Mitochondrial DNA deletions are abundant and cause 
functional impairment in aged human substantia nigra neurons. Nat Genet, 38(5), 
pp.518-520. 
Langston, J.W. et al., 1983. Chronic Parkinsonism in humans due to a product of 
meperidine-analog synthesis. Science (New York, N.Y.), 219(4587), pp.979-80. 
Larsen, K.E. et al., 2002. Methamphetamine-induced degeneration of dopaminergic 
neurons involves autophagy and upregulation of dopamine synthesis. The Journal 
of neuroscience!: the official journal of the Society for Neuroscience, 22(20), 
pp.8951-60. 
Larsen, P.J., Tang-Christensen, M. & Jessop, D.S., 1997. Central administration of 
glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. 
Endocrinology, 138(10), pp.4445-55. 
Lee, J.-K., Tran, T. & Tansey, Malú G, 2009. Neuroinflammation in Parkinson’s 
disease. Journal of neuroimmune pharmacology!: the official journal of the Society 
on NeuroImmune Pharmacology, 4(4), pp.419-29. 
Leibson, C.L. et al., 1997. Risk of dementia among persons with diabetes mellitus: a 
population-based cohort study. American journal of epidemiology, 145(4), pp.301-
8. 
Li, Hua, Lee, C.H., et al., 2010. Chronic treatment of exendin-4 affects cell proliferation 
and neuroblast differentiation in the adult mouse hippocampal dentate gyrus. 
Neuroscience letters, 486(1), pp.38-42. 
 
  
 
215 
 
 
Li, Hongliang & Yu, X., 2013. Emerging Role of JNK in Insulin Resistance. Current 
diabetes reviews. 
Li, L et al., 2005. Glucagon-like peptide-1 protects beta cells from cytokine-induced 
apoptosis and necrosis: role of protein kinase B. Diabetologia, 48(7), pp.1339-49. 
Li, Lin & Hölscher, C., 2007. Common pathological processes in Alzheimer disease and 
type 2 diabetes: a review. Brain research reviews, 56(2), pp.384-402. 
Li, Y, Tweedie, D., et al., 2010. Enhancing the GLP-1 receptor signaling pathway leads 
to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem, 
113(6), pp.1621-1631. 
Li, Y, Perry, T, et al., 2009. GLP-1 receptor stimulation preserves primary cortical and 
dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. 
Proc Natl Acad Sci U S A, 106(4), pp.1285-1290. 
Li, Y et al., 2012. Exendin-4 ameliorates motor neuron degeneration in cellular and 
animal models of amyotrophic lateral sclerosis. PloS one, 7(2), p.e32008. 
Lin, J. et al., 2002. Transcriptional co-activator PGC-1 alpha drives the formation of 
slow-twitch muscle fibres. Nature, 418(6899), pp.797-801. 
Lin, J., Handschin, C., & Spiegelman, B. M. (2005). Metabolic control through the 
PGC-1 family of transcription coactivators. Cell Metab, 1(6), 361-370.  
Lindström, P., 1986. Aromatic-L-amino-acid decarboxylase activity in mouse pancreatic 
islets. Biochimica et biophysica acta, 884(2), pp.276-81. 
Lipman, I.J., Boykin, M.E. & Flora, R.E., 1974. Glucose intolerance in Parkinson’s 
disease. Journal of chronic diseases, 27(11-12), pp.573-9. 
Liu, B., 2006. Modulation of Microglial Pro-infl ammatory and Neurotoxic Activity for 
the Treatment of Parkinson ’ s Disease. Brain, 8(3), pp.606-621. 
Liu, W.J. et al., 2011. Neuroprotective effect of the glucagon-like peptide-1 receptor 
agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. British journal 
of pharmacology, 164(5), pp.1410-20. 
Lodi, R. et al., 2000. Abnormal in vivo skeletal muscle energy metabolism in 
Huntington’s disease and dentatorubropallidoluysian atrophy. Annals of neurology, 
48(1), pp.72-6. 
Lovshin, J. a & Drucker, Daniel J, 2009. Incretin-based therapies for type 2 diabetes 
mellitus. Nature reviews. Endocrinology, 5(5), pp.262-9. 
Luciani, P. et al., 2010. Differentiating effects of the glucagon-like peptide-1 analogue 
exendin-4 in a human neuronal cell model. Cellular and molecular life sciences!: 
CMLS, 67(21), pp.3711-23. 
 
  
 
216 
 
 
Lundquist, I., Panagiotidis, G. & Stenström, A., 1991. Effect of L-dopa administration 
on islet monoamine oxidase activity and glucose-induced insulin release in the 
mouse. Pancreas, 6(5), pp.522-7. 
Luoma, P.T. et al., 2007. Mitochondrial DNA polymerase gamma variants in idiopathic 
sporadic Parkinson disease. Neurology, 69(11), pp.1152-9. 
Macconell, L., Brown, C., Gurney, K., & Han, J. 2012. Safety and tolerability of 
exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 
patients from 19 placebo-controlled and comparator-controlled clinical trials. 
Diabetes, metabolic syndrome and obesity!: targets and therapy, 5, 29-41. 
Mann, V.M. et al., 1994. Complex I, iron, and ferritin in Parkinson’s disease substantia 
nigra. Ann Neurol, 36(6), pp.876-881. 
Marek, K. et al., 2001. [123I]beta-CIT SPECT imaging assessment of the rate of 
Parkinson’s disease progression. Neurology, 57(11), pp.2089-94. 
Marino, J.S., Xu, Y. & Hill, J.W., 2011. Central insulin and leptin-mediated autonomic 
control of glucose homeostasis. Trends in endocrinology and metabolism: TEM, 
22(7), pp.275-85. 
Marinus, J. et al., 2003. Assessment of sleep and sleepiness in Parkinson disease. Sleep, 
26(8), pp.1049-54. 
Martin, B. et al., 2009. Exendin-4 improves glycemic control, ameliorates brain and 
pancreatic pathologies, and extends survival in a mouse model of Huntington’s 
disease. Diabetes, 58(2), pp.318-28. 
Martinez-Martin, P., 2013. Instruments for holistic assessment of Parkinson’s disease. 
Journal of neural transmission (Vienna, Austria!: 1996), 120(4), pp.559-64. 
Martinez-Martin, P. et al., 2007. Prevalence of nonmotor symptoms in Parkinson’s 
disease in an international setting; study using nonmotor symptoms questionnaire in 
545 patients. Movement disorders!: official journal of the Movement Disorder 
Society, 22(11), pp.1623-9. 
Martinez-Martin, P. et al., 2008. SCOPA-sleep and PDSS: two scales for assessment of 
sleep disorder in Parkinson’s disease. Movement disorders!: official journal of the 
Movement Disorder Society, 23(12), pp.1681-8. 
Matsuda, W. et al., 2009. Single nigrostriatal dopaminergic neurons form widely spread 
and highly dense axonal arborizations in the neostriatum. J Neurosci, 29(2), 
pp.444-453. 
Mazzulli, J.R. et al., 2011. Gaucher disease glucocerebrosidase and α-synuclein form a 
bidirectional pathogenic loop in synucleinopathies. Cell, 146(1), pp.37-52. 
 
  
 
217 
 
 
McCann, M.J. & Rogers, R.C., 1990. Oxytocin excites gastric-related neurones in rat 
dorsal vagal complex. The Journal of physiology, 428(1990), pp.95-108. 
McGeer, P.L. et al., 1988. Reactive microglia are positive for HLA-DR in the substantia 
nigra of Parkinson’s and Alzheimer's disease brains. Neurology, 38(8), pp.1285-
1291. 
McFarland, M. A., Ellis, C. E., Markey, S. P., & Nussbaum, R. L. (2008). Proteomics 
analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. 
Molecular & cellular proteomics!: MCP, 7(11), 2123-37.  
McKern, N.M. et al., 2006. Structure of the insulin receptor ectodomain reveals a 
folded-over conformation. Nature, 443(7108), pp.218-21. 
Montgomery, S.A. & Asberg, M., 1979. A new depression scale designed to be sensitive 
to change. The British journal of psychiatry!: the journal of mental science, 134, 
pp.382-9. 
Moreira, P.I. et al., 2009. An integrative view of the role of oxidative stress, 
mitochondria and insulin in Alzheimer’s disease. Journal of Alzheimer’s disease!: 
JAD, 16(4), pp.741-61. 
Moroo, I. et al., 1994. Loss of insulin receptor immunoreactivity from the substantia 
nigra pars compacta neurons in Parkinson’s disease. Acta neuropathologica, 87(4), 
pp.343-8. 
Morrish, P.K. et al., 1998. Measuring the rate of progression and estimating the 
preclinical period of Parkinson’s disease with [18F]dopa PET. Journal of 
neurology, neurosurgery, and psychiatry, 64(3), pp.314-9. 
Morrish, P.K., 2003. The harsh realities facing the use of SPECT imaging in monitoring 
disease progression in Parkinson’s disease. Journal of neurology, neurosurgery, 
and psychiatry, 74(10), p.1447; author reply 1447. 
Morrish, P.K., Sawle, G.V. & Brooks, D.J., 1996. The rate of progression of Parkinson’s 
disease. A longitudinal [18F]DOPA PET study. Advances in neurology, 69, pp.427-
31. 
Mounier, C., & Posner, B. I. 2006. Transcriptional regulation by insulin: from the 
receptor to the gene. Can J Physiol Pharmacol, 84(7), 713-724. 
Moss, J. & Bolam, J P, 2010. The relationship between dopaminergic axons and 
glutamatergic synapses in the striatum L. Iversen et al., eds., New York: Oxford 
University Press. 
Muftuoglu, M. et al., 2004. Mitochondrial complex I and IV activities in leukocytes 
from patients with parkin mutations. Mov Disord, 19(5), pp.544-548. 
 
  
 
218 
 
 
Muniyappa, R. et al., 2008. Current approaches for assessing insulin sensitivity and 
resistance in vivo: advantages, limitations, and appropriate usage. American journal 
of physiology. Endocrinology and metabolism, 294(1), pp.E15-26. 
Muslimović, D. et al., 2009. Cognitive decline in Parkinson’s disease: a prospective 
longitudinal study. Journal of the International Neuropsychological Society!: JINS, 
15(3), pp.426-37. 
NINDS NET-PD Investigators, 2007. A randomized clinical trial of coenzyme Q10 and 
GPI-1485 in early Parkinson disease. Neurology, 68(1), pp.20-8. 
NINDS NET-PD Investigators, 2006. A randomized, double-blind, futility clinical trial 
of creatine and minocycline in early Parkinson disease. Neurology, 66(5), pp.664-
71. 
Nachnani, J.S. et al., 2010. Biochemical and histological effects of exendin-4 (exenatide) 
on the rat pancreas. Diabetologia, 53(1), pp.153-9. 
Nalls, M.A. et al., 2011. Imputation of sequence variants for identification of genetic 
risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. 
Lancet, 377(9766), pp.641-649. 
Nathan, D.M. et al., 2009. Medical management of hyperglycemia in type 2 diabetes: a 
consensus algorithm for the initiation and adjustment of therapy: a consensus 
statement of the American Diabetes Association and the European Association for 
the Study of Diabetes. Diabetes care, 32(1), pp.193-203. 
Nauck, M A et al., 1997. Glucagon-like peptide 1 inhibition of gastric emptying 
outweighs its insulinotropic effects in healthy humans. The American journal of 
physiology, 273(5 Pt 1), pp.E981-8. 
Nauck, M. et al., 1986. Reduced incretin effect in type 2 (non-insulin-dependent) 
diabetes. Diabetologia, 29(1), pp.46-52. 
Nauck, Michael A, 2009. Unraveling the science of incretin biology. The American 
journal of medicine, 122(6 Suppl), p.S3-S10. 
Nauck, Michael A et al., 2002. Effects of glucagon-like peptide 1 on counterregulatory 
hormone responses, cognitive functions, and insulin secretion during 
hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. 
The Journal of clinical endocrinology and metabolism, 87(3), pp.1239-46. 
Nelson, D. & Cox, M., 2013. Lehninger. Principles of Biochemistry Sixth Edit., 
MacMillan. 
Nicholls, D.G., 2009. Spare respiratory capacity, oxidative stress and excitotoxicity. 
Biochemical Society transactions, 37(Pt 6), pp.1385-8. 
 
  
 
219 
 
 
Nielsen, L.L. & Baron, A.D., 2003. Pharmacology of exenatide (synthetic exendin-4) for 
the treatment of type 2 diabetes. Current opinion in investigational drugs (London, 
England!: 2000), 4(4), pp.401-5. 
Nurmi, E. et al., 2000. Progression in Parkinson’s disease: a positron emission 
tomography study with a dopamine transporter ligand [18F]CFT. Annals of 
neurology, 47(6), pp.804-8. 
Näslund, E. et al., 1999. Energy intake and appetite are suppressed by glucagon-like 
peptide-1 (GLP-1) in obese men. International journal of obesity and related 
metabolic disorders!: journal of the International Association for the Study of 
Obesity, 23(3), pp.304-11. 
Oh, V.M., 1991. Magic or medicine? Clinical pharmacological basis of placebo 
medication. Annals of the Academy of Medicine, Singapore, 20(1), pp.31-7. 
Olanow, C.W. et al., 2009. A double-blind, delayed-start trial of rasagiline in 
Parkinson’s disease. The New England journal of medicine, 361(13), pp.1268-78. 
Olanow, C.W., Kieburtz, K. & Schapira, A.H.V., 2008. Why have we failed to achieve 
neuroprotection in Parkinson’s disease? Annals of neurology, 64 Suppl 2, pp.S101-
10. 
Orimo, S. et al., 2011. Unmyelinated axons are more vulnerable to degeneration than 
myelinated axons of the cardiac nerve in Parkinson’s disease. Neuropathology and 
applied neurobiology, 37(7), pp.791-802. 
Ott, A. et al., 1999. Diabetes mellitus and the risk of dementia: The Rotterdam Study. 
Neurology, 53(9), pp.1937-42. 
Ott, V. et al., 2012. Intranasal administration of insulin to the brain impacts cognitive 
function and peripheral metabolism. Diabetes, obesity & metabolism, 14(3), 
pp.214-21. 
Paddock, M.L. et al., 2007. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial 
membrane protein stabilized by pioglitazone. Proc Natl Acad Sci U S A, 104(36), 
pp.14342-14347. 
Pagonabarraga, J. & Kulisevsky, J., 2012. Cognitive impairment and dementia in 
Parkinson’s disease. Neurobiology of disease, 46(3), pp.590-6. 
Palacino, J.J. et al., 2004. Mitochondrial dysfunction and oxidative damage in parkin-
deficient mice. J Biol Chem, 279(18), pp.18614-18622. 
Palacios, N. et al., 2011. Obesity, diabetes, and risk of Parkinson’s disease. Movement 
disorders!: official journal of the Movement Disorder Society, 26(12), pp.2253-9. 
 
  
 
220 
 
 
Palmer, T.D., Ray, J. & Gage, F.H., 1995. FGF-2-responsive neuronal progenitors reside 
in proliferative and quiescent regions of the adult rodent brain. Molecular and 
cellular neurosciences, 6(5), pp.474-86. 
Parkinson Study Group, 2002a. A controlled trial of rasagiline in early Parkinson 
disease: the TEMPO Study. Archives of neurology, 59(12), pp.1937-43. 
Parkinson Study Group, 2000. A randomized controlled trial comparing pramipexole 
with levodopa in early Parkinson’s disease: design and methods of the CALM-PD 
Study. Parkinson Study Group. Clinical neuropharmacology, 23(1), pp.34-44. 
Parkinson Study Group, 2002b. Dopamine transporter brain imaging to assess the effects 
of pramipexole vs levodopa on Parkinson disease progression. JAMA!: the journal 
of the American Medical Association, 287(13), pp.1653-61. 
Patti, M.E. et al., 2003. Coordinated reduction of genes of oxidative metabolism in 
humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. 
Proc Natl Acad Sci U S A, 100(14), pp.8466-8471. 
Peila, R., Rodriguez, B.L. & Launer, L.J., 2002. Type 2 diabetes, APOE gene, and the 
risk for dementia and related pathologies: The Honolulu-Asia Aging Study. 
Diabetes, 51(4), pp.1256-1262. 
Peppard, R.F. et al., 1992. Cerebral glucose metabolism in Parkinson’s disease with and 
without dementia. Archives of neurology, 49(12), pp.1262-8. 
Perier, C. et al., 2005. Complex I deficiency primes Bax-dependent neuronal apoptosis 
through mitochondrial oxidative damage. Proc Natl Acad Sci U S A, 102(52), 
pp.19126-19131. 
Perry, T, Haughey, N.J., et al., 2002a. Protection and reversal of excitotoxic neuronal 
damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther, 302(3), 
pp.881-888. 
Perry, TracyAnn, Lahiri, D.K., et al., 2002b. A novel neurotrophic property of glucagon-
like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 
cells. The Journal of pharmacology and experimental therapeutics, 300(3), pp.958-
66. 
Perry, TracyAnn et al., 2007. Evidence of GLP-1-mediated neuroprotection in an animal 
model of pyridoxine-induced peripheral sensory neuropathy. Experimental 
neurology, 203(2), pp.293-301. 
Petersen, K.F. et al., 2004. Impaired mitochondrial activity in the insulin-resistant 
offspring of patients with type 2 diabetes. N Engl J Med, 350(7), pp.664-671. 
Piboolnurak, P. et al., 2007. Levodopa response in long-term bilateral subthalamic 
stimulation for Parkinson’s disease. Mov Disord, 22(7), pp.990-997. 
 
  
 
221 
 
 
Pirker, W. et al., 2003. Measuring the rate of progression of Parkinson’s disease over a 
5-year period with beta-CIT SPECT. Movement disorders!: official journal of the 
Movement Disorder Society, 18(11), pp.1266-72. 
Ploeger, B.A. & Holford, N.H.G., 2009. Washout and delayed start designs for 
identifying disease modifying effects in slowly progressive diseases using disease 
progression analysis. Pharmaceutical statistics, 8(3), pp.225-38. 
Plowey, E.D. & Chu, C.T., 2011. Synaptic dysfunction in genetic models of Parkinson’s 
disease: a role for autophagy? Neurobiology of disease, 43(1), pp.60-7. 
Plum, L., Schubert, M. & Brüning, J.C., 2005. The role of insulin receptor signaling in 
the brain. Trends in endocrinology and metabolism: TEM, 16(2), pp.59-65. 
Poewe, W., 2009. Clinical measures of progression in Parkinson’s disease. Movement 
disorders!: official journal of the Movement Disorder Society, 24 Suppl 2, pp.S671-
6. 
Poon, H.F. et al., 2005. Mitochondrial associated metabolic proteins are selectively 
oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson’s 
disease. Neurobiol Dis, 18(3), pp.492-498. 
Pressley, J.C. et al., 2003. The impact of comorbid disease and injuries on resource use 
and expenditures in parkinsonism. Neurology, 60(1), pp.87-93. 
Pyle, A. et al., 2005. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of 
PD. Annals of neurology, 57(4), pp.564-7. 
Quinn, L.P. et al., 2008. The PPARgamma agonist pioglitazone is effective in the MPTP 
mouse model of Parkinson’s disease through inhibition of monoamine oxidase B. 
British journal of pharmacology, 154(1), pp.226-33. 
Rakovic, A. et al., 2010. Effect of endogenous mutant and wild-type PINK1 on Parkin in 
fibroblasts from Parkinson disease patients. Hum Mol Genet, 19(16), pp.3124-3137. 
Ramonet, D. et al., 2011. Dopaminergic neuronal loss, reduced neurite complexity and 
autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. 
PloS one, 6(4), p.e18568. 
Ranganath, L.R. et al., 1996. Attenuated GLP-1 secretion in obesity: cause or 
consequence? Gut, 38(6), pp.916-9. 
Rask, E. et al., 2001. Impaired incretin response after a mixed meal is associated with 
insulin resistance in nondiabetic men. Diabetes care, 24(9), pp.1640-5. 
Ren, H. et al., 2011. Oxidized DJ-1 interacts with the mitochondrial protein BCL-XL. 
The Journal of biological chemistry, 286(40), pp.35308-17. 
 
  
 
222 
 
 
de Rijk, M.C. et al., 2000. Prevalence of Parkinson’s disease in Europe: A collaborative 
study of population-based cohorts. Neurologic Diseases in the Elderly Research 
Group. Neurology, 54(11 Suppl 5), pp.S21-3. 
Roberge, J.N. & Brubaker, P L, 1993. Regulation of intestinal proglucagon-derived 
peptide secretion by glucose-dependent insulinotropic peptide in a novel 
enteroendocrine loop. Endocrinology, 133(1), pp.233-40. 
Rodriquez de Fonseca, F. et al., 2000. Peripheral versus central effects of glucagon-like 
peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. 
Metabolism: clinical and experimental, 49(6), pp.709-17. 
Rosenstock, J., Shenouda, S. K., Bergenstal, R. M., Buse, J. B., Glass, L. C., Heilmann, 
C. R., Kwan, A. Y. M., et al. 2012. Baseline factors associated with glycemic 
control and weight loss when exenatide twice daily is added to optimized insulin 
glargine in patients with type 2 diabetes. Diabetes care, 35(5), 955-8.  
Le Roith, D. et al., 1983. Insulin in brain and other extrapancreatic tissues of vertebrates 
and nonvertebrates. Advances in metabolic disorders, 10, pp.303-40. 
Rubí, B. et al., 2005. Dopamine D2-like receptors are expressed in pancreatic beta cells 
and mediate inhibition of insulin secretion. The Journal of biological chemistry, 
280(44), pp.36824-32. 
Saisho, Y. et al., 2008. Relationship between pancreatic vesicular monoamine 
transporter 2 (VMAT2) and insulin expression in human pancreas. Journal of 
molecular histology, 39(5), pp.543-51. 
Salkovic-Petrisic, M. & Hoyer, S., 2007. Central insulin resistance as a trigger for 
sporadic Alzheimer-like pathology: an experimental approach. Journal of neural 
transmission. Supplementum, (72), pp.217-33. 
Sandyk, R. (1993). The realtionship between Diabetes Mellitus and Parkinson’s Disease. 
Pharmacology, 69(1965), 125-130. 
Santiago, J.A. & Potashkin, J.A., 2013. Shared dysregulated pathways lead to 
Parkinson’s disease and diabetes. Trends in molecular medicine, 19(3), pp.176-86. 
Schapira, A.H., 2010. Complex I: inhibitors, inhibition and neurodegeneration. Exp 
Neurol, 224(2), pp.331-335. 
Schapira, A.H., 2008. Mitochondria in the aetiology and pathogenesis of Parkinson’s 
disease. Lancet Neurol, 7(1), pp.97-109. 
Schapira, A.H. et al., 1989. Mitochondrial complex I deficiency in Parkinson’s disease. 
Lancet, 1(8649), p.1269. 
Schaw, R.S., 1960. Progression and prognosis in Parkinson’s disease. The Journal of 
nervous and mental disease, 130, pp.556-66. 
 
  
 
223 
 
 
Scherer, T. et al., 2011. Brain insulin controls adipose tissue lipolysis and lipogenesis. 
Cell metabolism, 13(2), pp.183-94. 
Schintu, N. et al., 2009. PPAR-gamma-mediated neuroprotection in a chronic mouse 
model of Parkinson’s disease. The European journal of neuroscience, 29(5), 
pp.954-63. 
Schmidt, B., 2006. Proof of Principle studies. Epilepsy research, 68(1), pp.48-52. 
Schmidt, K.S. et al., 2006. Construct and concurrent validity of the Dementia Rating 
Scale-2 Alternate Form. Journal of clinical and experimental neuropsychology, 
28(5), pp.646-54. 
Schrag, A, Quinn, N.P. & Ben-Shlomo, Y., 2006. Heterogeneity of Parkinson’s disease. 
Journal of neurology, neurosurgery, and psychiatry, 77(2), pp.275-6. 
Schrag, Anette et al., 2007. Rate of clinical progression in Parkinson’s disease. A 
prospective study. Movement disorders!: official journal of the Movement Disorder 
Society, 22(7), pp.938-45. 
Schulingkamp, R.J. et al., 2000. Insulin receptors and insulin action in the brain: review 
and clinical implications. Neuroscience and biobehavioral reviews, 24(8), pp.855-
72. 
Schultz, W., 1998. Predictive reward signal of dopamine neurons. Journal of 
neurophysiology, 80(1), pp.1-27. 
Schulz-Schaeffer, W.J., 2010. The synaptic pathology of alpha-synuclein aggregation in 
dementia with Lewy bodies, Parkinson’s disease and Parkinson's disease dementia. 
Acta neuropathologica, 120(2), pp.131-43. 
Schwab, R.S., 1960. Progression and prognosis in Parkinson’s disease. The Journal of 
nervous and mental disease, 130, pp.556-66. 
Seibyl, J.P., 2003. Imaging studies in movement disorders. Seminars in nuclear 
medicine, 33(2), pp.105-13. 
Sherer, T. B., Chowdhury, S., Peabody, K., & Brooks, D. W. 2012. Overcoming 
obstacles in Parkinson’s disease. Movement disorders!: official journal of the 
Movement Disorder Society, 27(13), 1606-11.  
Shetty, N., Friedman, J. H., Kieburtz, K., Marshall, F. J., & Oakes, D. 1999. The placebo 
response in Parkinson’s disease. Parkinson Study Group. Clinical 
neuropharmacology, 22(4), 207-12. 
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., et 
al. 2011. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration 
in Parkinson’s disease. Cell, 144(5), 689-702.  
 
  
 
224 
 
 
 
Sidransky, E et al., 2009. Multicenter analysis of glucocerebrosidase mutations in 
Parkinson’s disease. The New England journal of medicine, 361(17), pp.1651-61. 
Simon, D.K. et al., 1999. Familial multisystem degeneration with parkinsonism 
associated with the 11778 mitochondrial DNA mutation. Neurology, 53(8), 
pp.1787-93. 
Sirtori, C.R., Bolme, P. & Azarnoff, D.L., 1972. Metabolic responses to acute and 
chronic L-dopa administration in patients with parkinsonism. The New England 
journal of medicine, 287(15), pp.729-33. 
Smith, B.J. et al., 2010. Structural resolution of a tandem hormone-binding element in 
the insulin receptor and its implications for design of peptide agonists. Proceedings 
of the National Academy of Sciences of the United States of America, 107(15), 
pp.6771-6. 
Solinas, G. et al., 2007. JNK1 in hematopoietically derived cells contributes to diet-
induced inflammation and insulin resistance without affecting obesity. Cell 
metabolism, 6(5), pp.386-97. 
Spillantini, M.G. et al., 1997. Alpha-synuclein in Lewy bodies. Nature, 388(6645), 
pp.839-40. 
Staffen, W. et al., 2000. Measuring the progression of idiopathic Parkinson’s disease 
with [123I] beta-CIT SPECT. Journal of neural transmission (Vienna, Austria!: 
1996), 107(5), pp.543-52. 
Stark, R. & Roden, M., 2007. ESCI Award 2006. Mitochondrial function and endocrine 
diseases. European journal of clinical investigation, 37(4), pp.236-48. 
Stichel, C.C. et al., 2000. Parkin expression in the adult mouse brain. Eur J Neurosci, 
12(12), pp.4181-4194. 
Summers, S. A., & Nelson, D. H. 2005. A Role for Sphingolipids in Producing the 
Common Features of Type 2 Diabetes , Metabolic Syndrome X , and Cushing ’ s 
Syndrome. Production, 54(March), 591-602. 
Takahashi, M. et al., 1996. Insulin receptor mRNA in the substantia nigra in Parkinson’s 
disease. Neuroscience letters, 204(3), pp.201-4. 
Talbot, K. et al., 2012. Demonstrated brain insulin resistance in Alzheimer’s disease 
patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive 
decline. The Journal of clinical investigation, 122(4), pp.1316-38. 
Tan, L.C.S., 2012. Mood disorders in Parkinson’s disease. Parkinsonism & related 
disorders, 18 Suppl 1, pp.S74-6. 
 
  
 
225 
 
 
Tansey, M G et al., 2008. Neuroinflammation in Parkinson’s disease: is there sufficient 
evidence for mechanism-based interventional therapy? Front Biosci, 13, pp.709-
717. 
Taupin, P., 2005. Adult neurogenesis in the mammalian central nervous system: 
functionality and potential clinical interest. Medical science monitor!: international 
medical journal of experimental and clinical research, 11(7), pp.RA247-252. 
Thambisetty, M. et al., 2013. Glucose Intolerance, Insulin Resistance, and Pathological 
Features of Alzheimer Disease in the Baltimore Longitudinal Study of Aging. 
JAMA neurology. 
Tissingh, G. et al., 1998. Drug-naive patients with Parkinson’s disease in Hoehn and 
Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as 
revealed by [123I]beta-CIT SPECT. Journal of neurology, 245(1), pp.14-20. 
Tomlinson, C.L. et al., 2010. Systematic review of levodopa dose equivalency reporting 
in Parkinson’s disease. Movement disorders!: official journal of the Movement 
Disorder Society, 25(15), pp.2649-53. 
Tuomilehto, J. et al., 1996. Diabetes mellitus as a risk factor for death from stroke. 
Prospective study of the middle-aged Finnish population. Stroke; a journal of 
cerebral circulation, 27(2), pp.210-5. 
Tureyen, K. et al., 2007. Peroxisome proliferator-activated receptor-gamma agonists 
induce neuroprotection following transient focal ischemia in normotensive, 
normoglycemic as well as hypertensive and type-2 diabetic rodents. Journal of 
neurochemistry, 101(1), pp.41-56. 
Unger, J.W., Livingston, J.N. & Moss, A.M., 1991. Insulin receptors in the central 
nervous system: localization, signalling mechanisms and functional aspects. 
Progress in neurobiology, 36(5), pp.343-62. 
Ustione, A., Piston, D.W. & Harris, P.E., 2013. Minireview: dopaminergic regulation of 
insulin secretion from the pancreatic islet. Molecular endocrinology (Baltimore, 
Md.), 27(8), pp.1198-207. 
Vandermeers, A. et al., 1987. Chemical, immunological and biological properties of 
peptides like vasoactive-intestinal-peptide and peptide-histidine-isoleucinamide 
extracted from the venom of two lizards (Heloderma horridum and Heloderma 
suspectum). European journal of biochemistry / FEBS, 164(2), pp.321-7. 
Vangoitsenhoven, R., Mathieu, C. & Van der Schueren, B., 2012. GLP1 and cancer: 
friend or foe? Endocrine-related cancer, 19(5), pp.F77-88. 
Varrone, A. et al., 2013. European multicentre database of healthy controls for [123I]FP-
CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of 
different methods of analysis. European journal of nuclear medicine and molecular 
imaging, 40(2), pp.213-27. 
 
  
 
226 
 
 
Verbaan, D., van Rooden, S. M., Visser, M., Marinus, J., & van Hilten, J. J. (2008). 
Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Movement 
disorders!: official journal of the Movement Disorder Society, 23(1), 35-41.  
Vilsbøll, T et al., 2001. Reduced postprandial concentrations of intact biologically active 
glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 50(3), pp.609-13. 
Vilsbøll, T et al., 2003. Similar elimination rates of glucagon-like peptide-1 in obese 
type 2 diabetic patients and healthy subjects. The Journal of clinical endocrinology 
and metabolism, 88(1), pp.220-4. 
Vilsbøll, Tina et al., 2012. Effects of glucagon-like peptide-1 receptor agonists on 
weight loss: systematic review and meta-analyses of randomised controlled trials. 
BMJ (Clinical research ed.), 344, p.d7771. 
Vives-Bauza, C & Przedborski, S, 2011. Mitophagy: the latest problem for Parkinson’s 
disease. Trends Mol Med, 17(3), pp.158-165. 
Vives-Bauza, Cristofol et al., 2010. PINK1-dependent recruitment of Parkin to 
mitochondria in mitophagy. Proceedings of the National Academy of Sciences of 
the United States of America, 107(1), pp.378-83. 
Wahner, A.D. et al., 2007. Nonsteroidal anti-inflammatory drugs may protect against 
Parkinson disease. Neurology, 69(19), pp.1836-1842. 
Wan, Q. et al., 1997. Recruitment of functional GABA(A) receptors to postsynaptic 
domains by insulin. Nature, 388(6643), pp.686-90. 
Wang, Q. et al., 2004. Glucagon-like peptide-1 regulates proliferation and apoptosis via 
activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia, 47(3), 
pp.478-87. 
Warner, T.T. & Schapira, A.H.V., 2003. Genetic and environmental factors in the cause 
of Parkinson’s disease. Annals of neurology, 53 Suppl 3, pp.S16-23; discussion 
S23-5. 
Weaver, F.M. et al., 2009. Bilateral deep brain stimulation vs best medical therapy for 
patients with advanced Parkinson disease: a randomized controlled trial. JAMA!: 
the journal of the American Medical Association, 301(1), pp.63-73. 
Wenten, M., Gaebler, J. A., Hussein, M., Pelletier, E. M., Smith, D. B., Girase, P., Noel, 
R. A., et al. (2012). Relative risk of acute pancreatitis in initiators of exenatide 
twice daily compared with other anti-diabetic medication: a follow-up study. 
Diabetic medicine!: a journal of the British Diabetic Association, 29(11), 1412-8.  
Werner, H. et al., 1993. Developmental regulation of the insulin and insulin-like growth 
factor receptors in the central nervous system. In M. P. editors. Zagon IS, ed. 
Receptors in the developing nervous system vol.1 growth factors and hormones. pp. 
109-27. 
 
  
 
227 
 
 
Westbroek, W., Gustafson, A.M. & Sidransky, Ellen, 2011. Exploring the link between 
glucocerebrosidase mutations and parkinsonism. Trends in molecular medicine, 
17(9), pp.485-93. 
Wettergren, A., Wøjdemann, M. & Holst, J J, 1998. The inhibitory effect of glucagon-
like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally 
truncated primary metabolite GLP-1 (9-36)amide. Peptides, 19(5), pp.877-82. 
Whitton, P.S., 2007. Inflammation as a causative factor in the aetiology of Parkinson’s 
disease. Br J Pharmacol, 150(8), pp.963-976. 
Whone, A.L. et al., 2003. Slower progression of Parkinson’s disease with ropinirole 
versus levodopa: The REAL-PET study. Annals of neurology, 54(1), pp.93-101. 
Wiley, S.E. et al., 2007. The outer mitochondrial membrane protein mitoNEET contains 
a novel redox-active 2Fe-2S cluster. The Journal of biological chemistry, 282(33), 
pp.23745-9. 
Van Woert, M.H. & Mueller, P.S., 1971. Glucose, insulin, and free fatty acid 
metabolism in Parkinson’s disease treated with levodopa. Clinical pharmacology 
and therapeutics, 12(2), pp.360-7. 
Wong, E. & Cuervo, A.M., 2010. Autophagy gone awry in neurodegenerative diseases. 
Nat Neurosci, 13(7), pp.805-811. 
Woods, S.C. et al., 1979. Chronic intracerebroventricular infusion of insulin reduces 
food intake and body weight of baboons. Nature, 282(5738), pp.503-5. 
Yamamoto, H. et al., 2003. Glucagon-like peptide-1-responsive catecholamine neurons 
in the area postrema link peripheral glucagon-like peptide-1 with central autonomic 
control sites. The Journal of neuroscience!: the official journal of the Society for 
Neuroscience, 23(7), pp.2939-46. 
Yokota, T. et al., 2003. Down regulation of DJ-1 enhances cell death by oxidative stress, 
ER stress, and proteasome inhibition. Biochem Biophys Res Commun, 312(4), 
pp.1342-1348. 
Yoo, B.K., Triller, D.M. & Yoo, D.J., 2006. Exenatide: a new option for the treatment of 
type 2 diabetes. The Annals of pharmacotherapy, 40(10), pp.1777-84. 
Zhang, L. et al., 2005. Mitochondrial localization of the Parkinson’s disease related 
protein DJ-1: implications for pathogenesis. Hum Mol Genet, 14(14), pp.2063-
2073. 
Zhao, W.-Q. et al., 2004. Insulin and the insulin receptor in experimental models of 
learning and memory. European journal of pharmacology, 490(1-3), pp.71-81. 
Zhao, W.Q. & Alkon, D.L., 2001. Role of insulin and insulin receptor in learning and 
memory. Molecular and cellular endocrinology, 177(1-2), pp.125-34. 
 
  
 
228 
 
 
Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, 
A. C., et al. 2010. PGC-1alpha, a potential therapeutic target for early intervention 
in Parkinson’s disease. Sci Transl Med, 2(52), 52ra73.  
Ziebell, M., 2011. Evaluation of the superselective radioligand [123I]PE2I for imaging 
of the dopamine transporter in SPECT. Danish medical bulletin, 58(5), p.B4279. 
 
 
 
 
 
